BioMedLib Search Engine
[ goto HOMEPAGE ]
Don't miss relevant answers!
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Clarify the query
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
choroid plexus papillomas drug therapy 2000:2010[pubdate] *count=100
194 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
drug therapy
' expands to
2 meanings
. Choose the one you intended:
Concept C0013216: drug therapy procedure;
details
Concept C0013217: pharmacologic therapy;
details
'
choroid plexus papillomas
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 194
1.
Steiner T, Pilz J, Schellinger P, Wirtz R, Friederichs V, Aschoff A, Hacke W:
Multimodal online monitoring in middle cerebral artery territory stroke.
Stroke
; 2001 Nov;32(11):2500-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND AND PURPOSE: Patients with large middle cerebral artery infarction and elevated
intracranial
pressure (ICP) who are undergoing invasive intensive care
therapy
require technical monitoring.
Furthermore, the effects of what is considered to be standard antiedema medical
treatment
are not fully understood.
METHODS: ICP, cerebral perfusion pressure (
CPP
), and partial
brain tissue
oxygen pressure (PbrO(2)) were continuously measured within the white matter of the frontal lobe unilaterally or bilaterally.
We analyzed the effects of antiedema
drugs
and looked for pattern changes in the PbrO(2) before transtentorial herniation in patients in whom this could not be prevented.
A total of 297 antiedema
drug
administrations were analyzed in 11 patients.
Hyper-HAES and mannitol were most often associated with an increase in
CPP
and PbrO(2), whereas the use of thiopental and tromethamine led to negative or contrary effects, although ICP was decreased in every case.
CONCLUSIONS: Multimodal monitoring can be used to monitor antiedema
drug
effects.
Furthermore, this method might help to optimize the timing of invasive
therapy
in space-occupying infarction.
[MeSH-major]
Infarction, Middle Cerebral Artery /
drug therapy
. Monitoring, Physiologic / methods. Online Systems
[MeSH-minor]
Brain
Edema /
drug therapy
. Feasibility Studies. Frontal Lobe / chemistry. Frontal Lobe / physiopathology. Humans.
Intracranial
Hypertension.
Intracranial
Pressure /
drug
effects. Oxygen / analysis. Partial Pressure
Hazardous Substances Data Bank.
OXYGEN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 11692007.001).
[ISSN]
1524-4628
[Journal-full-title]
Stroke; a journal of cerebral circulation
[ISO-abbreviation]
Stroke
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
S88TT14065 / Oxygen
2.
Le Foll B, Sokoloff P, Stark H, Goldberg SR:
Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects.
Neuropsychopharmacology
; 2005 Apr;30(4):720-30
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Environmental stimuli previously paired with
drug
taking appear to play a critical role in nicotine dependence.
Converging anatomical,
pharmacological
, and behavioral evidence implicates dopamine D3 receptors (D3Rs) in the mechanisms underlying stimulus-controlled
drug
-seeking behavior.
This study assessed the effects of BP 897, a D3R partial agonist and ST 198, a D3R antagonist, on nicotine-induced conditioned place preferences (CPPs), used as a measure of
drug
-seeking behavior, on food-maintained responding and on discrimination performance under a two-lever-choice nicotine discrimination
procedure
.
BP 897 and ST 198 both blocked the expression of nicotine-induced
CPP
at doses selective for D3R.
They had no effect on locomotor activity in
the CPP
apparatus and no significant effect on nicotine discrimination performance or food-maintained responding under the discrimination
procedure
.
Involvement of antidepressant actions in the effects of BP 897 and ST 198 on
CPP
is unlikely, since we found no effect of D3R blockade with BP 897 or genetic depletion of D3Rs in a forced swimming test, used as a behavioral test for antidepressant activity.
This suggests that D3R ligands reduce the motivational effects of nicotine by a mechanism distinct from those of nicotine replacement
therapy
and bupropion, the two currently used aids for smoking cessation in humans.
[MeSH-major]
Dopamine Agents / pharmacology. Nicotine / antagonists & inhibitors. Receptors, Dopamine D2 / agonists. Spatial Behavior /
drug
effects. Tobacco Use Disorder /
drug therapy
[MeSH-minor]
Acrylamides / pharmacology. Animals. Antidepressive Agents / pharmacology. Conditioning (Psychology) /
drug
effects. Conditioning (Psychology) / physiology. Discrimination (Psychology) /
drug
effects. Discrimination (Psychology) / physiology.
Disease
Models, Animal. Dopamine Agonists / pharmacology. Dopamine Antagonists / pharmacology.
Drug
Interactions / physiology. Female. Isoquinolines / pharmacology. Ligands. Limbic System /
drug
effects. Limbic System / metabolism. Limbic System / physiopathology. Male. Mice. Mice, Knockout. Piperazines / pharmacology. Rats. Rats, Sprague-Dawley. Receptors, Dopamine D3
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
NICOTINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15562293.001).
[ISSN]
0893-133X
[Journal-full-title]
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
[ISO-abbreviation]
Neuropsychopharmacology
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / ((E)-N-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)butyl)-3-phenylacrylamide; 0 / Acrylamides; 0 / Antidepressive Agents; 0 / BP 897; 0 / Dopamine Agents; 0 / Dopamine Agonists; 0 / Dopamine Antagonists; 0 / Drd3 protein, mouse; 0 / Drd3 protein, rat; 0 / Isoquinolines; 0 / Ligands; 0 / Piperazines; 0 / Receptors, Dopamine D2; 0 / Receptors, Dopamine D3; 6M3C89ZY6R / Nicotine
3.
Antoniazzi F, Zamboni G, Bertoldo F, Lauriola S, Tatò L:
Bone development during GH and GnRH analog treatment.
Eur J Endocrinol
; 2004 Aug;151 Suppl 1:S47-54
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Bone development during GH and GnRH analog
treatment
.
Treatment of
precocious puberty with GnRH analogs (GnRHa), by reducing sex steroid levels, leads to a situation of hypoestrogenism that may theoretically have a detrimental effect on bone mass during pubertal development.
A reduction in bone mineral density (BMD) during GnRHa
treatment
has been demonstrated, but GnRHa
treatment
in patients with central precocious puberty (
CPP
) does not seem to impair the achievement of normal peak bone mass (PBM) at final height.
In children and adolescents with GH deficiency (GHD), BMD assessed by dual-energy X-ray absorptiometry (DEXA) and bone turnover are significantly reduced, but they are stimulated by GH
treatment
.
GH
treatment
leads to improved bone density, function of the dose and duration
of treatment
, and patients may require prolonged GH
treatment
beyond
the time
of growth to improve PBM.
After the discontinuation of GH
therapy
, the more active population had higher bone mineral content (BMC) levels than patients with low physical activity.
In our experience,
the therapeutic
association of GH and calcium also represents a valuable tool in pursuing a proper BMC in GHD patients.
MedlinePlus Health Information.
consumer health - Growth Disorders
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15339244.001).
[ISSN]
0804-4643
[Journal-full-title]
European journal of endocrinology
[ISO-abbreviation]
Eur. J. Endocrinol.
[Language]
ENG
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
12629-01-5 / Human Growth Hormone; 33515-09-2 / Gonadotropin-Releasing Hormone; 79561-22-1 / LHRH, Ala(6)-Gly(10)-ethylamide-; 9002-72-6 / Growth Hormone
[Number-of-references]
69
Advertisement
4.
Levy ML, Goldfarb A, Hyder DJ, Gonzales-Gomez I, Nelson M, Gilles FH, McComb JG:
Choroid plexus tumors in children: significance of stromal invasion.
Neurosurgery
; 2001 Feb;48(2):303-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Choroid plexus
tumors in children: significance of stromal invasion.
OBJECTIVE: A group of
choroid plexus
tumors fit the cellular criteria for
choroid plexus
papilloma
(
CPP
) except for invasion into the adjacent parenchyma, with associated loss of the normal villus architecture at the site of invasion.
These tumors retain
a benign
cellular appearance.
In the existing literature, it is unclear whether these tumors are classified as
choroid plexus
carcinomas or as CPPs.
In our experience, although evidence of invasion is present, these tumors tend to exhibit
benign
behavior.
We suggest that stromal invasion of this
type
remains consistent
with a benign
clinical course, although surgical results may demonstrate higher morbidity rates, given the invasive nature of the tumors.
After gross total
tumor
removal, none of the eight children with CPPs received adjuvant
therapy
at our institution; all are alive without evidence
of tumor
recurrence after surgical excision (mean, 108 mo).
The one patient who underwent subtotal resection received
chemotherapy
at another facility.
CONCLUSION: It is recommended that CPPs
with a benign
cellular appearance but with evidence of local parenchymal invasion and loss of the normal villus architecture at the site of invasion be classified as CPPs.
Patients with these tumors respond to surgical
therapy
alone, without the need for adjuvant
treatment
.
[MeSH-major]
Choroid Plexus
Neoplasms / pathology.
Choroid Plexus
Neoplasms / surgery.
Papilloma
/ pathology.
Papilloma
/ surgery
[MeSH-minor]
Child. Child, Preschool. Humans. Infant.
Neoplasm
Invasiveness. Retrospective Studies.
Treatment
Outcome
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 11220372.001).
[ISSN]
0148-396X
[Journal-full-title]
Neurosurgery
[ISO-abbreviation]
Neurosurgery
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
5.
Municchi G, Marconcini S, D'Ambrosio A, Berardi R, Acquaviva A:
Central precocious puberty in multisystem Langerhans cell histiocytosis: a case report.
Pediatr Hematol Oncol
; 2002 Jun;19(4):273-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The authors describe a girl with multisystem Langerhans cell histiocytosis (LCH) who
developed
central precocious puberty (
CPP
).
She subsequently
developed
diabetes insipidus
with a
documented lesion of the pituitary stalk; she received
chemotherapy
and began
therapy
with l
-desamino-8-D-argininevasopressin.
Growth hormone deficiency was diagnosed at the age of 4.4 years and GH replacement
therapy
started.
The patient has been off
therapy
for LCH since the age of 6.
Signs of pubertal development appeared at 7.5 years (bone age 8 years) and gonadotropin-releasing hormone analog (GnRHa)
treatment
was started.
During the observation period she
developed
central hypothyroidism.
Development
of CPP
during LCH is extremely rare; to the authors 'knowledge, no patient has been described so far.
The authors believe that
CPP
was secondary to LCH and did not represent a casual
finding
, even in the absence of hypothalamic-pituitary axis involvement.
The possibility
of CPP
development should be considered during the follow-up of these patients.
Genetic Alliance.
consumer health - Histiocytosis
.
Genetic Alliance.
consumer health - Langerhans cell histiocytosis
.
Genetic Alliance.
consumer health - Precocious puberty
.
Genetic Alliance.
consumer health - Central precocious puberty
.
MedlinePlus Health Information.
consumer health - Diabetes Insipidus
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 12051595.001).
[ISSN]
0888-0018
[Journal-full-title]
Pediatric hematology and oncology
[ISO-abbreviation]
Pediatr Hematol Oncol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
[Chemical-registry-number]
9002-72-6 / Growth Hormone
6.
Lu L, Zeng S, Liu D, Ceng X:
Inhibition of the amygdala and hippocampal calcium/calmodulin-dependent protein kinase II attenuates the dependence and relapse to morphine differently in rats.
Neurosci Lett
; 2000 Sep 22;291(3):191-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Based on the recent
finding
that calcium/calmodulin protein kinase II (CaMKII) is essential in learning and memory processes, the present study was performed to examine whether inhibition of hippocampal and amygdala CaMKII prevents the dependence and relapse to morphine.
Microinjection of KN-62 into both hippocampus and amygdala suppressed the development of formation and reactivation of morphine conditioned place preference (
CPP
).
However, inhibition of CaMKII in amygdala, but not in hippocampus, could attenuate the maintenance of morphine
CPP
.
Inhibition of this kinase may have some
therapeutic
benefit in
the treatment
of opiate dependence and relapse.
[MeSH-minor]
Animals. Behavior, Animal /
drug
effects. Calcium-Calmodulin-Dependent Protein Kinase
Type
2. Conditioning (Psychology) /
drug
effects. Enzyme Inhibitors / administration & dosage. Male. Microinjections. Morphine / pharmacology. Naloxone / pharmacology. Rats. Rats, Sprague-Dawley. Substance Withdrawal Syndrome /
drug therapy
. Substance Withdrawal Syndrome / enzymology
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
NALOXONE
.
Hazardous Substances Data Bank.
MORPHINE
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 10984639.001).
[ISSN]
0304-3940
[Journal-full-title]
Neuroscience letters
[ISO-abbreviation]
Neurosci. Lett.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
IRELAND
[Chemical-registry-number]
0 / Enzyme Inhibitors; 127191-97-3 / KN 62; 36B82AMQ7N / Naloxone; 76I7G6D29C / Morphine; 84477-87-2 / 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinase Type 2; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
7.
Kumar B, Saraswat A, Kaur I:
Rediscovering hydroxyurea: its role in recalcitrant psoriasis.
Int J Dermatol
; 2001 Aug;40(8):530-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: There is an acute paucity of second-line systemic agents for the
treatment of
extensive chronic plaque psoriasis (
CPP
).
Recent studies using hydroxyurea in patients with HIV infection and sickle cell anemia have rekindled interest in this old
drug
and have provided more data regarding safety and dosage.
OBJECTIVE: We wanted to test the efficacy and tolerability of hydroxyurea in patients with extensive
CPP
who had to discontinue first-line oral agents for any reason.
Thirty-one patients, including 26 with prior history of systemic antipsoriatic
therapy
were given hydroxyurea 1-1.5 g per day
for a
median duration of 36 weeks.
They were followed up
for a
mean period of 36.1 +/- 13.8 weeks.
All adverse effects were mild and reversible and none of the patients required cessation of
therapy
.
CONCLUSION: Hydroxyurea is an effective, very safe but relatively slower acting alternative for patients with extensive
CPP
over the short-to-medium term.
[MeSH-major]
Enzyme Inhibitors /
therapeutic
use. Hydroxyurea /
therapeutic
use. Psoriasis /
drug therapy
[MeSH-minor]
Adult. Female. Humans. Male. Middle Aged. Prospective Studies. Skin Pigmentation /
drug
effects
Genetic Alliance.
consumer health - Psoriasis
.
MedlinePlus Health Information.
consumer health - Psoriasis
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
HYDROXYUREA
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 11703528.001).
[ISSN]
0011-9059
[Journal-full-title]
International journal of dermatology
[ISO-abbreviation]
Int. J. Dermatol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Enzyme Inhibitors; X6Q56QN5QC / Hydroxyurea
8.
Llena C, Forner L, Baca P:
Anticariogenicity of casein phosphopeptide-amorphous calcium phosphate: a review of the literature.
J Contemp Dent Pract
; 2009;10(3):1-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
AIM: This review of the literature examines the role of the natural components of saliva in maintaining tooth mineralization and the role of different casein phosphopeptide amorphous calcium phosphate-based (
CPP
-ACP) compounds in controlling demineralization/remineralization and their clinical applications.
BACKGROUND: A group of peptides, known as
CPP
, have been shown to stabilize calcium and phosphate preserving them in an amorphous or soluble form known as amorphous calcium phosphate (ACP).
Calcium and phosphate are essential components of enamel and dentine and form highly insoluble complexes, but in the presence
of CPP
they remain soluble and biologically available.
This
CPP
-ACP complex applied to teeth by means of chewing-gum, toothpaste, lozenges, mouth rinses, or sprays is able to adhere to the dental biofilm and enamel hydroxyapatite providing bioavailable calcium and phosphate ions.
REVIEW RESULTS: Significantly high levels of calcium and phosphate have been found in both biofilm and subsurface incipient caries lesions and in lower level demineralization of enamel or dentine surfaces previously treated
with CPP
-ACP based compounds.
When placed on the surface
of a
tooth with early carious lesions, pastes
with CPP
-ACP complexes can prevent tooth demineralization and improve enamel remineralization and enhance fluoride activity.
CLINICAL SIGNIFICANCE: Use
of CPP
-ACP based compounds offers a potential for use in the prevention of dental caries.
[MeSH-major]
Cariostatic Agents /
therapeutic
use. Caseins /
therapeutic
use. Dental Caries / prevention & control
[MeSH-minor]
Biofilms. Calcium / pharmacokinetics. Dental Enamel / metabolism. Dental Plaque / chemistry. Dentin / metabolism. Humans. Phosphates / pharmacokinetics. Saliva / physiology. Tooth Erosion / prevention & control. Tooth Remineralization / methods. Xerostomia /
drug therapy
MedlinePlus Health Information.
consumer health - Tooth Decay
.
Hazardous Substances Data Bank.
CALCIUM, ELEMENTAL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19430620.001).
[ISSN]
1526-3711
[Journal-full-title]
The journal of contemporary dental practice
[ISO-abbreviation]
J Contemp Dent Pract
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Cariostatic Agents; 0 / Caseins; 0 / Phosphates; 0 / casein phosphopeptide-amorphous calcium phosphate nanocomplex; SY7Q814VUP / Calcium
[Number-of-references]
31
9.
Lang EW, Chesnut RM:
A bedside method for investigating the integrity and critical thresholds of cerebral pressure autoregulation in severe traumatic brain injury patients.
Br J Neurosurg
; 2000 Apr;14(2):117-26
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A bedside method for investigating the integrity and critical thresholds of cerebral pressure autoregulation in severe traumatic
brain
injury patients.
To avoid ischaemic secondary insults after severe head injury (SHI) it would be helpful to know the relationship between cerebral perfusion pressure (
CPP
) and
intracranial
pressure (ICP).
Mean arterial pressure (MAP) was varied to detect changes in
intracranial
pressure (ICP) indicative of intact AR.
Three
types of
responses were observed:.
(3) MAP elevation lowers ICP; Changes between
types
1/2 and
type
3 suggests AR breakpoints.
Varying response
types
and breakpoints were observed between and within patients.
Lower AR breakpoints were seen from 60 to 80 mmHg
CPP
, upper breakpoints were as high as 112.
CPP
monitoring achieves a twofold utility in targeted
therapy
:.
Although the precise relationship between
pAR
breakpoints and the adequacy of cerebral perfusion to meet metabolic needs remains unclear, a technique such as described here is simple and has much to offer in targeting
therapy
toward specific pathophysiological processes in traumatic
brain
injury.
[MeSH-major]
Brain
Injuries / physiopathology. Homeostasis / physiology.
Intracranial
Pressure / physiology. Point-of-Care Systems
[MeSH-minor]
Adolescent. Adult. Blood Pressure /
drug
effects. Blood Pressure / physiology. Cerebrovascular Circulation /
drug
effects. Cerebrovascular Circulation / physiology. Glasgow Coma Scale. Humans. Male. Middle Aged. Phenylephrine / pharmacology. Vasoconstrictor Agents / pharmacology
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
PHENYLEPHRINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 10889883.001).
[ISSN]
0268-8697
[Journal-full-title]
British journal of neurosurgery
[ISO-abbreviation]
Br J Neurosurg
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
ENGLAND
[Chemical-registry-number]
0 / Vasoconstrictor Agents; 1WS297W6MV / Phenylephrine
10.
Chiu WT, Lin TJ, Lin JW, Huang SJ, Chang CK, Chen HY:
Multicenter evaluation of propofol for head-injured patients in Taiwan.
Surg Neurol
; 2006;66 Suppl 2:S37-42
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: The present study was a multicenter, retrospective study which aimed to evaluate the efficacy of propofol, a new choice
of pharmacotherapy
in head-injured patients.
Data on patients' demographics, laboratory data, GCS score, ICP,
CPP
, concurrent
medications
, and
therapeutic
outcomes were collected.
Mean
CPP for
the first 5 days in the ICU was 71.10 +/- 15.32 mm Hg in the propofol group and 43.20 +/- 29.92 mm Hg in the nonpropofol group (P<.001).
[MeSH-major]
Brain
Injuries /
drug therapy
.
Brain
Injuries / mortality. Hypnotics and Sedatives /
therapeutic
use. Propofol /
therapeutic
use
[MeSH-minor]
Adolescent. Adult. Aged. Child. Female. Glasgow Coma Scale. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Taiwan / epidemiology.
Treatment
Outcome
Hazardous Substances Data Bank.
PROPOFOL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17071254.001).
[ISSN]
0090-3019
[Journal-full-title]
Surgical neurology
[ISO-abbreviation]
Surg Neurol
[Language]
eng
[Publication-type]
Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Hypnotics and Sedatives; YI7VU623SF / Propofol
11.
Yang H, Liu S, Cai H, Wan L, Li S, Li Y, Cheng J, Lu X:
Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing of tumor cells by penetratin-directed mitochondria-disrupting peptides.
J Biol Chem
; 2010 Aug 13;285(33):25666-76
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing
of tumor
cells by penetratin-directed mitochondria-disrupting peptides.
The use of cell-penetrating peptides (CPPs) as
drug
carriers for targeted
therapy
is limited by the unrestricted cellular translocation of CPPs.
The preferential induction
of tumor
cell death by penetratin (Antp)-directed peptides (PNC27 and PNC28), however, suggests that
the CPP
Antp may contribute to the preferential cytotoxicity of these peptides.
The IC(50) values of PNC27 in
tumor
cells were 2-3
times
lower than in normal cells.
However, all three engineered peptides demonstrated similar cytotoxic effects in
tumor
and normal cells.
Another three chimeric peptides containing the leader peptide Antp with different mitochondria-disrupting peptides (KLA-Antp (KGA), B27-Antp (BA27), and B28-Antp (BA28)), preferentially induced apoptosis in
tumor
cells.
The IC(50) values of these peptides (3-10 microM) were 3-6
times
lower in
tumor
cells than in normal cells.
In contrast, TAT-directed peptides (TAT-KLA (TK), TAT-B27 (TB27), and TAT-B28 (TB28)), were cytotoxic to both
tumor
and normal cells.
Furthermore, Antp-directed peptides bind chondroitin sulfate (CS), and the removal of endogenous CS reduces the cytotoxic effects of Antp-directed peptides in
tumor
cells.
The overexpression of CS in
tumor
cells is positively correlated to the cell entry and cytotoxicity of Antp- directed peptides.
These results suggest that CS overexpression in
tumor
cells is an important molecular portal that mediates the preferential cytotoxicity of Antp-directed peptides.
[MeSH-major]
Apoptosis /
drug
effects. Carrier Proteins / pharmacology. Chondroitin Sulfates / pharmacology. Mitochondria /
drug
effects. Mitochondria / metabolism. Peptides / pharmacology
[MeSH-minor]
Animals. Biological Transport /
drug
effects. Cell Line. Cell Line,
Tumor
. Cell Survival /
drug
effects. Female. Glycosaminoglycans / metabolism. Glycosaminoglycans / pharmacology. HeLa Cells. Humans. Mice. Mice, Inbred BALB C. Mice, Nude.
Tumor
Suppressor Protein p53 / pharmacology.
Tumor
Suppressor Protein p53 /
therapeutic
use. Xenograft Model Antitumor Assays
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Res. 2006 Nov 1;66(21):10233-7
[
17079438.001
]
[Cites]
AAPS J. 2006;8(3):E532-51
[
17025272.001
]
[Cites]
Eur J Cancer. 2007 Jun;43(9):1460-6
[
17446061.001
]
[Cites]
Cancer Res. 2007 Jul 1;67(13):6368-75
[
17616696.001
]
[Cites]
Biochem Soc Trans. 2007 Aug;35(Pt 4):788-93
[
17635149.001
]
[Cites]
J Pharm Sci. 2008 Jan;97(1):144-62
[
17763452.001
]
[Cites]
Acc Chem Res. 2008 Jan;41(1):98-107
[
17705444.001
]
[Cites]
Bioconjug Chem. 2008 Jan;19(1):70-5
[
18001077.001
]
[Cites]
Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):580-97
[
18045730.001
]
[Cites]
Org Biomol Chem. 2008 Jul 7;6(13):2242-55
[
18563254.001
]
[Cites]
In Vivo. 2008 May-Jun;22(3):385-9
[
18610752.001
]
[Cites]
J Biol Chem. 2008 Aug 29;283(35):24274-84
[
18603532.001
]
[Cites]
Biochim Biophys Acta. 2008 Dec;1786(2):126-38
[
18440319.001
]
[Cites]
Ann Surg Oncol. 2008 Dec;15(12):3588-600
[
18931881.001
]
[Cites]
Curr Drug Discov Technol. 2008 Dec;5(4):289-301
[
19075609.001
]
[Cites]
Bioconjug Chem. 2008 Dec;19(12):2363-74
[
19053306.001
]
[Cites]
Cancer Metastasis Rev. 2009 Jun;28(1-2):233-45
[
19160015.001
]
[Cites]
J Biol Chem. 1999 Dec 3;274(49):34924-31
[
10574967.001
]
[Cites]
Curr Opin Cell Biol. 2000 Aug;12(4):400-6
[
10873818.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12438-43
[
11606716.001
]
[Cites]
Mol Cell Biol. 2002 Mar;22(6):1926-35
[
11865069.001
]
[Cites]
Cancer Res. 2002 Aug 1;62(15):4282-8
[
12154030.001
]
[Cites]
Biochem Biophys Res Commun. 2002 Nov 1;298(3):439-49
[
12413961.001
]
[Cites]
Oncogene. 2003 Mar 13;22(10):1431-44
[
12629507.001
]
[Cites]
Blood. 2003 Aug 15;102(4):1307-15
[
12738679.001
]
[Cites]
J Biol Chem. 2003 Sep 12;278(37):35109-14
[
12837762.001
]
[Cites]
Cell Mol Life Sci. 2004 Jul;61(14):1785-94
[
15241554.001
]
[Cites]
J Biol Chem. 1996 Nov 8;271(45):28375-81
[
8910461.001
]
[Cites]
Cell. 1997 Feb 7;88(3):323-31
[
9039259.001
]
[Cites]
Biochemistry. 1997 Feb 25;36(8):2104-11
[
9047309.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6079-84
[
9600920.001
]
[Cites]
Nat Med. 1999 Sep;5(9):1032-8
[
10470080.001
]
[Cites]
Int J Cancer. 2005 May 20;115(1):55-64
[
15645452.001
]
[Cites]
Biochem J. 2005 Sep 1;390(Pt 2):407-18
[
15859953.001
]
[Cites]
Cancer Res. 2005 Sep 1;65(17):7840-6
[
16140953.001
]
[Cites]
Cancer Res. 2005 Dec 1;65(23):10646-50
[
16322205.001
]
[Cites]
Mol Cancer Ther. 2006 Jan;5(1):20-8
[
16432159.001
]
[Cites]
Cancer Res. 2006 Apr 1;66(7):3764-72
[
16585203.001
]
[Cites]
Int J Cancer. 2006 Oct 1;119(7):1577-85
[
16688716.001
]
[Cites]
Mol Cancer Ther. 2006 Aug;5(8):1944-9
[
16928814.001
]
[Cites]
J Am Chem Soc. 2007 Apr 25;129(16):4961-72
[
17397150.001
]
(PMID = 20484051.001).
[ISSN]
1083-351X
[Journal-full-title]
The Journal of biological chemistry
[ISO-abbreviation]
J. Biol. Chem.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Carrier Proteins; 0 / Glycosaminoglycans; 0 / PNC-27; 0 / Peptides; 0 / Tumor Suppressor Protein p53; 0 / penetratin; 9007-28-7 / Chondroitin Sulfates
[Other-IDs]
NLM/ PMC2919130
12.
Nishiyama T, Yokoyama T, Matsukawa T, Hanaoka K:
Continuous nicardipine infusion to control blood pressure after evacuation of acute cerebral hemorrhage.
Can J Anaesth
; 2000 Dec;47(12):1196-201
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
PURPOSE: To explore the long-term effects of the calcium antagonist, nicardipine, on cerebral hemodynamics in patients with acute cerebral hemorrhage, we investigated the effects of nicardipine infusion on
intracranial
pressure (ICP), middle cerebral arterial blood flow velocity (Vmca) , and computed tomographical (CT) findings of bleeding and edema.
Blood pressure, heart rate, conscious level, Vmca, pulsatility index (PI, using transcranial Doppler), ICP, cerebral perfusion pressure (
CPP
) and platelet counts were monitored.
CT examination was also performed to detect the changes of bleeding (hematoma) and/or
brain
edema.
The CPP
decreased at 24 hr (75 +/- 14 mmHg, P = 0.026) and 72 hr (73 +/- 15 mmHg, P = 0.024) from the baseline (99 +/- 17 mmHg).
CONCLUSION: In patients with acute cerebral hemorrhage, nicardipine infusion to decrease blood pressure by 20 to 30% had no effect on Vmca, ICP, cerebral bleeding and edema, but decreased
CPP
.
[MeSH-major]
Blood Pressure /
drug
effects. Calcium Channel Blockers /
therapeutic
use. Cerebral Hemorrhage / physiopathology. Nicardipine /
therapeutic
use
[MeSH-minor]
Aged.
Brain
Edema /
drug therapy
.
Brain
Edema / physiopathology. Cerebrovascular Circulation /
drug
effects. Female. Heart Rate /
drug
effects. Humans.
Intracranial
Pressure /
drug
effects. Male. Middle Aged. Middle Cerebral Artery / physiology. Platelet Count.
Tomography
, X-Ray Computed
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 11132741.001).
[ISSN]
0832-610X
[Journal-full-title]
Canadian journal of anaesthesia = Journal canadien d'anesthésie
[ISO-abbreviation]
Can J Anaesth
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
Canada
[Chemical-registry-number]
0 / Calcium Channel Blockers; CZ5312222S / Nicardipine
13.
Udy A, Boots R, Senthuran S, Stuart J, Deans R, Lassig-Smith M, Lipman J:
Augmented creatinine clearance in traumatic brain injury.
Anesth Analg
; 2010 Dec;111(6):1505-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Augmented creatinine clearance in traumatic
brain
injury.
BACKGROUND: Hypertonic saline and/or norepinephrine infusion are routinely used to achieve a desired cerebral perfusion pressure (
CPP
) in the management of traumatic
brain
injury (TBI).
METHODS: This was an observational cohort study in TBI patients older than 16 years with normal serum creatinine concentrations, requiring maintenance
of CPP
.
Demographic data, use of vasoactive
medications
, fluid balance, feeding regimen, and hemodynamic variables were recorded throughout the study period.
The mean maximum CrCl was 179 mL/min/1.73 m(2) while receiving
CPP
therapy
(95% confidence interval [CI], 159-198), returning to a mean of 111 mL/min/1.73 m(2) (95% CI, 91-131; P < 0.001) when measured after discharge from the intensive care unit.
The mean CrCl in the intensive care unit while not receiving
CPP
therapy
was 150 mL/min/1.73 m(2) (95% CI, 134-167; P = 0.03).
The mean
time
to reach peak CrCl while receiving active
treatment
was 4.7 days (95% CI, 3.0-6.4).
CONCLUSIONS: Augmented CrCls are common in TBI patients receiving active management
of CPP
and persist even after discontinuation of such
therapy
.
Further work is needed to clarify the impact of such clearances on renally excreted
drugs
in this setting.
[MeSH-major]
Adrenergic alpha-Agonists / administration & dosage.
Brain
Injuries /
therapy
. Creatinine / urine. Fluid
Therapy
. Norepinephrine / administration & dosage
[MeSH-minor]
Adult. Biomarkers / urine. Female. Humans. Intensive Care Units.
Intracranial
Pressure /
drug
effects. Male. Queensland.
Time
Factors.
Treatment
Outcome. Up-Regulation. Young Adult
MedlinePlus Health Information.
consumer health - Creatinine
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
Norepinephrine
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21048095.001).
[ISSN]
1526-7598
[Journal-full-title]
Anesthesia and analgesia
[ISO-abbreviation]
Anesth. Analg.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Adrenergic alpha-Agonists; 0 / Biomarkers; AYI8EX34EU / Creatinine; X4W3ENH1CV / Norepinephrine
14.
Baviera M, Invernizzi RW, Carli M:
Haloperidol and clozapine have dissociable effects in a model of attentional performance deficits induced by blockade of NMDA receptors in the mPFC.
Psychopharmacology (Berl)
; 2008 Feb;196(2):269-80
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVE: The aim of this study was to compare the effects of conventional and atypical antipsychotics in a model of attentional performance deficit of schizophrenia induced by blockade
of N
-methyl-D: -aspartate (NMDA) receptors in the medial prefrontal cortex.
MATERIALS AND METHODS: Attentional performance was assessed using the five-choice serial reaction
time
task.
The task provides indices of attentional functioning (% correct responses), executive control (measured by anticipatory and perseverative responding),
decision time
(measured by correct response latency), and omissions.
Haloperidol and clozapine were given intraperitoneally (IP) to animals that had received vehicle or a competitive NMDA receptor antagonist, 3-(R)-2-carboxypiperazin-4-propyl-1-phosphonic acid (
CPP
), directly into the medial prefrontal cortex.
RESULTS: Fifty nanograms/side
of CPP
reduced accuracy (% correct responses) and increased anticipatory and perseverative responding.
Haloperidol (0.03 mg/kg IP) reduced
the CPP
-induced anticipatory and perseverative overresponding but not the impairment in accuracy.
CPP
increased
decision time
and omissions, but these effects were not affected by either haloperidol or clozapine.
[MeSH-major]
Attention /
drug
effects. Clozapine / pharmacology. Haloperidol / pharmacology. Prefrontal Cortex /
drug
effects. Schizophrenia / physiopathology
[MeSH-minor]
Analysis of Variance. Animals. Antipsychotic Agents / administration & dosage. Antipsychotic Agents / pharmacology. Behavior, Animal /
drug
effects. Dopamine Antagonists / administration & dosage. Dopamine Antagonists / pharmacology. Dose-Response Relationship,
Drug
. Injections, Intraperitoneal. Male. Microinjections. Piperazines / administration & dosage. Piperazines / toxicity. Rats. Reaction
Time
/
drug
effects. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors. Serial Learning /
drug
effects. Serotonin Antagonists / administration & dosage. Serotonin Antagonists / pharmacology
MedlinePlus Health Information.
consumer health - Schizophrenia
.
Hazardous Substances Data Bank.
HALOPERIDOL
.
Hazardous Substances Data Bank.
CLOZAPINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Neuron. 2006 Feb 16;49(4):603-15
[
16476668.001
]
[Cites]
Neuropharmacology. 1999 Aug;38(8):1185-94
[
10462131.001
]
[Cites]
Behav Neurosci. 2001 Aug;115(4):812-25
[
11508720.001
]
[Cites]
J Neurosci. 1997 Dec 1;17(23):9285-97
[
9364074.001
]
[Cites]
Psychopharmacology (Berl). 2006 Jul;187(1):73-85
[
16767417.001
]
[Cites]
Synapse. 2005 Apr;56(1):12-20
[
15700289.001
]
[Cites]
Schizophr Bull. 1999;25(2):201-22
[
10416727.001
]
[Cites]
Neuropsychopharmacology. 2001 Oct;25(4):476-88
[
11557161.001
]
[Cites]
Behav Brain Res. 1999 Apr;100(1-2):99-112
[
10212057.001
]
[Cites]
Eur J Pharmacol. 2005 Sep 5;519(1-2):114-7
[
16099452.001
]
[Cites]
Behav Neurosci. 2001 Aug;115(4):799-811
[
11508719.001
]
[Cites]
Psychopharmacology (Berl). 1998 May;137(1):33-42
[
9631954.001
]
[Cites]
Psychopharmacology (Berl). 2002 Oct;163(3-4):362-80
[
12373437.001
]
[Cites]
Behav Brain Res. 1983 Sep;9(3):361-80
[
6639741.001
]
[Cites]
Psychopharmacology (Berl). 1999 Oct;146(4):348-61
[
10550486.001
]
[Cites]
J Pharmacol Exp Ther. 1997 Nov;283(2):666-74
[
9353384.001
]
[Cites]
Psychopharmacology (Berl). 1992;106(2):228-34
[
1532259.001
]
[Cites]
Psychopharmacology (Berl). 2003 May;167(3):304-14
[
12677356.001
]
[Cites]
Neuropsychopharmacology. 2006 Sep;31(9):1854-63
[
16319908.001
]
[Cites]
Neuron. 2004 May 27;42(4):653-63
[
15157425.001
]
[Cites]
Neuropsychopharmacology. 2002 Jun;26(6):716-28
[
12007742.001
]
[Cites]
Am J Psychiatry. 1996 Mar;153(3):321-30
[
8610818.001
]
[Cites]
J Pharmacol Exp Ther. 1998 Dec;287(3):839-46
[
9864262.001
]
[Cites]
Neuroscience. 1993 Feb;52(3):595-604
[
8450961.001
]
[Cites]
Behav Brain Res. 1997 Dec;89(1-2):135-49
[
9475622.001
]
[Cites]
Brain Res. 1995 Jan 23;670(1):165-8
[
7719718.001
]
[Cites]
J Pharmacol Exp Ther. 1997 Oct;283(1):226-34
[
9336328.001
]
[Cites]
J Pharmacol Exp Ther. 1993 Sep;266(3):1374-84
[
8103793.001
]
[Cites]
Neuropsychopharmacology. 2006 Sep;31(9):1900-9
[
16421514.001
]
[Cites]
Psychopharmacology (Berl). 1987;91(4):458-66
[
3108926.001
]
[Cites]
J Neurosci. 2000 Feb 1;20(3):1208-15
[
10648725.001
]
[Cites]
Neuropsychopharmacology. 1998 Feb;18(2):63-101
[
9430133.001
]
[Cites]
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72
[
14642974.001
]
[Cites]
Psychopharmacology (Berl). 1999 Jul;145(2):193-204
[
10463321.001
]
[Cites]
Am J Psychiatry. 2004 Jun;161(6):985-95
[
15169686.001
]
[Cites]
J Neurosci. 1999 Jun 1;19(11):4585-94
[
10341256.001
]
[Cites]
Psychopharmacology (Berl). 1998 Jan;135(2):194-200
[
9497025.001
]
[Cites]
Neuropsychopharmacology. 2006 Apr;31(4):757-67
[
16192987.001
]
[Cites]
Cereb Cortex. 1996 May-Jun;6(3):470-81
[
8670672.001
]
[Cites]
J Clin Psychiatry. 1994 Sep;55 Suppl B:8-14
[
7961581.001
]
[Cites]
J Comp Neurol. 2002 Jan 21;442(4):392-404
[
11793342.001
]
[Cites]
Behav Brain Res. 2003 Jan 6;138(1):59-69
[
12493630.001
]
[Cites]
J Neural Transm Gen Sect. 1995;101(1-3):127-48
[
8695043.001
]
[Cites]
J Neurochem. 2001 Mar;76(5):1521-31
[
11238736.001
]
[Cites]
Psychopharmacology (Berl). 1993;111(3):339-44
[
7870972.001
]
[Cites]
Psychopharmacology (Berl). 2003 Nov;170(3):309-19
[
12904968.001
]
[Cites]
Psychopharmacology (Berl). 2004 Nov;176(3-4):376-85
[
15232674.001
]
[Cites]
J Pharmacol Exp Ther. 1994 Nov;271(2):787-94
[
7965797.001
]
[Cites]
Neuropsychopharmacology. 2007 Feb;32(2):273-83
[
16641946.001
]
[Cites]
Eur Neuropsychopharmacol. 1996 Nov;6(4):305-10
[
8985714.001
]
[Cites]
J Neurosci. 1996 Jan;16(1):373-9
[
8613804.001
]
[Cites]
Am J Psychiatry. 1991 Oct;148(10):1301-8
[
1654746.001
]
[Cites]
Neuropsychopharmacology. 2004 Sep;29(9):1637-47
[
15127084.001
]
[Cites]
Neuropsychopharmacology. 1996 Feb;14 (2):87-96
[
8822531.001
]
[Cites]
Schizophr Bull. 1999;25(2):233-55
[
10416729.001
]
[Cites]
Brain Res. 2002 Aug 30;947(2):157-65
[
12176156.001
]
[Cites]
Br J Psychiatry. 1993 Oct;163:451-5
[
7902766.001
]
[Cites]
Biol Psychiatry. 2001 Nov 15;50(10 ):750-7
[
11720693.001
]
[Cites]
Neuroscience. 1998 Mar;83(2):489-99
[
9460757.001
]
[Cites]
Neuropsychopharmacology. 1995 Feb;12(1):57-64
[
7766287.001
]
[Cites]
Psychopharmacology (Berl). 2005 Apr;179(1):99-107
[
15678364.001
]
[Cites]
Neuropsychopharmacology. 1994 Nov;11(3):167-77
[
7865098.001
]
[Cites]
Neurosci Lett. 1993 Apr 2;152(1-2):61-4
[
8100055.001
]
[Cites]
Cereb Cortex. 2003 Apr;13(4):400-8
[
12631569.001
]
[Cites]
Eur J Pharmacol. 1996 Aug 1;309(1):1-11
[
8864686.001
]
[Cites]
Am J Psychiatry. 2001 Feb;158(2):176-84
[
11156796.001
]
[Cites]
Psychopharmacology (Berl). 2003 Sep;169(3-4):404-11
[
12590356.001
]
[Cites]
Biol Psychiatry. 2002 Jun 15;51(12):972-8
[
12062881.001
]
[Cites]
J Neurophysiol. 2001 Feb;85(2):659-70
[
11160501.001
]
[Cites]
Schizophr Bull. 2000;26(1):119-36
[
10755673.001
]
[Cites]
J Neurosci. 2004 Jan 28;24(4):773-80
[
14749421.001
]
[Cites]
Arch Gen Psychiatry. 2000 Mar;57(3):249-58
[
10711911.001
]
[Cites]
Brain. 1993 Oct;116 ( Pt 5):1159-75
[
8221053.001
]
(PMID = 17940750.001).
[ISSN]
0033-3158
[Journal-full-title]
Psychopharmacology
[ISO-abbreviation]
Psychopharmacology (Berl.)
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antipsychotic Agents; 0 / Dopamine Antagonists; 0 / Piperazines; 0 / Receptors, N-Methyl-D-Aspartate; 0 / Serotonin Antagonists; 98Y1I8ZD4M / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; J60AR2IKIC / Clozapine; J6292F8L3D / Haloperidol
15.
Pak AC, Ashby CR Jr, Heidbreder CA, Pilla M, Gilbert J, Xi ZX, Gardner EL:
The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions.
Int J Neuropsychopharmacol
; 2006 Oct;9(5):585-602
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced
brain
reward and nicotine-paired environmental cue functions.
Increasing evidence suggests that enhanced dopamine (DA) neurotransmission in the nucleus accumbens (NAc) may play a role in mediating the reward and reinforcement produced by addictive
drugs
and in the attentional processing of
drug
-associated environmental cues.
The meso-accumbens DA system is selectively enriched with DA D3 receptors, a DA receptor
subtype
increasingly implicated in reward-related
brain
and behavioural processes.
From a variety of evidence, it has been suggested that selective DA D3 receptor antagonism may be a useful
pharmacotherapeutic
approach for treating addiction.
The present experiments tested the efficacy of SB-277011A, a selective DA D3 receptor antagonist, in rat models of nicotine-enhanced electrical
brain
-stimulation reward (BSR), nicotine-induced conditioned locomotor activity (LMA), and nicotine-induced conditioned place preference (
CPP
).
SB-277011A, given intraperitoneally within the dose range of 1-12 mg/kg, dose-dependently reduced nicotine-enhanced BSR, nicotine-induced conditioned LMA, and nicotine-induced
CPP
.
The results suggest that selective D3 receptor antagonism constitutes a new and promising
pharmacotherapeutic
approach to
the treatment
of nicotine dependence.
[MeSH-major]
Brain
/
drug
effects. Conditioning, Operant /
drug
effects. Dopamine Antagonists / pharmacology. Nicotine / pharmacology. Nicotinic Agonists / pharmacology. Nitriles / pharmacology. Reward. Tetrahydroisoquinolines / pharmacology
[MeSH-minor]
Analysis of Variance. Animals. Area Under Curve. Association Learning /
drug
effects. Behavior, Animal /
drug
effects. Cues. Dose-Response Relationship,
Drug
.
Drug
Interactions. Male. Motor Activity /
drug
effects. Rats. Rats, Long-Evans
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
NICOTINE
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Pharmacol Exp Ther. 2000 Sep;294(3):1154-65
[
10945872.001
]
[Cites]
Synapse. 1998 May;29(1):72-9
[
9552176.001
]
[Cites]
Neuropsychopharmacology. 2003 Feb;28(2):329-38
[
12589386.001
]
[Cites]
Behav Brain Res. 1998 Nov;96(1-2):185-8
[
9821554.001
]
[Cites]
Annu Rev Psychol. 1989;40:191-225
[
2648975.001
]
[Cites]
Pharmacol Biochem Behav. 1993 Oct;46(2):453-7
[
8265701.001
]
[Cites]
Psychopharmacology (Berl). 2003 Dec;170(4):409-22
[
12955296.001
]
[Cites]
Neuropsychopharmacology. 2003 Jun;28(6):1150-9
[
12700684.001
]
[Cites]
Behav Neurosci. 1987 Apr;101(2):209-14
[
3580122.001
]
[Cites]
Prog Neurobiol. 1998 Dec;56(6):613-72
[
9871940.001
]
[Cites]
Eur J Pharmacol. 2001 Aug 24;426(1-2):R1-2
[
11525784.001
]
[Cites]
Life Sci. 1996;58(25):PL365-72
[
8649214.001
]
[Cites]
Psychopharmacology (Berl). 1995 Jul;120(1):10-20
[
7480530.001
]
[Cites]
Naunyn Schmiedebergs Arch Pharmacol. 1989 Jan-Feb;339(1-2):208-13
[
2725697.001
]
[Cites]
Nature. 1996 Jul 18;382(6588):255-7
[
8717040.001
]
[Cites]
Science. 1975 Feb 14;187(4176):547-9
[
1114313.001
]
[Cites]
Synapse. 1995 Oct;21(2):140-8
[
8584975.001
]
[Cites]
Behav Pharmacol. 1995 Jun;6(4):333-347
[
11224342.001
]
[Cites]
Behav Brain Res. 2000 Aug;113(1-2):97-103
[
10942036.001
]
[Cites]
Ciba Found Symp. 1990;152:153-62; discussion 162-8
[
2209252.001
]
[Cites]
Exp Clin Psychopharmacol. 1999 Feb;7(1):72-8
[
10036612.001
]
[Cites]
Neuropharmacology. 2004;47 Suppl 1:190-201
[
15464137.001
]
[Cites]
Synapse. 2003 Mar;47(3):176-83
[
12494400.001
]
[Cites]
Neuroreport. 2003 Jan 20;14(1):93-8
[
12544838.001
]
[Cites]
Synapse. 2002 May;44(2):61-3
[
11891877.001
]
[Cites]
Eur J Pharmacol. 2000 Oct 27;407(1-2):47-51
[
11050289.001
]
[Cites]
Eur J Pharmacol. 1988 Jul 7;151(2):233-42
[
2844553.001
]
[Cites]
Respiration. 2002;69(5):381-4
[
12232442.001
]
[Cites]
Pharmacol Rev. 1997 Sep;49(3):231-52
[
9311022.001
]
[Cites]
Eur J Pharmacol. 2000 Mar 30;393(1-3):295-314
[
10771025.001
]
[Cites]
Brain Res Brain Res Rev. 2005 Jul;49(1):77-105
[
15960988.001
]
[Cites]
Eur J Pharmacol. 1987 Sep 23;141(3):395-9
[
3666033.001
]
[Cites]
J Med Chem. 2000 May 4;43(9):1878-85
[
10794704.001
]
[Cites]
Psychopharmacology (Berl). 1996 Feb;123(3):280-8
[
8833421.001
]
[Cites]
Psychiatr Med. 1985;3(4):445-60
[
2893431.001
]
[Cites]
Recent Adv Biol Psychiatry. 1961;4:288-309
[
13916635.001
]
[Cites]
Synapse. 2000 Feb;35(2):160-2
[
10611642.001
]
[Cites]
Neuropsychopharmacology. 2003 May;28(5):839-49
[
12637956.001
]
[Cites]
J Neurosci. 2002 Nov 1;22(21):9595-603
[
12417684.001
]
[Cites]
Behav Brain Res. 2003 Jul 14;143(1):65-74
[
12842297.001
]
[Cites]
Neurosci Biobehav Rev. 1989 Summer-Fall;13(2-3):123-8
[
2530477.001
]
[Cites]
Synapse. 2003 Jun 1;48(3):154-6
[
12645041.001
]
[Cites]
Neuropharmacology. 2005 Sep;49(4):525-41
[
15963538.001
]
[Cites]
Am J Addict. 2000 Fall;9(4):285-313
[
11155784.001
]
[Cites]
Nicotine Tob Res. 2002 Aug;4(3):259-66
[
12215234.001
]
[Cites]
Behav Brain Res. 1987 Oct;26(1):57-62
[
3675835.001
]
[Cites]
NIDA Res Monogr. 1994;145:191-206
[
8742814.001
]
[Cites]
Neuropsychopharmacology. 2003 Jul;28(7):1272-80
[
12700694.001
]
[Cites]
Neuropsychobiology. 2002;45(2):87-94
[
11893865.001
]
[Cites]
Synapse. 1997 May;26(1):93-4
[
9097409.001
]
[Cites]
Pharmacol Biochem Behav. 1999 Apr;62(4):659-72
[
10208371.001
]
[Cites]
Pharmacol Biochem Behav. 2005 May;81(1):190-7
[
15894078.001
]
[Cites]
Psychopharmacology (Berl). 1976 Aug 17;48(3):311-8
[
823588.001
]
[Cites]
Mol Psychiatry. 2003 Feb;8(2):225-30
[
12610655.001
]
[Cites]
Physiol Behav. 1985 Sep;35(3):395-403
[
3840902.001
]
[Cites]
Ann N Y Acad Sci. 1992 Jun 28;654:192-8
[
1632583.001
]
[Cites]
J Neurosci. 1997 Nov 1;17(21):8580-7
[
9334429.001
]
[Cites]
Synapse. 1998 Oct;30(2):181-93
[
9723788.001
]
[Cites]
Drug Discov Today. 2005 Jul 1;10(13):917-25
[
15993811.001
]
[Cites]
Br J Pharmacol. 1989 Sep;98(1):135-40
[
2804543.001
]
[Cites]
Synapse. 1999 Jan;31(1):76-86
[
10025686.001
]
[Cites]
Synapse. 2005 Jul;57(1):17-28
[
15858839.001
]
[Cites]
Psychopharmacology (Berl). 2002 Feb;160(1):56-66
[
11862374.001
]
[Cites]
Science. 1993 Jun 18;260(5115):1814-6
[
8099761.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1976-81
[
11172061.001
]
[Cites]
Curr Opin Pharmacol. 2005 Feb;5(1):107-18
[
15661634.001
]
[Cites]
Behav Pharmacol. 2003 May;14(3):191-8
[
12799520.001
]
[Cites]
J Neurosci. 2001 Aug 1;21(15):5841-6
[
11466456.001
]
[Cites]
Pharmacol Biochem Behav. 1991 Jun;39(2):465-8
[
1682950.001
]
[Cites]
Eur J Neurosci. 2005 Jun;21(12):3427-38
[
16026480.001
]
[Cites]
Psychopharmacologia. 1960 Feb 12;1:251-6
[
13834123.001
]
[Cites]
Eur J Pharmacol. 2001 Jul 20;424(2):85-90
[
11476753.001
]
[Cites]
Psychopharmacology (Berl). 2000 May;149(4):388-96
[
10867966.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4321-6
[
10760299.001
]
[Cites]
Eur J Pharmacol. 1986 Dec 16;132(2-3):337-8
[
3816984.001
]
[Cites]
Drugs Today (Barc). 2004 Apr;40(4):355-65
[
15190388.001
]
[Cites]
Psychopharmacology (Berl). 1982;78(3):204-9
[
6296898.001
]
[Cites]
Pharmacol Biochem Behav. 2001 Jan;68(1):135-45
[
11274718.001
]
[Cites]
Pharmacol Biochem Behav. 1992 Apr;41(4):755-9
[
1594644.001
]
[Cites]
Nature. 1999 Jul 22;400(6742):371-5
[
10432116.001
]
[Cites]
Addiction. 2000 Aug;95(8):1173-83
[
11092065.001
]
[Cites]
J Med Chem. 2005 Jun 2;48(11):3663-79
[
15916415.001
]
[Cites]
Pharmacol Biochem Behav. 1994 Aug;48(4):853-62
[
7972288.001
]
[Cites]
Pharmacol Biochem Behav. 1997 Aug;57(4):915-21
[
9259024.001
]
[Cites]
Neuropsychopharmacology. 2003 Nov;28(11):1903-15
[
12915863.001
]
[Cites]
Nat Med. 2003 Jun;9(6):762-7
[
12740572.001
]
[Cites]
Psychopharmacology (Berl). 2005 May;179(3):567-75
[
15619116.001
]
[Cites]
Behav Neurosci. 1993 Feb;107(1):161-5
[
8095392.001
]
[Cites]
Psychopharmacology (Berl). 2005 Apr;178(4):481-92
[
15765262.001
]
[Cites]
Psychopharmacology (Berl). 2004 Oct;176(1):57-65
[
15083257.001
]
[Cites]
Brain Res. 1994 Aug 8;653(1-2):278-84
[
7982062.001
]
[Cites]
Neuroreport. 1997 Jul 7;8(9-10):2373-7
[
9243643.001
]
[Cites]
Neuropsychopharmacology. 2005 Apr;30(4):720-30
[
15562293.001
]
[Cites]
Psychopharmacology (Berl). 1992;107(2-3):285-9
[
1615127.001
]
[Cites]
Trends Pharmacol Sci. 1991 Dec;12(12):467-73
[
1792691.001
]
[Cites]
Psychopharmacology (Berl). 1997 Nov;134(2):187-92
[
9399383.001
]
[Cites]
J Pharmacol Exp Ther. 1994 Oct;271(1):294-301
[
7965727.001
]
[Cites]
Can J Psychol. 1977 Dec;31(4):195-203
[
608135.001
]
(PMID = 16942635.001).
[ISSN]
1461-1457
[Journal-full-title]
The international journal of neuropsychopharmacology
[ISO-abbreviation]
Int. J. Neuropsychopharmacol.
[Language]
eng
[Grant]
United States / Intramural NIH HHS / / Z99 DA999999
[Publication-type]
Comparative Study; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Dopamine Antagonists; 0 / Nicotinic Agonists; 0 / Nitriles; 0 / SB 277011; 0 / Tetrahydroisoquinolines; 6M3C89ZY6R / Nicotine
[Other-IDs]
NLM/ NIHMS493706; NLM/ PMC3732043
16.
Concolino D, Muzzi G, Pisaturo L, Piccirillo A, Di Natale P, Strisciuglio P:
Precocious puberty in Sanfilippo IIIA disease: diagnosis and follow-up of two new cases.
Eur J Med Genet
; 2008 Sep-Oct;51(5):466-71
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Precocious puberty in Sanfilippo IIIA
disease
:
diagnosis
and follow-up of two new cases.
We observed two children affected by MPS IIIA with central precocious puberty (
CPP
) both treated with GnRH agonists.
The occurrence
of CPP
in both patients with MPS IIIA suggests that it is necessary to look for an association between the two conditions.
The follow-up of our two patients leads us to believe also that GnRH agonist
treatment
can have a beneficial effect on final height and probably on the improvement of behavioural problems.
[MeSH-major]
Mucopolysaccharidosis III / complications. Mucopolysaccharidosis III /
diagnosis
. Mutation. Puberty, Precocious / complications
[MeSH-minor]
Adolescent. Body Height /
drug
effects.
Brain
/ pathology. Child. Child Behavior Disorders / complications. Child Behavior Disorders /
drug therapy
. DNA Mutational Analysis. Gonadotropin-Releasing Hormone / agonists. Humans. Luteolytic Agents /
therapeutic
use. Magnetic Resonance Imaging / methods. Male. Triptorelin Pamoate /
therapeutic
use
Genetic Alliance.
consumer health - Precocious puberty
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18586597.001).
[ISSN]
1769-7212
[Journal-full-title]
European journal of medical genetics
[ISO-abbreviation]
Eur J Med Genet
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Luteolytic Agents; 33515-09-2 / Gonadotropin-Releasing Hormone; 57773-63-4 / Triptorelin Pamoate
17.
Maffeis C, Franceschi R, Moghetti P, Camilot M, Lauriola S, Tatò L:
Circulating ghrelin levels in girls with central precocious puberty are reduced during treatment with LHRH analog.
Eur J Endocrinol
; 2007 Jan;156(1):99-103
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Circulating ghrelin levels in girls with central precocious puberty are reduced during
treatment with
LHRH analog.
No data are available for girls with central precocious puberty (
CPP
).
AIMS: To explore ghrelin changes before, during, and after GnRH analog
treatment
in girls
with CPP
.
SUBJECTS AND METHODS: A sample of 20 Caucasian girls (8.08 +/- 0.65 years of age)
with CPP
was recruited.
Height and weight, bone age, LH, FSH, 17beta estradiol (E(2)), and ghrelin were measured before starting
treatment with
GnRH analog, 18 months after
therapy
began and again 6 months after
therapy
discontinuation.
RESULTS: LH and E(2) serum levels decreased significantly during
treatment
(2.45 +/- 2.03 vs 0.67 +/- 0.49 UI/l, P < 0.01 and 28.17 +/- 9.7 vs 15 pmol/l, P < 0.01 respectively), returning to baseline levels after the discontinuation of
therapy
(4.75 +/- 1.66 UI/l and 29.23 +/- 6.99 pmol/l respectively).
LH peaked following LHRH stimulation significantly (P < 0.01) decreased during
treatment
(24.45 +/- 14.17 vs 1.3 +/- 0.18 UI/l) and then increased after
therapy
discontinuation (12.58 +/- 6.09, P < 0.01).
Ghrelin decreased significantly (P < 0.05) during
treatment
(1849 +/- 322 vs 1207 +/- 637 pg/ml), and increased, though not significantly (P = 0.09) after
therapy
withdrawal (1567 +/- 629 pg/ml).
CONCLUSIONS: Contrary to what is expected in physiologic puberty, where ghrelin is progressively reduced, the prepubertal hormone milieau induced by GnRHa
treatment
in patients suffering from central precocious puberty (
CPP
) did not promote an increase in ghrelin circulating levels.
Therefore, in
CPP
, ghrelin secretion seems to be independent from pubertal development per
se
.
Concomitant estrogen suppression during
treatment
may play a potential role in the regulation of ghrelin secretion in these girls.
Genetic Alliance.
consumer health - Precocious puberty
.
Genetic Alliance.
consumer health - Central precocious puberty
.
Hazardous Substances Data Bank.
ESTRADIOL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17218731.001).
[ISSN]
0804-4643
[Journal-full-title]
European journal of endocrinology
[ISO-abbreviation]
Eur. J. Endocrinol.
[Language]
ENG
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Ghrelin; 0 / Gonadal Steroid Hormones; 0 / Peptide Hormones; 33515-09-2 / Gonadotropin-Releasing Hormone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone
18.
Fishbain DA, Lewis JE, Cole B, Cutler B, Rosomoff HL, Rosomoff RS:
Lidocaine 5% patch: an open-label naturalistic chronic pain treatment trial and prediction of response.
Pain Med
; 2006 Mar-Apr;7(2):135-42
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Lidocaine 5% patch: an open-label naturalistic chronic pain
treatment
trial and prediction of response.
OBJECTIVE: There have been a few open-label nonplacebo reports on the successful use of lidocaine 5% patch (L5P) for other
types of
pain besides postherpetic neuralgia, such as chronic low back pain.
The purpose of this report was to describe the results
of a
retrospective review of this open-label naturalistic L5P chronic pain
treatment
trial and to attempt to delineate predictors of perceived clinical response.
DESIGN: Consecutive CPPs were selected for this clinical trial according to the following inclusion criteria: the CPPs with pain greater than 6-month duration and either a hyperalgesic pain area or trigger point, which could be covered by one L5P, were offered a 3-day L5P naturalistic
treatment
trial.
The senior author also completed a baseline information tool on each
CPP
entering this naturalistic trial.
The apparent
CPP
perceived clinical improvement was not associated with any particular useful clinical indicator.
As such, at present, no variable can be recommended for use in selecting CPPs for such a naturalistic L5P clinical
treatment
trial.
[MeSH-major]
Lidocaine / administration & dosage. Pain, Intractable /
drug therapy
[MeSH-minor]
Administration, Cutaneous. Adult. Aged. Aged, 80 and over. Anesthetics, Local / administration & dosage. Chronic
Disease
/
drug therapy
. Female. Humans. Logistic Models. Male. Middle Aged. Pain Clinics. Pain Measurement. Pain Threshold /
drug
effects. Pain Threshold / physiology. Predictive Value of Tests. Retrospective Studies.
Treatment
Outcome
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
LIDOCAINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16634726.001).
[ISSN]
1526-2375
[Journal-full-title]
Pain medicine (Malden, Mass.)
[ISO-abbreviation]
Pain Med
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Anesthetics, Local; 98PI200987 / Lidocaine
19.
Hu L, Chu NN, Sun LL, Zhang R, Han JS, Cui CL:
Electroacupuncture treatment reverses morphine-induced physiological changes in dopaminergic neurons within the ventral tegmental area.
Addict Biol
; 2009 Sep;14(4):431-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Electroacupuncture
treatment
reverses morphine-induced physiological changes in dopaminergic neurons within the ventral tegmental area.
These transient morphological changes are accompanied by a reduced sensitivity of morphine-induced conditioned place preference (
CPP
) after chronic exposure to the
drug
.
In this study we examined alterations in the firing rate of DAergic neurons by means of extracellular recording following chronic morphine exposure and applied 100 Hz electroacupuncture (EA)
treatment
to reverse the reduced firing rate of these neurons.
In the first set of experiments we show that in rats, which received chronic morphine
treatment for
14 days, a small dose of morphine was not able to induce
a CPP
response anymore.
However, the sensitivity to morphine was reinstated by consecutive EA
treatment for
10 days.
Our findings suggest that 100 Hz EA is a potential
therapy
for the
treatment of
opiate addiction by normalizing the activity of VTA DA neurons.
[MeSH-major]
Analgesics, Opioid / pharmacology. Dopamine / metabolism. Electroacupuncture / methods. Morphine / pharmacology. Neurons /
drug
effects. Neurons / metabolism. Ventral Tegmental Area /
drug
effects. Ventral Tegmental Area / metabolism
[MeSH-minor]
Animals. Choice Behavior.
Drug
Administration Schedule. Male. Rats. Rats, Sprague-Dawley. Substantia Nigra /
drug
effects. Substantia Nigra / metabolism
Hazardous Substances Data Bank.
DOPAMINE
.
Hazardous Substances Data Bank.
MORPHINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19489751.001).
[ISSN]
1369-1600
[Journal-full-title]
Addiction biology
[ISO-abbreviation]
Addict Biol
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Analgesics, Opioid; 76I7G6D29C / Morphine; VTD58H1Z2X / Dopamine
20.
Nanobashvili A, Woldbye DP, Husum H, Bolwig TG, Kokaia M:
Neuropeptide Y Y5 receptors suppress in vitro spontaneous epileptiform bursting in the rat hippocampus.
Neuroreport
; 2004 Feb 9;15(2):339-43
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In the present study, using the new highly selective Y5 receptor antagonist, CGP71683A, and agonist, [
cPP
]hPP, we show that the Y5 receptor
subtype
is centrally involved in NPY-induced suppression of spontaneous epileptiform (interictaform) bursting in the CA3 area of rat hippocampal slices.
This novel
finding
underscores the importance of Y5 receptors as a potential target for future antiepileptic
therapy
, particularly, for interictal components of temporal lobe epilepsy.
[MeSH-minor]
Action Potentials /
drug
effects. Action Potentials / physiology. Animals. Anticonvulsants / pharmacology. Female. In Vitro Techniques. Magnesium Deficiency / metabolism. Male. Naphthalenes / pharmacology. Neurons /
drug
effects. Neurons / metabolism. Pyrimidines / pharmacology. Rats. Rats, Wistar
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15076765.001).
[ISSN]
0959-4965
[Journal-full-title]
Neuroreport
[ISO-abbreviation]
Neuroreport
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Anticonvulsants; 0 / CGP 71683 A; 0 / Naphthalenes; 0 / Neuropeptide Y; 0 / Pyrimidines; 0 / Receptors, Neuropeptide Y; 0 / neuropeptide Y5 receptor
21.
Abekawa T, Ito K, Koyama T:
Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex.
Naunyn Schmiedebergs Arch Pharmacol
; 2006 Dec;374(3):177-93
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Clozapine (CLZ) can improve both the positive and negative symptoms
of treatment
-resistant schizophrenia (TRS), which does not respond to typical antipsychotics.
This suggests that elucidation of the
pharmacological
mechanism for CLZ could lead to further clarification of the pathophysiology of TRS.
This study examined the effects of CLZ on phencyclidine (PCP)-induced hyperlocomotion and on the acute increases in glutamate levels that occur in the medial prefrontal cortex (mPFC) in order to test the hypothesis that CLZ effect is associated with the simultaneous enhancement
of N
-methyl-D: -aspartate (NMDA) and dopamine D(1) receptor-mediated neurotransmission.
CLZ also blocked, in a dose-related manner, acute increases in glutamate levels in the mPFC that were induced by local perfusion
with a
competitive NMDA receptor antagonist,
CPP
, in this region.
Although an enhanced blocking effect of the sub-threshold concentration of NMDA perfusion on PCP-induced acute increases in glutamate levels in the mPFC was noted after co-perfusion
with a
dopamine D(1) receptor agonist, SKF-38393, perfusion with SKF-38393 did not reverse the CLZ blocking of PCP-induced increases in glutamate levels.
[MeSH-major]
Antipsychotic Agents / pharmacology. Behavior, Animal /
drug
effects. Clozapine / pharmacology. Glutamic Acid / metabolism. Receptors, Dopamine D1 /
drug
effects. Receptors, N-Methyl-D-Aspartate /
drug
effects
[MeSH-minor]
Analysis of Variance. Animals. Dose-Response Relationship,
Drug
.
Drug
Resistance. Haloperidol / pharmacology. Humans. Male. Microdialysis. Motor Activity /
drug
effects. Phencyclidine. Prefrontal Cortex / metabolism. Rats. Rats, Sprague-Dawley. Schizophrenia /
drug therapy
. Schizophrenia / physiopathology
Hazardous Substances Data Bank.
GLUTAMIC ACID HYDROCHLORIDE
.
Hazardous Substances Data Bank.
HALOPERIDOL
.
Hazardous Substances Data Bank.
CLOZAPINE
.
Hazardous Substances Data Bank.
PHENCYCLIDINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Neurosci. 1998 Jul 15;18(14):5545-54
[
9651235.001
]
[Cites]
Arch Gen Psychiatry. 1988 Sep;45(9):789-96
[
3046553.001
]
[Cites]
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):173-80
[
14687871.001
]
[Cites]
Psychopharmacology (Berl). 2003 Sep;169(3-4):215-33
[
12955285.001
]
[Cites]
Science. 1998 Aug 28;281(5381):1349-52
[
9721099.001
]
[Cites]
J Neurosci. 2003 Feb 1;23(3):867-75
[
12574415.001
]
[Cites]
J Neurochem. 1998 Jan;70(1):198-209
[
9422363.001
]
[Cites]
Neuropsychopharmacology. 1996 May;14(5):301-7
[
8703299.001
]
[Cites]
Brain Res Bull. 2002 Mar 15;57(5):623-30
[
11927365.001
]
[Cites]
Pharmacol Toxicol. 1999 May;84(5):193-6
[
10361974.001
]
[Cites]
Eur J Pharmacol. 1979 Nov 16;59(3-4):169-79
[
575093.001
]
[Cites]
J Comp Neurol. 1992 Feb 15;316(3):314-47
[
1577988.001
]
[Cites]
NIDA Res Monogr. 1978 Aug;(21):241-53
[
101872.001
]
[Cites]
Brain Res. 2000 Jun 9;867(1-2):250-4
[
10837822.001
]
[Cites]
Arch Gen Psychiatry. 1994 Mar;51(3):199-214
[
8122957.001
]
[Cites]
Eur J Pharmacol. 1976 Nov;40(1):45-56
[
1033072.001
]
[Cites]
J Pharmacol Exp Ther. 1997 Oct;283(1):226-34
[
9336328.001
]
[Cites]
Eur J Neurosci. 2003 Mar;17(6):1306-12
[
12670320.001
]
[Cites]
J Neurophysiol. 2002 May;87(5):2324-36
[
11976371.001
]
[Cites]
J Pharmacol Exp Ther. 2005 May;313(2):594-603
[
15659539.001
]
[Cites]
Synapse. 1997 Nov;27(3):242-61
[
9329159.001
]
[Cites]
J Pharmacol Exp Ther. 2000 Feb;292(2):731-6
[
10640312.001
]
[Cites]
J Clin Psychiatry. 1994 Sep;55 Suppl B:8-14
[
7961581.001
]
[Cites]
Am J Psychiatry. 2002 Feb;159(2):255-62
[
11823268.001
]
[Cites]
Br J Pharmacol. 1998 May;124(2):377-85
[
9641556.001
]
[Cites]
Psychopharmacology (Berl). 1998 Jul;138(1):89-95
[
9694531.001
]
[Cites]
Neuropsychopharmacology. 1998 Mar;18(3):197-209
[
9471117.001
]
[Cites]
Biol Psychiatry. 1997 Oct 15;42(8):664-8
[
9325559.001
]
[Cites]
Am J Psychiatry. 1991 Oct;148(10):1301-8
[
1654746.001
]
[Cites]
Psychopharmacology (Berl). 2003 Sep;169(3-4):247-56
[
12898123.001
]
[Cites]
J Neurochem. 2004 Oct;91(1):189-99
[
15379899.001
]
[Cites]
Biol Psychiatry. 2001 Nov 15;50(10 ):750-7
[
11720693.001
]
[Cites]
Cereb Cortex. 2001 May;11(5):452-62
[
11313297.001
]
[Cites]
J Neurosci Methods. 1995 Mar;57(1):93-9
[
7791370.001
]
[Cites]
Neuroscience. 1981;6(5):863-73
[
6113562.001
]
[Cites]
J Pharmacol Exp Ther. 1993 May;265(2):498-508
[
7684443.001
]
[Cites]
Neuropsychopharmacology. 1995 Aug;13(1):9-19
[
8526975.001
]
[Cites]
Synapse. 2003 May;48(2):66-79
[
12619040.001
]
[Cites]
Eur J Pharmacol. 1998 Jan 2;341(1):45-56
[
9489855.001
]
(PMID = 17103144.001).
[ISSN]
0028-1298
[Journal-full-title]
Naunyn-Schmiedeberg's archives of pharmacology
[ISO-abbreviation]
Naunyn Schmiedebergs Arch. Pharmacol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antipsychotic Agents; 0 / Receptors, Dopamine D1; 0 / Receptors, N-Methyl-D-Aspartate; 3KX376GY7L / Glutamic Acid; J1DOI7UV76 / Phencyclidine; J60AR2IKIC / Clozapine; J6292F8L3D / Haloperidol
22.
Turk DC, Swanson KS, Gatchel RJ:
Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis.
Clin J Pain
; 2008 Jul-Aug;24(6):497-508
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
However, a minority may develop aberrant
drug
behaviors.
OBJECTIVE: To synthesize the evidence of published strategies for identifying at-risk patients to guide clinicians' decisions and practices for prescribing opioid
treatment for
chronic pain patients (
CPP
).
Studies were limited to human studies in the English language related to screening for predictors of aberrant
drug
behaviors in
CPP
who were prescribed long-term opioids.
We included studies reviewing, developing measures, or investigating outcomes related to screening for aberrant opioid behaviors in
CPP
.
RESULTS: We identified 6 published articles addressing clinician-based predictors of substance misuse of opioids and 9 published studies evaluating the predictive ability of clinical interviews and self-report measures for aberrant opioid behaviors in
CPP
.
CONCLUSION: Review of the published studies reveals that no one
procedure
or set of predictor variables is sufficient to identify
CPP
at-risk for opioid misuse or abuse.
Strong predictors include a personal history of illicit
drug
and alcohol abuse.
Prospective studies, especially ones
with CPP
who have not already been started on chronic opioid
therapy
, are needed.
[MeSH-major]
Analgesics, Opioid / adverse effects. Opioid-Related Disorders / etiology. Pain /
drug therapy
[MeSH-minor]
Chronic
Disease
. Humans. MEDLINE / statistics & numerical data. Predictive Value of Tests
MedlinePlus Health Information.
consumer health - Pain
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18574359.001).
[ISSN]
1536-5409
[Journal-full-title]
The Clinical journal of pain
[ISO-abbreviation]
Clin J Pain
[Language]
eng
[Grant]
United States / NIGMS NIH HHS / GM / 5K23GM071400-03
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Analgesics, Opioid
[Number-of-references]
64
23.
Belfort MA:
Is high cerebral perfusion pressure and cerebral flow predictive of impending seizures in preeclampsia? A case report.
Hypertens Pregnancy
; 2005;24(1):59-63
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Transcranial Doppler ultrasound was used to demonstrate elevated estimated cerebral perfusion pressure (
CPP
) and cerebral flow index (CFI) in a preeclamptic patient.
She subsequently
developed
eclampsia.
After magnesium sulfate
therapy
her
CPP
and CFI were within the normal range and she did not experience further seizures.
This
finding
suggests that cerebral overperfusion may be at least one of the etiologies involved in the pathogenesis of eclampsia.
[MeSH-major]
Intracranial
Hypertension / ultrasonography. Pre-Eclampsia / ultrasonography. Pregnancy Outcome. Seizures /
diagnosis
. Ultrasonography, Doppler, Transcranial
[MeSH-minor]
Adult. Blood Flow Velocity. Cerebrovascular Circulation / physiology. Eclampsia /
diagnosis
. Eclampsia /
drug therapy
. Female. Humans. Magnesium Sulfate /
therapeutic
use. Parity. Predictive Value of Tests. Pregnancy. Pregnancy Trimester, Third. Risk Assessment
Genetic Alliance.
consumer health - Preeclampsia
.
Genetic Alliance.
consumer health - Seizures
.
MedlinePlus Health Information.
consumer health - Seizures
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
MAGNESIUM SULFATE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16036391.001).
[ISSN]
1064-1955
[Journal-full-title]
Hypertension in pregnancy
[ISO-abbreviation]
Hypertens Pregnancy
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
7487-88-9 / Magnesium Sulfate
24.
Valencak J, Dietrich W, Raderer M, Dieckmann K, Prayer D, Hainfellner JA, Marosi C:
Evidence of therapeutic efficacy of CCNU in recurrent choroid plexus papilloma.
J Neurooncol
; 2000 Sep;49(3):263-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Evidence
of therapeutic
efficacy of CCNU in recurrent
choroid plexus
papilloma
.
A pregnant 33-year old woman
developed
nystagmus and cerebellar ataxia.
A tumor
in the roof of the fourth ventricle was diagnosed.
The tumor
was subtotally removed using microneurosurgical techniques.
The histopathological
diagnosis
was
choroid plexus
papilloma
(
CPP
).
Twenty-one months later,
the tumor
recurred and was reoperated.
Histologically
the tumor
displayed now increased mitotic activity and pleomorphism.
Radiation
therapy
of the neuroaxis was performed.
Within 59 months,
the CPP
recurred 3 more
times with
neuroradiological evidence of extensive spinal seeding.
After several palliative irradiations, including 2 gamma-knife boosts, the patient was referred to
chemotherapy
.
The course
of disease
in our patient provides evidence
for therapeutic
efficacy of CCNU in recurrent
CPP
.
[MeSH-major]
Antineoplastic Agents, Alkylating /
therapeutic
use.
Choroid Plexus
Neoplasms /
drug therapy
. Lomustine /
therapeutic
use.
Papilloma
/
drug therapy
. Pregnancy Complications, Neoplastic /
drug therapy
[MeSH-minor]
Adult. Combined Modality
Therapy
. Female. Humans. Magnetic Resonance Imaging.
Neoplasm
Recurrence, Local.
Neoplasm
Seeding. Pregnancy. Reoperation
Genetic Alliance.
consumer health - Choroid Plexus Papilloma
.
MedlinePlus Health Information.
consumer health - Tumors and Pregnancy
.
Hazardous Substances Data Bank.
LOMUSTINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int Rev Cytol. 1980;65:117-91
[
6248480.001
]
[Cites]
J Comput Assist Tomogr. 1979 Aug;3(4):530-2
[
457968.001
]
[Cites]
Lancet. 1999 Jun 19;353(9170):2126
[
10382700.001
]
[Cites]
J Neurosurg. 1982 May;56(5):722-7
[
7069487.001
]
[Cites]
J Neurooncol. 1985;3(3):259-62
[
2414413.001
]
[Cites]
J Clin Oncol. 1987 Aug;5(8):1221-31
[
3040919.001
]
[Cites]
Surg Neurol. 1991 Jul;36(1):54-8
[
2053075.001
]
[Cites]
J Neurosurg. 1987 Jun;66(6):800-5
[
3572508.001
]
[Cites]
Surg Neurol. 1984 Nov;22(5):472-6
[
6495155.001
]
[Cites]
Acta Neurochir (Wien). 1996;138(7):802-10
[
8869707.001
]
[Cites]
J Neurosurg. 1977 Sep;47(3):442-50
[
894346.001
]
[Cites]
Klin Padiatr. 1995 Mar-Apr;207(2):52-8
[
7752600.001
]
[Cites]
J Neurosurg. 1960 Nov;17:1002-27
[
13768200.001
]
[Cites]
Brain. 1967 Mar;90(1):177-86
[
6023072.001
]
[Cites]
Cancer. 1983 Feb 1;51(3):470-5
[
6821827.001
]
[Cites]
J Neurosurg. 1980 Feb;52(2):251-5
[
7351566.001
]
[Cites]
J Neurosurg. 1988 Dec;69(6):843-9
[
3193190.001
]
[Cites]
Acta Cytol. 1985 Sep-Oct;29(5):846-9
[
3863432.001
]
[Cites]
J Neurooncol. 1992 Jan;12 (1):69-74
[
1541980.001
]
[Cites]
Zentralbl Allg Pathol. 1959 Nov 30;100:136-42
[
13818457.001
]
[Cites]
Histopathology. 1996 Aug;29(2):147-51
[
8872148.001
]
[Cites]
Pediatr Neurosci. 1988;14(3):134-9
[
3075286.001
]
(PMID = 11212906.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 7BRF0Z81KG / Lomustine
[Number-of-references]
30
25.
Crookes BA, Cohn SM, Bonet H, Burton EA, Nelson J, Majetschak M, Varon AJ, Linden JM, Proctor KG:
Building a better fluid for emergency resuscitation of traumatic brain injury.
J Trauma
; 2004 Sep;57(3):547-54
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Building a better fluid for emergency resuscitation of traumatic
brain
injury.
Three series of experiments were designed to evaluate
the therapeutic
potential of HEX+/-ATL-146e for emergency resuscitation from traumatic
brain
injury (TBI) + hemorrhagic hypotension.
In Series 1, resuscitation consisted of unlimited crystalloid (n = 8) or HEX (n = 8) to correct systolic arterial pressure >100 mm Hg and heart rate <100 bpm for the first 60 minutes ("emergency phase"), and then maintain cerebral perfusion pressure (
CPP
) > 70 mm Hg for 60-240 minutes.
In Series 2 (n = 31), resuscitation consisted
of a
1 L bolus of HEX + ATL-146e (10 ng/kg/min, n = 10) or HEX +placebo (n = 10) followed by crystalloid to the same endpoints.
Upon resuscitation, these values corrected but
intracranial
pressure progressively rose from <5 mm Hg to 15-20 mm Hg.
Series 1: With HEX (n = 8) versus crystalloid (n = 8),
CPP
was less labile, acid/base was maintained, and the fluid requirement was reduced by 60% (all p < 0.05) Series 2: With ATL-146e (n = 10) versus placebo (n = 10), stroke volume and cardiac output were improved by 40-60%, and the fluid requirement was reduced by 30% (all p < 0.05).
An adenosine A2A agonist combined with 1
L of
HEX safely and effectively counteracted a decrease in cardiac performance noted after TBI+hemorrhage without causing hypotension or bradycardia.
[MeSH-major]
Brain
Injuries /
therapy
. Cyclohexanecarboxylic Acids /
therapeutic
use. Hydroxyethyl Starch Derivatives /
therapeutic
use. Plasma Substitutes /
therapeutic
use. Purines /
therapeutic
use. Resuscitation / methods
[MeSH-minor]
Animals. Blood Pressure /
drug
effects. Cardiac Output /
drug
effects. Female. Male. Shock, Hemorrhagic /
therapy
. Stroke Volume /
drug
effects. Swine
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15454801.001).
[ISSN]
0022-5282
[Journal-full-title]
The Journal of trauma
[ISO-abbreviation]
J Trauma
[Language]
eng
[Publication-type]
Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / ATL 146e; 0 / Cyclohexanecarboxylic Acids; 0 / Hydroxyethyl Starch Derivatives; 0 / Plasma Substitutes; 0 / Purines
26.
Said Hassane F, Saleh AF, Abes R, Gait MJ, Lebleu B:
Cell penetrating peptides: overview and applications to the delivery of oligonucleotides.
Cell Mol Life Sci
; 2010 Mar;67(5):715-26
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Cell penetrating peptides (
CPP
), also named protein transduction domains, comprise short and usually basic amino acids-rich peptides originating from proteins able to cross biological barriers, such as the viral Tat protein, or are rationally designed.
They have emerged as a new class of non-viral vectors allowing the delivery of various biomolecules across biological barriers from low molecular weight
drugs
to nanosized particles.
Encouraging data
with CPP
-conjugated oligonucleotides have been obtained both in vitro and in vivo in animal models
of diseases
such as Duchenne muscular dystrophy.
Whether
CPP
-cargo conjugates enter cells by direct translocation across the plasma membrane or by endocytosis remains controversial.
[MeSH-major]
Cells / metabolism.
Drug
Delivery Systems. Oligonucleotides / administration & dosage. Peptides / pharmacokinetics
[MeSH-minor]
Animals. Cell Membrane Permeability /
drug
effects. Gene Transfer Techniques. Humans. Muscular Dystrophy, Duchenne /
therapy
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Curr Protein Pept Sci. 2003 Apr;4(2):133-40
[
12678852.001
]
[Cites]
FEBS Lett. 2007 Feb 20;581(4):702-6
[
17274989.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17867-72
[
15601762.001
]
[Cites]
J Biol Chem. 2003 Sep 5;278(36):34141-9
[
12773529.001
]
[Cites]
Cardiovasc Res. 2007 Mar 1;73(4):699-709
[
17234167.001
]
[Cites]
Org Lett. 2003 Sep 18;5(19):3459-62
[
12967299.001
]
[Cites]
Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):452-72
[
18164781.001
]
[Cites]
Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):499-516
[
18093693.001
]
[Cites]
Biochemistry. 1998 May 5;37(18):6235-9
[
9572837.001
]
[Cites]
Biochim Biophys Acta. 2004 Oct 11;1665(1-2):48-56
[
15471570.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14814-9
[
18806224.001
]
[Cites]
J Biol Chem. 1994 Apr 8;269(14):10444-50
[
8144628.001
]
[Cites]
Eur J Biochem. 2001 Mar;268(5):1304-14
[
11231282.001
]
[Cites]
J Control Release. 2005 Jan 20;102(1):247-53
[
15653149.001
]
[Cites]
J Biol Chem. 2005 Apr 15;280(15):15300-6
[
15687490.001
]
[Cites]
Bioconjug Chem. 2000 May-Jun;11(3):301-5
[
10821645.001
]
[Cites]
Bioconjug Chem. 1999 Mar-Apr;10(2):186-91
[
10077466.001
]
[Cites]
Biochem Soc Trans. 2007 Aug;35(Pt 4):821-5
[
17635156.001
]
[Cites]
FASEB J. 1998 Jan;12(1):67-77
[
9438412.001
]
[Cites]
J Biol Chem. 2001 Jul 13;276(28):26204-10
[
11346640.001
]
[Cites]
Biochim Biophys Acta. 2001 Dec 1;1515(2):101-9
[
11718666.001
]
[Cites]
Hum Mol Genet. 2009 Nov 15;18(22):4405-14
[
19692354.001
]
[Cites]
Nucleic Acids Res. 2001 Oct 1;29(19):3965-74
[
11574678.001
]
[Cites]
J Pharm Sci. 2008 Jan;97(1):144-62
[
17763452.001
]
[Cites]
J Control Release. 2008 Nov 24;132(1):21-5
[
18727945.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):42-7
[
11120883.001
]
[Cites]
Biochem J. 2002 Nov 1;367(Pt 3):761-9
[
12137567.001
]
[Cites]
J Biol Chem. 2003 Dec 12;278(50):50188-94
[
14517218.001
]
[Cites]
Nucleic Acids Res. 1997 Jul 15;25(14):2730-6
[
9207018.001
]
[Cites]
J Virol. 2007 Jun;81(11):5637-48
[
17344287.001
]
[Cites]
Nat Med. 2004 Mar;10(3):310-5
[
14770178.001
]
[Cites]
Lancet Neurol. 2009 Oct;8(10):918-28
[
19713152.001
]
[Cites]
Curr Opin Mol Ther. 2001 Apr;3(2):147-52
[
11338927.001
]
[Cites]
Nucleic Acids Res. 2008 Nov;36(20):6343-54
[
18796528.001
]
[Cites]
J Biol Chem. 2003 Sep 12;278(37):35109-14
[
12837762.001
]
[Cites]
Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):664-8
[
8290579.001
]
[Cites]
Oligonucleotides. 2006 Summer;16(2):145-57
[
16764538.001
]
[Cites]
Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):608-13
[
18037528.001
]
[Cites]
J Biol Chem. 1997 Jun 20;272(25):16010-7
[
9188504.001
]
[Cites]
Trends Neurosci. 2007 Jun;30(6):260-7
[
17418905.001
]
[Cites]
Science. 1999 Sep 3;285(5433):1569-72
[
10477521.001
]
[Cites]
Adv Drug Deliv Rev. 2008 Aug 17;60(11):1241-51
[
18508157.001
]
[Cites]
Nat Med. 2006 Feb;12(2):175-7
[
16444267.001
]
[Cites]
Nat Biotechnol. 2009 Jun;27(6):567-71
[
19448630.001
]
[Cites]
Bioconjug Chem. 2000 Nov-Dec;11(6):762-71
[
11087323.001
]
[Cites]
J Control Release. 2009 Mar 19;134(3):221-7
[
19105971.001
]
[Cites]
Adv Drug Deliv Rev. 2005 Feb 28;57(4):579-96
[
15722165.001
]
[Cites]
Nucleic Acids Res. 2007;35(13):4495-502
[
17584792.001
]
[Cites]
Biochem Biophys Res Commun. 2002 Feb 22;291(2):367-71
[
11846414.001
]
[Cites]
J Pept Res. 2000 Nov;56(5):318-25
[
11095185.001
]
[Cites]
Mol Biol Cell. 2004 May;15(5):2347-60
[
15020715.001
]
[Cites]
Traffic. 2007 Jul;8(7):848-66
[
17587406.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12128-33
[
18713866.001
]
[Cites]
Nat Biotechnol. 1998 Sep;16(9):857-61
[
9743120.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8786-91
[
11438707.001
]
[Cites]
J Biol Chem. 2009 Feb 6;284(6):3370-8
[
19047062.001
]
[Cites]
Biol Cell. 2008 Apr;100(4):201-17
[
18341479.001
]
[Cites]
Mol Pharmacol. 2002 Oct;62(4):864-72
[
12237333.001
]
[Cites]
Mol Pharm. 2009 May-Jun;6(3):686-95
[
19397332.001
]
[Cites]
N Engl J Med. 2007 Dec 27;357(26):2677-86
[
18160687.001
]
[Cites]
J Control Release. 2006 Feb 21;110(3):595-604
[
16377019.001
]
[Cites]
Hum Mol Genet. 2008 Dec 15;17(24):3909-18
[
18784278.001
]
[Cites]
Mol Ther. 2007 Sep;15(9):1587-92
[
17579573.001
]
[Cites]
Nucleic Acids Res. 2005 Nov 30;33(21):6837-49
[
16321967.001
]
[Cites]
Int J Mol Sci. 2008 Jun;9(7):1276-320
[
19325804.001
]
[Cites]
Eur J Cardiothorac Surg. 2005 Jan;27(1):117-21
[
15621482.001
]
[Cites]
Chembiochem. 2006 Oct;7(10):1497-515
[
16972294.001
]
[Cites]
RNA. 2007 Oct;13(10):1609-24
[
17684229.001
]
[Cites]
Nucleic Acids Res. 2008 Nov;36(20):6418-28
[
18842625.001
]
[Cites]
FEBS Lett. 2006 Feb 20;580(5):1451-6
[
16460737.001
]
[Cites]
J Biol Chem. 2003 Jan 3;278(1):585-90
[
12411431.001
]
[Cites]
New Biol. 1991 Nov;3(11):1121-34
[
1777485.001
]
[Cites]
Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):517-29
[
18037527.001
]
[Cites]
J Neurosci. 2004 Aug 4;24(31):6880-8
[
15295022.001
]
[Cites]
J Control Release. 2006 Dec 1;116(3):304-13
[
17097177.001
]
[Cites]
Nucleic Acids Res. 2009 Aug;37(14):4559-69
[
19483097.001
]
[Cites]
Biochemistry. 2001 Feb 13;40(6):1824-34
[
11327845.001
]
[Cites]
Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):548-58
[
18053612.001
]
[Cites]
Curr Pharm Des. 2008;14(24):2415-47
[
18781991.001
]
[Cites]
J Med Chem. 2002 Aug 15;45(17):3612-8
[
12166934.001
]
[Cites]
J Pept Sci. 2008 Apr;14(4):455-60
[
18236382.001
]
[Cites]
Bioconjug Chem. 2005 Sep-Oct;16(5):1176-80
[
16173795.001
]
[Cites]
Hum Mol Genet. 1998 Jul;7(7):1083-90
[
9618164.001
]
[Cites]
Curr Pharm Des. 2008;14(34):3628-36
[
19075739.001
]
[Cites]
J Gene Med. 2006 Feb;8(2):207-16
[
16285002.001
]
[Cites]
Cancer Res. 2001 Mar 1;61(5):1768-75
[
11280720.001
]
[Cites]
Cell. 1988 Dec 23;55(6):1189-93
[
2849510.001
]
[Cites]
Mol Ther. 2008 Sep;16(9):1624-9
[
18545222.001
]
[Cites]
Biochim Biophys Acta. 1998 Nov 11;1414(1-2):127-39
[
9804921.001
]
[Cites]
Expert Opin Drug Deliv. 2006 Nov;3(6):739-46
[
17076596.001
]
[Cites]
Nat Med. 2000 Nov;6(11):1253-7
[
11062537.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):198-203
[
15608067.001
]
[Cites]
J Control Release. 2007 Apr 2;118(2):216-24
[
17239466.001
]
[Cites]
Chem Biol. 2005 Aug;12(8):923-9
[
16125104.001
]
[Cites]
Biopolymers. 2008;90(5):604-10
[
18381624.001
]
[Cites]
J Biol Chem. 2001 Feb 23;276(8):5836-40
[
11084031.001
]
[Cites]
Pharm Res. 2004 Sep;21(9):1662-9
[
15497694.001
]
(PMID = 19898741.001).
[ISSN]
1420-9071
[Journal-full-title]
Cellular and molecular life sciences : CMLS
[ISO-abbreviation]
Cell. Mol. Life Sci.
[Language]
eng
[Grant]
United Kingdom / Medical Research Council / / MC/ U105178803
[Publication-type]
Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
Switzerland
[Chemical-registry-number]
0 / Oligonucleotides; 0 / Peptides
[Number-of-references]
99
27.
Zhang H, Zhao Q, Bhattacharya S, Waheed AA, Tong X, Hong A, Heck S, Curreli F, Goger M, Cowburn D, Freed EO, Debnath AK:
A cell-penetrating helical peptide as a potential HIV-1 inhibitor.
J Mol Biol
; 2008 May 2;378(3):565-80
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The capsid domain of the human immunodeficiency virus
type
1 (HIV-1) Gag polyprotein is a critical determinant of virus assembly, and is therefore a potential target for developing
drugs for
AIDS
therapy
.
Using this structural information, we have utilized a structure-based rational design approach to stabilize the alpha-helical structure of CAI and convert it to a cell-penetrating peptide (
CPP
).
This proof-of-concept cell-penetrating peptide may aid validation of capsid as an anti-HIV-1
drug
target and may help in designing peptidomimetics and small molecule
drugs
targeted to this protein.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
COS Scholar Universe.
author profiles
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nature. 2000 Sep 21;407(6802):409-13
[
11014200.001
]
[Cites]
Biophys J. 2001 Jul;81(1):586-94
[
11423440.001
]
[Cites]
AIDS. 2001;15 Suppl 5:S13-20
[
11816161.001
]
[Cites]
J Virol. 2002 Mar;76(6):2641-7
[
11861830.001
]
[Cites]
J Virol. 2002 Jul;76(14):6900-8
[
12072491.001
]
[Cites]
Virology. 2006 Apr 25;348(1):84-95
[
16442581.001
]
[Cites]
J Virol. 2006 Jun;80(12):5716-22
[
16731910.001
]
[Cites]
J Virol. 2006 Aug;80(16):7939-51
[
16873251.001
]
[Cites]
PLoS Biol. 2006 Dec;4(12):e435
[
17147474.001
]
[Cites]
J Virol. 2007 Jul;81(14):7476-90
[
17507489.001
]
[Cites]
Antimicrob Agents Chemother. 2002 Nov;46(11):3597-605
[
12384371.001
]
[Cites]
J Biol Chem. 2003 Jan 3;278(1):585-90
[
12411431.001
]
[Cites]
J Mol Biol. 2003 Jan 24;325(4):759-72
[
12507478.001
]
[Cites]
J Mol Biol. 2003 Apr 11;327(5):1013-20
[
12662926.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11273-8
[
13679575.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13555-60
[
14573704.001
]
[Cites]
Angew Chem Int Ed Engl. 2005 Oct 14;44(40):6525-9
[
16172999.001
]
[Cites]
J Virol. 2004 Jan;78(2):922-9
[
14694123.001
]
[Cites]
J Virol. 2004 Feb;78(3):1375-83
[
14722292.001
]
[Cites]
J Virol. 2004 Mar;78(5):2545-52
[
14963157.001
]
[Cites]
Bioorg Med Chem Lett. 2004 Mar 22;14(6):1403-6
[
15006371.001
]
[Cites]
J Virol. 2004 Jun;78(11):5670-8
[
15140964.001
]
[Cites]
Protein Sci. 2004 Jun;13(6):1512-23
[
15152086.001
]
[Cites]
Biochemistry. 2004 Aug 17;43(32):10435-41
[
15301542.001
]
[Cites]
Science. 2004 Sep 3;305(5689):1466-70
[
15353804.001
]
[Cites]
J Gen Virol. 2004 Oct;85(Pt 10):2903-13
[
15448352.001
]
[Cites]
Antimicrob Agents Chemother. 2004 Nov;48(11):4349-59
[
15504864.001
]
[Cites]
J Virol. 1986 Aug;59(2):284-91
[
3016298.001
]
[Cites]
J Exp Med. 1991 Dec 1;174(6):1557-63
[
1836013.001
]
[Cites]
J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74
[
8207412.001
]
[Cites]
J Virol. 1996 Aug;70(8):5106-14
[
8764018.001
]
[Cites]
Science. 1997 Oct 31;278(5339):849-53
[
9346481.001
]
[Cites]
Eur J Biochem. 1997 Oct 15;249(2):592-600
[
9370371.001
]
[Cites]
Virology. 1998 Nov 10;251(1):1-15
[
9813197.001
]
[Cites]
Biochemistry. 2004 Nov 9;43(44):13926-31
[
15518540.001
]
[Cites]
J Biol Chem. 2005 May 6;280(18):17664-70
[
15734744.001
]
[Cites]
Nat Struct Mol Biol. 2005 Aug;12(8):678-82
[
16041386.001
]
[Cites]
Nat Struct Mol Biol. 2005 Aug;12(8):671-7
[
16041387.001
]
[Cites]
Biochemistry. 2000 Sep 26;39(38):11657-66
[
10995233.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3503-8
[
10725407.001
]
[Cites]
J Virol. 2000 Apr;74(8):3859-70
[
10729160.001
]
[Cites]
J Virol. 2004 Jan;78(2):724-32
[
14694104.001
]
(PMID = 18374356.001).
[ISSN]
1089-8638
[Journal-full-title]
Journal of molecular biology
[ISO-abbreviation]
J. Mol. Biol.
[Language]
ENG
[Grant]
United States / Intramural NIH HHS / / Z01 BC010778-01; United States / NIGMS NIH HHS / GM / P41 GM066354-05; United States / NIGMS NIH HHS / GM / GM-66354; United States / NIGMS NIH HHS / GM / P41 GM066354; United States / NIGMS NIH HHS / GM / P41 GM066354-01; United States / NIGMS NIH HHS / GM / GM066354-01
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Anti-HIV Agents; 0 / Gene Products, gag; 0 / NYAD-1 peptide; 0 / Peptides; 0 / Peptides, Cyclic
[Other-IDs]
NLM/ NIHMS76587; NLM/ PMC2695608
28.
Hobbs A, Foster P, Prescott C, Scotland R, Ahluwalia A:
Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endothelium-derived C-type natriuretic peptide.
Circulation
; 2004 Sep 7;110(10):1231-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endothelium-derived C-
type
natriuretic peptide.
BACKGROUND: Ischemia/reperfusion (I/R) injury complicates myocardial infarction and stroke by exacerbating
tissue
damage and increasing risk of mortality.
We have recently identified C-
type
natriuretic peptide (CNP) as an endothelium-derived hyperpolarizing factor in the mesenteric resistance vasculature and described a novel signaling pathway involving activation of natriuretic peptide receptor C (NPR-C), which plays a pivotal role in the regulation of local blood flow.
METHODS AND RESULTS: CNP and (Cys18)-atrial natriuretic factor (4-23) amide (cANF(4-23)) elicited dose-dependent decreases in coronary perfusion pressure (
CPP
) that were blocked by Ba(2+) and ouabain in the isolated Langendorff rat heart.
CNP and cANF(4-23) reduced infarct size after 25 minutes of global ischemia and 120 minutes of reperfusion, maintaining
CPP
and left ventricular pressure at preischemic values.
Moreover, this newly defined pathway represents a protective mechanism against I/R injury and a novel target
for therapeutic
intervention in ischemic cardiovascular disorders.
[MeSH-major]
Coronary Circulation /
drug
effects. Natriuretic Peptide, C-
Type
/ physiology. Receptors, Atrial Natriuretic Factor / physiology
[MeSH-minor]
Acetylcholine / pharmacology. Animals. Atrial Natriuretic Factor / pharmacology. Atrial Natriuretic Factor /
therapeutic
use. Barium / pharmacology.
Drug
Evaluation, Preclinical. Endothelium, Vascular /
drug
effects. Endothelium, Vascular / secretion. Male. Myocardial Infarction /
drug therapy
. Myocardial Infarction / pathology. Myocardial Reperfusion Injury / prevention & control. NG-Nitroarginine Methyl Ester / pharmacology. Nitric Oxide / physiology. Ouabain / pharmacology. Peptide Fragments / pharmacology. Peptide Fragments /
therapeutic
use. Rats. Rats, Wistar. Signal Transduction. Vasodilation /
drug
effects. Vasodilator Agents / pharmacology. Vasodilator Agents /
therapeutic
use
COS Scholar Universe.
author profiles
.
Gene Ontology.
gene/protein/disease-specific - Gene Ontology annotations from this paper
.
Guide to Pharmacology.
gene/protein/disease-specific - Natriuretic peptide receptor family - overview and references
.
Guide to Pharmacology.
gene/protein/disease-specific - natriuretic peptide receptor 3 - data and references
.
Hazardous Substances Data Bank.
NITRIC OXIDE
.
Hazardous Substances Data Bank.
OUABAIN
.
Hazardous Substances Data Bank.
Barium, Elemental
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15337698.001).
[ISSN]
1524-4539
[Journal-full-title]
Circulation
[ISO-abbreviation]
Circulation
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Peptide Fragments; 0 / Vasodilator Agents; 111863-73-1 / atrial natriuretic factor (4-23)NH2, de-Gln(18)-de-Ser(19)-de-Gly(20,22)-de-Leu(21)-; 127869-51-6 / Natriuretic Peptide, C-Type; 24GP945V5T / Barium; 31C4KY9ESH / Nitric Oxide; 5ACL011P69 / Ouabain; 85637-73-6 / Atrial Natriuretic Factor; EC 4.6.1.2 / Receptors, Atrial Natriuretic Factor; EC 4.6.1.2 / atrial natriuretic factor receptor C; N9YNS0M02X / Acetylcholine; V55S2QJN2X / NG-Nitroarginine Methyl Ester
29.
Ciccocioppo R, Economidou D, Fedeli A, Massi M:
The nociceptin/orphanin FQ/NOP receptor system as a target for treatment of alcohol abuse: a review of recent work in alcohol-preferring rats.
Physiol Behav
; 2003 Jun;79(1):121-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The nociceptin/orphanin FQ/NOP receptor system as a target
for treatment
of alcohol abuse: a review of recent work in alcohol-preferring rats.
Studies aimed at
the pharmacological
characterization of the receptor, which mediates the effect, have shown that the C-terminal 13 amino acid sequence is crucial for activity and that the selective NOP receptor antagonist [Nphe(1)]N/OFQ(1-13)NH(2) blocks the effect
of N
/OFQ on ethanol drinking.
In place conditioning studies, N/OFQ abolishes the conditioned place preference (
CPP
) induced by ethanol in msP rats, or by morphine in nonselected Wistar rats; these findings suggest that N/OFQ is able to abolish the rewarding properties of ethanol and morphine.
Together, these findings suggest that N/OFQ and its receptor may represent an interesting target
for pharmacological treatment of
alcohol abuse.
[MeSH-minor]
Animals. Association Learning /
drug
effects. Association Learning / physiology. Conditioning, Classical /
drug
effects. Conditioning, Classical / physiology. Ethanol / pharmacology. Humans. Injections, Intraventricular. Mice. Morphine / pharmacology. Morphine Dependence / physiopathology. Motivation. Rats. Social Environment. Stress, Psychological / complications. Ventral Tegmental Area /
drug
effects. Ventral Tegmental Area / physiopathology
MedlinePlus Health Information.
consumer health - Alcohol
.
MedlinePlus Health Information.
consumer health - Alcoholism and Alcohol Abuse
.
Hazardous Substances Data Bank.
MORPHINE
.
Hazardous Substances Data Bank.
ETHANOL
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 12818717.001).
[ISSN]
0031-9384
[Journal-full-title]
Physiology & behavior
[ISO-abbreviation]
Physiol. Behav.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Alcohol Deterrents; 0 / Opioid Peptides; 0 / Peptide Fragments; 0 / Receptors, Opioid; 0 / nociceptin orphanin FQ(1-17)OH; 0 / nociceptin receptor; 3K9958V90M / Ethanol; 76I7G6D29C / Morphine
30.
El-Andaloussi S, Johansson HJ, Holm T, Langel U:
A novel cell-penetrating peptide, M918, for efficient delivery of proteins and peptide nucleic acids.
Mol Ther
; 2007 Oct;15(10):1820-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We present a novel
CPP
, M918, that efficiently translocates various cells in a non-toxic fashion.
Our data demonstrate that M918 is a novel
CPP
that can be used to translocate different cargoes inside various cells efficiently.
[MeSH-minor]
Amino Acid Sequence. Endocytosis. Glycosaminoglycans / metabolism. HeLa Cells. Humans. Molecular Sequence Data. RNA Splicing /
drug
effects
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17622242.001).
[ISSN]
1525-0016
[Journal-full-title]
Molecular therapy : the journal of the American Society of Gene Therapy
[ISO-abbreviation]
Mol. Ther.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Glycosaminoglycans; 0 / Peptide Nucleic Acids; 0 / Proteins
31.
Han Y, Li CS:
[Effects of hypertension state induced by norepinephrine on liver in a swine model of cardiopulmonary resuscitation].
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue
; 2010 Feb;22(2):89-92
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
At the same
time
, the animals of two groups received normal saline at the speed of 10 ml * kg(-1) * h(-1).
RESULTS: The heart rate (HR), MAP, cardiac output (CO) and coronary perfusion pressure (
CPP
) were obviously higher, while the oxygen extraction ratio was lower in the HT group than in the NP group.
[MeSH-major]
Heart Arrest /
therapy
. Hypertension / chemically induced. Liver /
drug
effects. Norepinephrine / pharmacology
[MeSH-minor]
Animals. Cardiopulmonary Resuscitation.
Disease
Models, Animal. Female. Hemodynamics /
drug
effects. Male. Swine. Ventricular Fibrillation / pathology. Ventricular Fibrillation / physiopathology. Ventricular Fibrillation /
therapy
MedlinePlus Health Information.
consumer health - Cardiac Arrest
.
MedlinePlus Health Information.
consumer health - High Blood Pressure
.
Hazardous Substances Data Bank.
Norepinephrine
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20170612.001).
[ISSN]
1003-0603
[Journal-full-title]
Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue
[ISO-abbreviation]
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue
[Language]
chi
[Publication-type]
English Abstract; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
X4W3ENH1CV / Norepinephrine
32.
Baudy RB, Fletcher H 3rd, Yardley JP, Zaleska MM, Bramlett DR, Tasse RP, Kowal DM, Katz AH, Moyer JA, Abou-Gharbia M:
Design, synthesis, SAR, and biological evaluation of highly potent benzimidazole-spaced phosphono-alpha-amino acid competitive NMDA antagonists of the AP-6 type.
J Med Chem
; 2001 May 10;44(10):1516-29
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Design, synthesis, SAR, and biological evaluation of highly potent benzimidazole-spaced phosphono-alpha-amino acid competitive NMDA antagonists of the AP-6
type
.
A series of 2-amino-(phosphonoalkyl)-1H-benzimidazole-2-alkanoic acids was synthesized and evaluated for NMDA receptor affinity using a [3H]
CPP
binding assay.
Several compounds of the AP-6
type
demonstrated potent and selective NMDA antagonistic activity both in vitro and in vivo.
In particular, [R(-)]-2-amino-3-(5-chloro-1-phosphonomethyl-1H-benzoimidazol-2-yl)-propionic acid (1) displayed an IC(50) value of 7.1 nM in the [3H]
CPP
binding assay and an ED(50) value of 0.13 mg/kg (ip) in the NMDA lethality model.
Compound 1, when administered intravenously as a single bolus dose of 3 mg/kg following permanent occlusion of the middle cerebral artery in the rat, reduced the volume of infarcted
brain tissue
by 45%.
These results support a promising
therapeutic
potential for compound 1 as a neuroprotective agent.
[MeSH-minor]
Animals. Arterial Occlusive
Diseases
/ complications. Binding, Competitive.
Brain
/ metabolism.
Brain
/ pathology. Carotid Artery
Diseases
/ complications.
Drug
Evaluation, Preclinical. In Vitro Techniques. Infarction, Middle Cerebral Artery /
drug therapy
. Infarction, Middle Cerebral Artery / etiology. Infarction, Middle Cerebral Artery / pathology. Male. Mice. Models, Molecular. Organophosphonates. Radioligand Assay. Rats. Rats, Inbred F344. Stereoisomerism
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 11334562.001).
[ISSN]
0022-2623
[Journal-full-title]
Journal of medicinal chemistry
[ISO-abbreviation]
J. Med. Chem.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / 2-amino-3-(5-chloro-1-phosphonomethyl-1H-benzoimidazol-2-yl)propionic acid; 0 / Benzimidazoles; 0 / Excitatory Amino Acid Antagonists; 0 / Neuroprotective Agents; 0 / Organophosphonates; 0 / Propionates; 0 / Receptors, N-Methyl-D-Aspartate
33.
Soustiel JF, Mahamid E, Chistyakov A, Shik V, Benenson R, Zaaroor M:
Comparison of moderate hyperventilation and mannitol for control of intracranial pressure control in patients with severe traumatic brain injury--a study of cerebral blood flow and metabolism.
Acta Neurochir (Wien)
; 2006 Aug;148(8):845-51; discussion 851
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Comparison of moderate hyperventilation and mannitol for control
of intracranial
pressure control in patients with severe traumatic
brain
injury--a study of cerebral blood flow and metabolism.
OBJECTIVE: To compare the respective effects of established measures used for management of traumatic
brain
injury (TBI) patients on cerebral blood flow (CBF) and cerebral metabolic rates of oxygen (CMRO2), glucose (CMRGlc) and lactate (CMRLct).
METHODS: Thirty-six patients suffering from severe traumatic
brain
injury (TBI) were prospectively evaluated.
Intracranial
and cerebral perfusion pressure (ICP,
CPP
), CBF and arterial jugular differences in oxygen, glucose and lactate contents were measured for calculation of CMRO2, CMRGlc and CMRLct.
[MeSH-major]
Brain
Edema /
therapy
.
Brain
Injuries / complications. Cerebrovascular Circulation /
drug
effects. Hyperventilation / metabolism.
Intracranial
Hypertension /
therapy
. Mannitol /
therapeutic
use
[MeSH-minor]
Adolescent. Adult. Aged.
Brain
Ischemia / etiology.
Brain
Ischemia / physiopathology.
Brain
Ischemia /
therapy
. Cerebral Cortex /
drug
effects. Cerebral Cortex / metabolism. Cerebral Cortex / physiopathology. Diuretics, Osmotic /
therapeutic
use. Female. Glucose / metabolism. Glycolysis /
drug
effects. Glycolysis / physiology. Humans. Lactic Acid / metabolism. Male. Middle Aged. Oxygen Consumption /
drug
effects. Prospective Studies. Respiration, Artificial / adverse effects. Respiration, Artificial / standards.
Treatment
Outcome
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
LACTIC ACID
.
Hazardous Substances Data Bank.
GLUCOSE
.
Hazardous Substances Data Bank.
D-MANNITOL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16763735.001).
[ISSN]
0001-6268
[Journal-full-title]
Acta neurochirurgica
[ISO-abbreviation]
Acta Neurochir (Wien)
[Language]
eng
[Publication-type]
Clinical Trial; Comparative Study; Journal Article
[Publication-country]
Austria
[Chemical-registry-number]
0 / Diuretics, Osmotic; 33X04XA5AT / Lactic Acid; 3OWL53L36A / Mannitol; IY9XDZ35W2 / Glucose
34.
Wang YQ, Zhou W, Liu YY, Liu YH, Peng T, Wang ZR:
[The role of circadian gene period1 in morphine reward in mice].
Space Med Med Eng (Beijing)
; 2004 Oct;17(5):383-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVE: To investigate the role of circadian gene Period1 on
drug
dependence.
Conditional place preference (
CPP
) paradigm used to investigate the effect of intracerebroventricular (ICV) injection of pcDNA 3.1-per1RZ on
drug
reward in BALB/C mice.
CPP
test displayed the block of
drug
reward in pcDNA 3.1-per1RZ ICV injection group.
Period1 expression in
brain
was attenuated of pcDNA 3.1-per1RZ ICV injection group demonstrated by western blot.
CONCLUSION: Interfere the Period1 expression in
brain
could attenuate the psychological dependence of
drug
in mammals.
[MeSH-major]
Circadian Rhythm / genetics. Morphine / pharmacology. Morphine Dependence /
drug therapy
. Nuclear Proteins / pharmacology. Substance-Related Disorders /
drug therapy
[MeSH-minor]
Animals. Behavior, Animal /
drug
effects. Behavior, Animal / physiology. Cell Cycle Proteins.
Disease
Models, Animal. Genetic
Therapy
. Mice. Mice, Inbred BALB C. Period Circadian Proteins. RNA, Messenger / metabolism
MedlinePlus Health Information.
consumer health - Drug Abuse
.
MedlinePlus Health Information.
consumer health - Opioid Abuse and Addiction
.
Hazardous Substances Data Bank.
MORPHINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15926241.001).
[ISSN]
1002-0837
[Journal-full-title]
Hang tian yi xue yu yi xue gong cheng = Space medicine & medical engineering
[ISO-abbreviation]
Space Med Med Eng (Beijing)
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
[Chemical-registry-number]
0 / Cell Cycle Proteins; 0 / Nuclear Proteins; 0 / Per1 protein, mouse; 0 / Period Circadian Proteins; 0 / RNA, Messenger; 76I7G6D29C / Morphine
[Other-IDs]
NASA/ 00031288
35.
Carlotti CG Jr, Salhia B, Weitzman S, Greenberg M, Dirks PB, Mason W, Becker LE, Rutka JT:
Evaluation of proliferative index and cell cycle protein expression in choroid plexus tumors in children.
Acta Neuropathol
; 2002 Jan;103(1):1-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Evaluation of proliferative index and cell cycle protein expression in
choroid plexus
tumors in children.
Choroid plexus
tumors are papillary neoplasms originating from the epithelium of the
choroid plexus
within the cerebral ventricles.
Accordingly, we performed a clinicopathological correlation study of neoplasms arising from the
choroid plexus
in children using immunohistochemistry to characterize both their proliferative potential and their degree of cell cycle dysregulation when compared to non-neoplastic
choroid
epithelium.
Twelve children with
choroid plexus papillomas
(CPPs) and 11 with
choroid plexus
carcinomas (CPCs) were identified from
the time
period 1982-1997.
The outcome and survival of these children following
treatment
was determined from the medical record.
Immunohistochemical studies were performed on CPPs and CPCs in this patient population and on non-neoplastic
choroid
epithelium using antibodies to MIB-1, p53, cyclin E, retinoblastoma protein (pRB), p107, and E2F-1.
In 5 children with CPCs,
tumor tissue
was available for immunohistochemistry at a second surgery after cycles
of chemotherapy
had been given.
The mean survival for patients with CPPs was 8.5 years, and with CPCs 5.2 years
with a
minimum follow-up of 4 years for the group.
The expression of cell cycle markers and MIB-1 was greater in CPCs than in CPPs or normal
choroid plexus
.
The expression of MIB-1, p53, pRB, and E2F-1 was significantly lower in patients with CPCs after
chemotherapy
than before.
The MIB-1 labeling index for CPC patients who are alive and well after
treatments
was 15.19+/-3.2 compared to 22.63+/-3.04 for patients who have died from their
disease
(P<0.05).
Chemotherapy
may work in part on CPCs to decrease their proliferative potential and expression of cell cycle regulatory proteins.
[MeSH-major]
Cell Cycle Proteins / analysis.
Choroid Plexus
Neoplasms / chemistry.
Choroid Plexus
Neoplasms / pathology. DNA-Binding Proteins.
Papilloma
,
Choroid Plexus
/ chemistry.
Papilloma
,
Choroid Plexus
/ pathology
[MeSH-minor]
Adolescent. Antigens, Nuclear. Cell Division. Child. Child, Preschool. Cyclin E / analysis. E2F Transcription Factors. E2F1 Transcription Factor. Female. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry. Infant. Ki-67 Antigen. Male. Nuclear Proteins / analysis. Retinoblastoma Protein / analysis. Retinoblastoma-Like Protein p107. Survival Analysis. Synaptophysin / analysis. Transcription Factors / analysis.
Tumor
Suppressor Protein p53 / analysis
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 11837741.001).
[ISSN]
0001-6322
[Journal-full-title]
Acta neuropathologica
[ISO-abbreviation]
Acta Neuropathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antigens, Nuclear; 0 / Cell Cycle Proteins; 0 / Cyclin E; 0 / DNA-Binding Proteins; 0 / E2F Transcription Factors; 0 / E2F1 Transcription Factor; 0 / E2F1 protein, human; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; 0 / RBL1 protein, human; 0 / Retinoblastoma Protein; 0 / Retinoblastoma-Like Protein p107; 0 / Synaptophysin; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53
36.
Takamatsu Y, Yamanishi Y, Hagino Y, Yamamoto H, Ikeda K:
Differential effects of donepezil on methamphetamine and cocaine dependencies.
Ann N Y Acad Sci
; 2006 Aug;1074:418-26
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Donepezil, a choline esterase inhibitor, has been widely used as a medicine for Alzheimer'
s disease
.
Recently, a study showed that donepezil inhibited addictive behaviors induced by cocaine, including cocaine-conditioned place preference (
CPP
) and locomotor sensitization to cocaine.
In counterbalanced
CPP
tests, the intraperitoneal (i.p.) administration of 3 mg/kg donepezil prior to 2 mg/kg METH i.p. failed to inhibit METH
CPP
, whereas pretreatment with 3 mg/kg donepezil abolished
the CPP
for cocaine (10 mg/kg, i.p.).
[MeSH-minor]
Amphetamine-Related Disorders /
drug therapy
. Animals. Behavior, Animal /
drug
effects. Cocaine-Related Disorders /
drug therapy
. Conditioning (Psychology). Male. Mice. Mice, Inbred C57BL. Motor Activity /
drug
effects
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17105940.001).
[ISSN]
0077-8923
[Journal-full-title]
Annals of the New York Academy of Sciences
[ISO-abbreviation]
Ann. N. Y. Acad. Sci.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Indans; 0 / Piperidines; 8SSC91326P / donepezil
37.
Stocchetti N, Rossi S, Zanier ER, Colombo A, Beretta L, Citerio G:
Pyrexia in head-injured patients admitted to intensive care.
Intensive Care Med
; 2002 Nov;28(11):1555-62
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
(b) to elucidate the relationships between pyrexia and neurological severity, length of stay in the ICU,
intracranial
hypertension, and cerebral perfusion pressure (
CPP
); and (c) to describe the effects of antipyretic
therapy
on temperature,
intracranial
pressure (ICP) and
CPP
.
PATIENTS: 110 patients with traumatic
brain
injury.
Various antipyretic
therapies
were used in 66 patients.
Pharmacological treatment
was slightly effective (mean temperature reduction 0.58+/-0.7 degrees C) but caused a significant drop in
CPP
(6.5+/-12.5 mmHg).
Its incidence is higher in more severe cases and is correlated
with a
longer ICU stay.
It may affect ICP, but its contribution is difficult to assess when other major causes of increased
intracranial
volume are present.
Antipyretic
therapy
is poorly effective for controlling body temperature and may be deleterious
for CPP
.
[MeSH-major]
Analgesics, Non-Narcotic /
therapeutic
use. Craniocerebral Trauma / complications. Fever /
drug therapy
. Fever / etiology
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Humans. Intensive Care Units / statistics & numerical data.
Intracranial
Pressure. Length of Stay / statistics & numerical data. Logistic Models. Male. Middle Aged. Retrospective Studies. Risk Factors. Statistics, Nonparametric
MedlinePlus Health Information.
consumer health - Fever
.
MedlinePlus Health Information.
consumer health - Head Injuries
.
MedlinePlus Health Information.
consumer health - Pain Relievers
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 12415441.001).
[ISSN]
0342-4642
[Journal-full-title]
Intensive care medicine
[ISO-abbreviation]
Intensive Care Med
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study
[Publication-country]
United States
[Chemical-registry-number]
0 / Analgesics, Non-Narcotic
38.
Bortolato M, Campolongo P, Mangieri RA, Scattoni ML, Frau R, Trezza V, La Rana G, Russo R, Calignano A, Gessa GL, Cuomo V, Piomelli D:
Anxiolytic-like properties of the anandamide transport inhibitor AM404.
Neuropsychopharmacology
; 2006 Dec;31(12):2652-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We also evaluated whether AM404 might influence motivation (in the conditioned place preference (
CPP
) test), sensory reactivity (acoustic startle reflex) and sensorimotor gating (prepulse inhibition (PPI) of the startle reflex).
In
the CPP
test, AM404 (1.25-10 mg kg(-1), i.p.) elicited rewarding effects in rats housed under enriched conditions, but not in rats kept in standard cages.
These results support a role of anandamide in the regulation of emotion and point to the anandamide transport system as a potential target for anxiolytic
drugs
.
[MeSH-major]
Anxiety Disorders /
drug therapy
. Arachidonic Acids / metabolism. Arachidonic Acids / pharmacology.
Brain
/
drug
effects. Cannabinoid Receptor Modulators / metabolism. Carrier Proteins /
drug
effects. Polyunsaturated Alkamides / metabolism
[MeSH-minor]
Animals. Animals, Newborn. Anti-Anxiety Agents / pharmacology. Anxiety, Separation /
drug therapy
. Anxiety, Separation / metabolism. Anxiety, Separation / physiopathology. Behavior, Animal /
drug
effects. Behavior, Animal / physiology.
Disease
Models, Animal. Endocannabinoids. Male. Maze Learning /
drug
effects. Maze Learning / physiology. Neural Inhibition /
drug
effects. Neural Inhibition / physiology. Piperidines / pharmacology. Pyrazoles / pharmacology. Rats. Rats, Sprague-Dawley. Rats, Wistar. Receptor, Cannabinoid, CB1 / agonists. Receptor, Cannabinoid, CB1 / antagonists & inhibitors. Receptor, Cannabinoid, CB1 / metabolism. Reflex, Startle /
drug
effects. Reflex, Startle / physiology
MedlinePlus Health Information.
consumer health - Anxiety
.
COS Scholar Universe.
author profiles
.
eScholarship, California Digital Library, University of California.
Full text from University of California eScholarship
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16541083.001).
[ISSN]
0893-133X
[Journal-full-title]
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
[ISO-abbreviation]
Neuropsychopharmacology
[Language]
eng
[Grant]
United States / NIDA NIH HHS / DA / DA-12447; United States / NIDA NIH HHS / DA / DA-3412
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Anti-Anxiety Agents; 0 / Arachidonic Acids; 0 / Cannabinoid Receptor Modulators; 0 / Carrier Proteins; 0 / Endocannabinoids; 0 / N-(4-hydroxyphenyl)arachidonylamide; 0 / Piperidines; 0 / Polyunsaturated Alkamides; 0 / Pyrazoles; 0 / Receptor, Cannabinoid, CB1; 158681-13-1 / rimonabant; 94421-68-8 / anandamide
39.
Wrede B, Liu P, Wolff JE:
Chemotherapy improves the survival of patients with choroid plexus carcinoma: a meta-analysis of individual cases with choroid plexus tumors.
J Neurooncol
; 2007 Dec;85(3):345-51
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Chemotherapy
improves the survival of patients with
choroid plexus
carcinoma: a meta-analysis of individual cases with
choroid plexus
tumors.
BACKGROUND:
Choroid plexus
carcinomas (CPC) are rare
brain
tumors
with a
dismal prognosis.
Although the role of surgery has been well established, the question of whether
chemotherapy
improves the prognosis is still under discussion.
METHODS: We created a database of all cases of
choroid plexus
tumors (CPT) reported in the literature up to the year 2004 to determine prognostic factors and different
therapeutic
modalities.
RESULTS: Of 857 documented cases of CPT (median patient age at
diagnosis
, 3 years), 347 were CPC, 15 atypical
choroid plexus
papilloma
(APP), and 495
choroid plexus
papilloma
(
CPP
).
The 104 CPC patients who received
chemotherapy
had a statistically better survival than those without
chemotherapy
(P = .0004).
When subgroups were defined by radiation
treatment
,
chemotherapy
remained beneficial in the subgroup of nonirradiated tumors (P = .0001).
The benefit
of chemotherapy
was also significant when the analysis was restricted to the subgroup of patients with less than completely resected CPC (2-year overall survival (OS) 54.8 +/- 7% (standard deviation (SD) vs. 24.4 +/- 7%, P < .0001) and when this subgroup was further divided into smaller subgroups.
Likewise, in a multivariate analysis,
chemotherapy
was highly significantly linked to better prognosis (P = .0001).
CONCLUSION: Patients with less than completely resected CPC should receive
chemotherapy
.
[MeSH-major]
Antineoplastic Agents /
therapeutic
use. Carcinoma /
drug therapy
.
Choroid Plexus
Neoplasms /
drug therapy
[MeSH-minor]
Adolescent. Adult. Age Factors. Aged. Child. Child, Preschool. Combined Modality
Therapy
. Databases, Bibliographic. Databases, Factual. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Prognosis. Survival Analysis.
Treatment
Outcome
Genetic Alliance.
consumer health - Choroid Plexus Carcinoma
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Neurooncol. 2002 Apr;57(2):123-6
[
12125972.001
]
[Cites]
Pediatr Neurosurg. 1999 Sep;31(3):127-30
[
10708353.001
]
[Cites]
Med Pediatr Oncol. 1993;21(7):480-7
[
8341215.001
]
[Cites]
Lancet. 1999 Jun 19;353(9170):2126
[
10382700.001
]
[Cites]
Eur J Pediatr. 1983 Mar;140(1):51-6
[
6873113.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):249-54
[
10760416.001
]
[Cites]
Cancer. 1992 Jan 15;69(2):580-5
[
1728390.001
]
[Cites]
Brain Pathol. 2003 Jul;13(3):409-14
[
12946029.001
]
[Cites]
Am J Hum Genet. 1999 Nov;65(5):1342-8
[
10521299.001
]
[Cites]
Med Pediatr Oncol. 1994;22(4):274-8
[
8107660.001
]
[Cites]
Pediatr Neurosci. 1989;15(4):195-206
[
2485914.001
]
[Cites]
Pediatr Neurosurg. 1991-1992;17(5):225-33
[
1822687.001
]
[Cites]
J Neurosurg. 1987 Jun;66(6):800-5
[
3572508.001
]
[Cites]
Anticancer Res. 2005 Nov-Dec;25(6C):4429-33
[
16334121.001
]
[Cites]
Histopathology. 1995 Feb;26(2):137-43
[
7737660.001
]
[Cites]
Indian Pediatr. 1993 Oct;30(10):1217-8
[
8077013.001
]
[Cites]
J Neurosurg. 1983 Sep;59(3):369-83
[
6886750.001
]
[Cites]
Acta Neurochir (Wien). 1979;50(1-2):79-90
[
316268.001
]
[Cites]
Acta Neurochir (Wien). 1998;140(6):557-63
[
9755322.001
]
[Cites]
Noshuyo Byori. 1996 Nov;13(2):99-105
[
8958514.001
]
[Cites]
Neuropediatrics. 1996 Jun;27(3):143-8
[
8837074.001
]
[Cites]
Neurol Med Chir (Tokyo). 1995 Oct;35(10):742-4
[
8532130.001
]
[Cites]
Pediatr Neurosurg. 1995;22(4):189-96
[
7619719.001
]
[Cites]
Acta Oncol. 1990;29(2):241-3
[
2185805.001
]
[Cites]
Neurosurgery. 1998 Mar;42(3):470-5
[
9526979.001
]
[Cites]
J Neurosurg. 1980 Feb;52(2):251-5
[
7351566.001
]
[Cites]
J Neurosurg. 1988 Dec;69(6):843-9
[
3193190.001
]
[Cites]
Br J Cancer. 2002 Nov 4;87(10):1086-91
[
12402146.001
]
[Cites]
Neoplasma. 2004;51(4):306-12
[
15254663.001
]
[Cites]
Childs Brain. 1975;1(2-3):81-115
[
1081032.001
]
[Cites]
Childs Nerv Syst. 1999 Oct;15(10):571-7
[
10550588.001
]
[Cites]
Neurosurgery. 1980 Apr;6(4):380-4
[
7393420.001
]
[Cites]
Neurosurgery. 1989 Sep;25(3):327-35
[
2771002.001
]
[Cites]
Neurol Med Chir (Tokyo). 1996 Mar;36(3):179-84
[
8869156.001
]
[Cites]
J Neurooncol. 1992 Jan;12 (1):69-74
[
1541980.001
]
[Cites]
Am J Surg Pathol. 2006 Jan;30(1):66-74
[
16330944.001
]
[Cites]
J Neuropathol Exp Neurol. 2005 May;64(5):391-7
[
15892296.001
]
[Cites]
J Neurosurg. 1998 Mar;88(3):521-8
[
9488307.001
]
[Cites]
Pediatr Neurosci. 1988;14(3):134-9
[
3075286.001
]
(PMID = 17576522.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Journal Article; Meta-Analysis
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents
40.
Himmelseher S, Pfenninger E:
[Neuroprotection in neuroanesthesia: current practices in Germany].
Anaesthesist
; 2000 May;49(5):412-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Since the questions concerning "neuroprotective
therapy
" were linked to a general survey on clinical neuroanesthesia performed by the scientific neuroanesthesia working group of the DGAI, the only departments that were assessed were those which had participated in an earlier study on neuroanesthesia in 1991.
Therapy
varied considerably between departments.
Following head trauma 69% of injured patients were managed with enhanced cerebral perfusion pressure (
CPP
) within the range of 70-90 mmHg.
If necessary,
CPP
increase was induced by vasopressors (exogenous supply of catecholamines in 100% of instances) and the administration of fluids (97% of instances).
The most commonly used
therapeutic
approaches to treat
intracranial
hypertension were mannitol (95% of instances), hyperventilation (91% of instances), cerebrospinal fluid drainage (89% of instances), and barbiturates (86% of instances).
Tris (hydroxymethyl)-aminomethane was administered in almost 49%, mild hypothermia in 37%, and hypertonic-hyperoncotic solutions in 28% of patients treated for an increase in
intracranial
pressure.
Following
intracranial
aneurysm surgery "triple-H"
therapy
was used in 74% of patients, applied as hemodilution in 94% and as hypervolemia and hypertension in 87% of instances.
It was used in 83% of patients during perioperative care and in 52% of patients during intensive care
therapy
.
Specific neuroprotective
drugs
were applied in 68% of departments, with barbiturates (38% of instances), nimodipine (23% of instances), and corticosteroids (10% of instances) as the main agents named.
These
brain
-protective
medications
were administered especially in
intracranial
hypertension in 30%, in
intracranial
aneurysms in 21%, and in subarachnoid hemorrhages subsequent to head trauma in 18% of instances described.
CONCLUSION: These findings demonstrate that the neuroprotective
therapy
administered in anesthesiological departments in Germany is not yet standardized, i.e., there is a wide variation.
[MeSH-minor]
Blood Pressure / physiology. Cerebrovascular Circulation /
drug
effects. Cerebrovascular Circulation / physiology. Craniocerebral Trauma / surgery. Data Collection. Germany. Humans. Hypothermia, Induced.
Intracranial
Aneurysm / surgery.
Intracranial
Hypertension / prevention & control.
Intracranial
Hypertension /
therapy
. Neuroprotective Agents /
therapeutic
use. Respiration, Artificial. Surveys and Questionnaires
MedlinePlus Health Information.
consumer health - Anesthesia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 10883355.001).
[ISSN]
0003-2417
[Journal-full-title]
Der Anaesthesist
[ISO-abbreviation]
Anaesthesist
[Language]
ger
[Publication-type]
English Abstract; Journal Article
[Publication-country]
GERMANY
[Chemical-registry-number]
0 / Neuroprotective Agents
41.
Tseng MY, Al-Rawi PG, Czosnyka M, Hutchinson PJ, Richards H, Pickard JD, Kirkpatrick PJ:
Enhancement of cerebral blood flow using systemic hypertonic saline therapy improves outcome in patients with poor-grade spontaneous subarachnoid hemorrhage.
J Neurosurg
; 2007 Aug;107(2):274-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Enhancement of cerebral blood flow using systemic hypertonic saline
therapy
improves outcome in patients with poor-grade spontaneous subarachnoid hemorrhage.
METHODS: Thirty-five patients with poor-grade spontaneous SAH received 2 ml/kg 23.5% hypertonic saline intravenously, and they underwent bedside transcranial Doppler (TCD) ultrasonography and
intracranial
pressure (ICP) monitoring.
Seventeen of them underwent Xe-enhanced computed
tomography
(CT) scanning for measuring CBF.
RESULTS: The authors observed a maximum increase in blood pressure by 10.3% (p < 0.05) and cerebral perfusion pressure (
CPP
) by 21.2% (p < 0.01) at 30 minutes, followed by a maximum decrease in ICP by 93.1% (p < 0.01) at 60 minutes.
Changes in ICP and
CPP
persisted for longer than 180 and 90 minutes, respectively.
A dose-dependent effect of CBF increments on favorable outcome was seen on Xe-CT scans (mRS Score 1-3, odds ratio 1.27 per 1 ml/100 g
tissue
x min, p = 0.045).
CONCLUSIONS: Bolus systemic hypertonic saline
therapy
may be used for reversal of cerebral ischemia to normal perfusion in patients with poor-grade SAH.
[MeSH-major]
Cerebrovascular Circulation /
drug
effects. Homeostasis /
drug
effects. Saline Solution, Hypertonic / administration & dosage. Subarachnoid Hemorrhage / physiopathology. Subarachnoid Hemorrhage /
therapy
[MeSH-minor]
Adult. Aged. Blood Flow Velocity /
drug
effects. Blood Pressure /
drug
effects. Female. Follow-Up Studies. Humans. Injections, Intravenous.
Intracranial
Pressure /
drug
effects. Male. Middle Aged.
Treatment
Outcome
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
J Neurosurg. 2008 Mar;108(3):632; author reply 632-3
[
18312116.001
]
(PMID = 17695380.001).
[ISSN]
0022-3085
[Journal-full-title]
Journal of neurosurgery
[ISO-abbreviation]
J. Neurosurg.
[Language]
eng
[Grant]
United Kingdom / Medical Research Council / / G0001237; United Kingdom / Medical Research Council / / G0600986; United Kingdom / Medical Research Council / / G9439390
[Publication-type]
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Saline Solution, Hypertonic
42.
da Silva JC, de Lima Fde M, Valença MM, de Azevedo Filho HR:
Hypertonic saline more efficacious than mannitol in lethal intracranial hypertension model.
Neurol Res
; 2010 Mar;32(2):139-43
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Hypertonic saline more efficacious than mannitol in lethal
intracranial
hypertension model.
BACKGROUND: Medical management
of brain
edema and elevated
intracranial
pressure (ICP) is a crucial challenge in neurosurgical practice.
Depending on the cause,
the treatments for brain
edema fall into three categories: stabilization of the blood-
brain
barrier, depletion
of brain
water and surgical decompression.
Although mannitol is the mainstay of hyperosmolar
therapy
, hypertonic saline (HS) is emerging as an effective alternative to traditional osmotic agents.
METHODS: Experimental elevated ICP (50 mmHg) was induced in rabbits using an
intracranial
balloon.
During 90 minutes, continuous recording of ICP, mean arterial pressure (MAP) and cerebral perfusion pressure (
CPP
) was realized.
There was statistical difference between mannitol and HS; the 10% NaCl group had lower values of ICP (p=0.0116) and higher values of MAP (p<0.0001) and
CPP
(p<0.0001).
CONCLUSION: The findings demonstrate higher efficacy of the 10% NaCl
treatment
in this comparison with 20% mannitol.
Further efforts should be directed toward development of clinical studies using iso-osmotic doses of mannitol and HS in specific etiologies
of intracranial
hypertension.
[MeSH-major]
Disease
Models, Animal.
Intracranial
Hypertension /
drug therapy
. Mannitol /
therapeutic
use. Saline Solution, Hypertonic /
therapeutic
use
[MeSH-minor]
Animals.
Intracranial
Pressure /
drug
effects.
Intracranial
Pressure / physiology. Male. Rabbits.
Treatment
Outcome
Hazardous Substances Data Bank.
D-MANNITOL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19309542.001).
[ISSN]
1743-1328
[Journal-full-title]
Neurological research
[ISO-abbreviation]
Neurol. Res.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Saline Solution, Hypertonic; 3OWL53L36A / Mannitol
43.
Dhanikula AB, Lamontagne D, Leroux JC:
Rescue of amitriptyline-intoxicated hearts with nanosized vesicles.
Cardiovasc Res
; 2007 Jun 1;74(3):480-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVE: Amitriptyline, one of the most prescribed antidepressants, is reported to claim a large number of human lives due to
drug
overdose related cardiac arrest.
Vesicles bearing an internal pH of 3.0 or 7.4 were then infused into amitriptyline pre-intoxicated isolated rat hearts, and changes in coronary perfusion pressure (
CPP
), the first derivative of left ventricular pressure (dP/
dt
max) and heart rate were monitored.
RESULTS: Based on the recoveries in
CPP
observed, the efficacies of the formulations were ranked as follows: control=pH 7.4-spherulites<pH 3.0-spherulites; whereas the ranking for the recoveries in heart rate was: control<pH 7.4-spherulites<pH 3.0-spherulites.
The significantly faster and higher recoveries in pH 3.0- vs. 7.4-spherulite-treated hearts demonstrated the importance of pH-gradient formulation for efficient extraction
of tissue
-bound amitriptyline.
CONCLUSION: These data suggest that spherulites have a protective effect against acute cardiovascular failure following intoxication with amitriptyline and possibly other cardiotoxic
drugs
.
[MeSH-major]
Amitriptyline / toxicity. Antidepressive Agents, Tricyclic / toxicity. Heart Arrest / chemically induced. Heart Arrest /
therapy
. Lipids / administration & dosage
[MeSH-minor]
Animals. Heart /
drug
effects. Lipid Metabolism. Male. Nanoparticles. Perfusion. Rats. Rats, Sprague-Dawley
MedlinePlus Health Information.
consumer health - Cardiac Arrest
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
AMITRIPTYLINE HYDROCHLORIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17359955.001).
[ISSN]
0008-6363
[Journal-full-title]
Cardiovascular research
[ISO-abbreviation]
Cardiovasc. Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Antidepressive Agents, Tricyclic; 0 / Lipids; 1806D8D52K / Amitriptyline
44.
Velázquez-Sánchez C, Ferragud A, Hernández-Rabaza V, Nácher A, Merino V, Cardá M, Murga J, Canales JJ:
The dopamine uptake inhibitor 3 alpha-[bis(4'-fluorophenyl)metoxy]-tropane reduces cocaine-induced early-gene expression, locomotor activity, and conditioned reward.
Neuropsychopharmacology
; 2009 Nov;34(12):2497-507
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Benztropine (BZT) analogs, a family of high-affinity dopamine transporter ligands, are molecules that exhibit
pharmacological
and behavioral characteristics predictive of significant
therapeutic
potential in cocaine addiction.
Here, we examined in mice the effects of 3 alpha-[bis(4'-fluorophenyl)metoxy]-tropane (AHN-1055) on motor activity, conditioned place preference (
CPP
) and c-Fos expression in the striatum.
Interaction assays showed that cocaine's ability to stimulate locomotor activity was decreased by AHN-1055
treatment
, but not by
treatment with
D-amphetamine.
Remarkably, the BZT analog dose-dependently blocked cocaine-induced
CPP
without producing
CPP
when given alone, and blocked in conditioned mice cocaine-stimulated early-gene activation in the nucleus accumbens and dorsomedial striatum.
These observations provide evidence that AHN-1055 does not behave as a classical psychomotor stimulant and that some of its properties, including attenuation of cocaine-induced striatal c-Fos expression, locomotor stimulation, and
CPP
, support its candidacy, and that of structurally related molecules, as possible
pharmacotherapies
in cocaine addiction.
[MeSH-major]
Benztropine / analogs & derivatives. Cocaine-Related Disorders /
drug therapy
. Conditioning, Classical /
drug
effects. Dopamine Uptake Inhibitors / pharmacology. Gene Expression /
drug
effects. Motor Activity /
drug
effects
[MeSH-minor]
Animals.
Brain
/
drug
effects.
Brain
/ metabolism. Cocaine / pharmacology. Dose-Response Relationship,
Drug
. Male. Mice. Nomifensine / pharmacology. Proto-Oncogene Proteins c-fos / metabolism. Reward. Space Perception /
drug
effects. Stereotyped Behavior /
drug
effects
MedlinePlus Health Information.
consumer health - Cocaine
.
Hazardous Substances Data Bank.
NOMIFENSINE
.
Hazardous Substances Data Bank.
COCAINE
.
Hazardous Substances Data Bank.
BENZTROPINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19606084.001).
[ISSN]
1740-634X
[Journal-full-title]
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
[ISO-abbreviation]
Neuropsychopharmacology
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Dopamine Uptake Inhibitors; 0 / N-methyl-3-(bis(4'-fluorophenyl)methoxy)tropane; 0 / Proto-Oncogene Proteins c-fos; 1LGS5JRP31 / Nomifensine; 1NHL2J4X8K / Benztropine; I5Y540LHVR / Cocaine
45.
Braun K, Ehemann V, Wiessler M, Pipkorn R, Didinger B, Mueller G, Waldeck W:
High-resolution flow cytometry: a suitable tool for monitoring aneuploid prostate cancer cells after TMZ and TMZ-BioShuttle treatment.
Int J Med Sci
; 2009;6(6):338-47
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
High-resolution flow cytometry: a suitable tool for monitoring aneuploid prostate cancer cells after TMZ and TMZ-BioShuttle
treatment
.
If metastatic prostate cancer gets resistant to antiandrogen
therapy
, there are few
treatment
options, because prostate cancer is not very sensitive to cytostatic agents.
Temozolomide (TMZ) as an orally applicable chemotherapeutic substance has been proven to be effective and well tolerated with occasional moderate toxicity especially
for brain
tumors and an application to prostate cancer cells seemed to be promising.
Unfortunately, TMZ was inefficient in
the treatment
of symptomatic progressive hormone-refractory prostate cancer (HRPC).
The reasons could be a low sensitivity against TMZ the short plasma half-life of TMZ, non-adapted application regimens and additionally, the aneuploid DNA content of prostate cancer cells suggesting different sensitivity against therapeutical interventions e.g. radiation
therapy
or
chemotherapy
.
The modular-composed carrier consists
of a
transmembrane transporter (
CPP
), connected to a nuclear localization sequence (NLS) cleavably-bound, which in turn was coupled with TMZ.
The NLS-sequence allows an active delivery of the TMZ into the cell nucleus after transmembrane passage of the TMZ-BioShuttle and intra-cytoplasm enzymatic cleavage and separation from
the CPP
.
This TMZ-BioShuttle could contribute to improve
therapeutic
options exemplified by the hormone refractory prostate cancer.
The high-resolution flow cytometric analysis showed to be an appropriate system
for a
better
detection
and distinction of several cell populations dependent on their different DNA-indices as well as changes in proliferation of cell populations after chemotherapeutical
treatment
.
[MeSH-major]
Aneuploidy. Antineoplastic Agents, Alkylating / administration & dosage. Dacarbazine / analogs & derivatives.
Drug
Monitoring / methods.
Drug
Resistance,
Neoplasm
. Flow Cytometry / methods. Prostatic Neoplasms /
drug therapy
[MeSH-minor]
Cell Line,
Tumor
. DNA,
Neoplasm
/ analysis.
Drug
Delivery Systems. Humans. Male
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
Hazardous Substances Data Bank.
DACARBAZINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Chemother Pharmacol. 2000;45(6):509-12
[
10854140.001
]
[Cites]
Med Res Rev. 2010 Jan;30(1):23-66
[
19536866.001
]
[Cites]
Nature. 2001 May 17;411(6835):366-74
[
11357144.001
]
[Cites]
J Mol Biol. 2002 Apr 26;318(2):237-43
[
12051833.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):427-35
[
12243818.001
]
[Cites]
Biochem Soc Trans. 2002 Nov;30(Pt 6):952-8
[
12440953.001
]
[Cites]
Anticancer Res. 2002 Nov-Dec;22(6C):4147-50
[
12553046.001
]
[Cites]
Urol Int. 2003;70(1):1-14
[
12566808.001
]
[Cites]
Cancer Lett. 2003 May 8;194(1):125-31
[
12706866.001
]
[Cites]
Cell Cycle. 2004 Jan;3(1):46-50
[
14657665.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):928-42
[
15234026.001
]
[Cites]
Chembiochem. 2004 Oct 4;5(10):1432-47
[
15457527.001
]
[Cites]
Int J Cancer. 1978 Mar 15;21(3):274-81
[
631930.001
]
[Cites]
Biochem Pharmacol. 1987 Feb 15;36(4):457-62
[
3470008.001
]
[Cites]
Adv Cancer Res. 1991;57:1-46
[
1950701.001
]
[Cites]
Biochem Int. 1992 Aug;27(4):567-77
[
1417893.001
]
[Cites]
J Histochem Cytochem. 1994 Jun;42(6):697-704
[
8189032.001
]
[Cites]
Curr Opin Immunol. 1994 Apr;6(2):279-89
[
8011211.001
]
[Cites]
J Urol. 1994 Nov;152(5 Pt 2):1816
[
7933240.001
]
[Cites]
J Urol. 1994 Nov;152(5 Pt 2):1837-42
[
7523731.001
]
[Cites]
Cancer Res. 1995 Jul 15;55(14):2959-62
[
7606709.001
]
[Cites]
Antimicrob Agents Chemother. 1995 Dec;39(12):2620-4
[
8592990.001
]
[Cites]
J Clin Oncol. 1996 May;14(5):1617-25
[
8622080.001
]
[Cites]
Cancer Res. 1997 Feb 1;57(3):524-31
[
9012485.001
]
[Cites]
Int J Cancer. 1997 May 16;71(4):698-704
[
9178829.001
]
[Cites]
J Clin Oncol. 1998 Jun;16(6):2272-9
[
9626231.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):491-500
[
9635694.001
]
[Cites]
Semin Nephrol. 1998 Sep;18(5):505-18
[
9754603.001
]
[Cites]
Oncogene. 1998 Dec 24;17(25):3225-36
[
9916985.001
]
[Cites]
Cancer Lett. 1999 Apr 26;138(1-2):101-6
[
10378780.001
]
[Cites]
J Natl Cancer Inst. 1999 Sep 15;91(18):1574-80
[
10491435.001
]
[Cites]
Ann Oncol. 2004 Nov;15(11):1613-21
[
15520061.001
]
[Cites]
Radiother Oncol. 2004 Dec;73 Suppl 2:S119-22
[
15971325.001
]
[Cites]
JAMA. 2005 Jul 13;294(2):238-44
[
16014598.001
]
[Cites]
In Vivo. 2006 Jan-Feb;20(1):17-23
[
16433023.001
]
[Cites]
Ann Oncol. 2006 Jun;17(6):952-6
[
16565212.001
]
[Cites]
Hinyokika Kiyo. 2006 Jul;52(7):515-21
[
16910582.001
]
[Cites]
Cochrane Database Syst Rev. 2006;(4):CD005247
[
17054249.001
]
[Cites]
J Mol Histol. 2006 Sep;37(5-7):253-60
[
16841236.001
]
[Cites]
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
[
17237035.001
]
[Cites]
Urology. 2007 Feb;69(2):347-51
[
17320676.001
]
[Cites]
BJU Int. 2007 Mar;99(3):497-501
[
17092283.001
]
[Cites]
Amino Acids. 2007;32(3):373-9
[
17077962.001
]
[Cites]
Drug Resist Updat. 2007 Feb-Apr;10(1-2):51-8
[
17387035.001
]
[Cites]
Clin Genitourin Cancer. 2007 Mar;5(4):278-83
[
17553208.001
]
[Cites]
Pathol Oncol Res. 2007;13(2):84-90
[
17607368.001
]
[Cites]
J Clin Oncol. 2007 Sep 1;25(25):3965-70
[
17761981.001
]
[Cites]
Cancer Treat Rev. 2007 Oct;33(6):521-7
[
17658220.001
]
[Cites]
Hepatology. 2007 Sep;46(3):759-68
[
17663418.001
]
[Cites]
Int J Oncol. 2008 Feb;32(2):341-7
[
18202756.001
]
[Cites]
Biochim Biophys Acta. 2008 Jan;1779(1):3-16
[
18078840.001
]
[Cites]
Biostatistics. 2008 Apr;9(2):333-54
[
17873151.001
]
[Cites]
Int J Med Sci. 2008;5(5):273-84
[
18797509.001
]
[Cites]
J Pept Sci. 2009 Mar;15(3):235-41
[
19177421.001
]
[Cites]
Br J Cancer. 2008 Sep 16;99(6):900-10
[
19238631.001
]
[Cites]
Biomaterials. 2009 Jul;30(20):3466-75
[
19304320.001
]
[Cites]
Oncol Rep. 2009 Aug;22(2):345-8
[
19578775.001
]
[Cites]
BMC Cancer. 2009;9:210
[
19563641.001
]
[Cites]
DNA Repair (Amst). 2009 Sep 2;8(9):1153-65
[
19501553.001
]
[Cites]
Int J Cancer. 2009 Dec 15;125(12):2978-90
[
19422046.001
]
[Cites]
Nature. 2001 May 17;411(6835):342-8
[
11357141.001
]
(PMID = 19946604.001).
[ISSN]
1449-1907
[Journal-full-title]
International journal of medical sciences
[ISO-abbreviation]
Int J Med Sci
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Australia
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 0 / DNA, Neoplasm; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
[Other-IDs]
NLM/ PMC2781174
[Keywords]
NOTNLM ; Flow Cytometry / Prostate Cancer Cells / TMZ-BioShuttle
46.
Català-Temprano A, Claret Teruel G, Cambra Lasaosa FJ, Pons Odena M, Noguera Julián A, Palomeque Rico A:
Intracranial pressure and cerebral perfusion pressure as risk factors in children with traumatic brain injuries.
J Neurosurg
; 2007 Jun;106(6 Suppl):463-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Intracranial
pressure and cerebral perfusion pressure as risk factors in children with traumatic
brain
injuries.
OBJECT: The authors evaluated the initial
intracranial
pressure (ICP) and cerebral perfusion pressure (
CPP
) as prognostic factors in severe head injury in children and tried to determine the optimal
CPP
range.
METHODS: The authors performed a 9-year retrospective review of all patients with severe traumatic
brain
injuries (TBIs) who required invasive ICP monitoring and were admitted to the pediatric intensive care unit at their institution between January 1995 and December 2003.
An unfavorable outcome was observed in more than 60% of patients with an initial
CPP
lower than 40 mm Hg.
CONCLUSIONS: Initial ICP and
CPP
measurements were useful as prognostic factors in pediatric patients with severe TBIs: patients with initial CPPs between 40 and 70 mm Hg were found to have a better neurological prognosis than those with CPPs either higher or lower than that range.
[MeSH-major]
Blood Pressure.
Brain
Injuries / physiopathology. Cerebrovascular Circulation.
Intracranial
Pressure
[MeSH-minor]
Adolescent. Child. Child, Preschool. Glasgow Coma Scale. Glasgow Outcome Scale. Humans. Infant.
Intracranial
Hypertension /
drug therapy
.
Intracranial
Hypertension / etiology. Prognosis. Retrospective Studies. Risk Factors. Trauma Severity Indices.
Treatment
Outcome
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17566403.001).
[ISSN]
0022-3085
[Journal-full-title]
Journal of neurosurgery
[ISO-abbreviation]
J. Neurosurg.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
47.
Celik T, Kayir H, Ceyhan M, Demirtaş S, Coşar A, Uzbay IT:
CPP and amlodipine alter the decrease in basal acetylcholine and choline release by audiogenic stimulus in hippocampus of ethanol-withdrawn rats in vivo.
Brain Res Bull
; 2004 Sep 30;64(3):243-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
CPP
and amlodipine alter the decrease in basal acetylcholine and choline release by audiogenic stimulus in hippocampus of ethanol-withdrawn rats in vivo.
Effects
of N
-methyl-D-aspartate (NMDA) receptor and Ca2+ channel antagonists on extracellular acetylcholine and choline release in the hippocampus of ethanol-withdrawn rats were investigated by in vivo microdialysis.
Either an NMDA receptor antagonist (+/-)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (
CPP
) or a calcium channel antagonist amlodipine was administered, and 15 min later, an audiogenic stimulus (100 dB, 1 min) was applied to rats.
CPP
(15 mg/kg) and amlodipine (20 mg/kg) reversed the decrement in acetylcholine and increment in choline release in EW rats.
[MeSH-major]
Acetylcholine / metabolism. Amlodipine / pharmacology. Ethanol / adverse effects. Hippocampus /
drug
effects. Piperazines / pharmacology. Substance Withdrawal Syndrome / metabolism
[MeSH-minor]
Acoustic Stimulation / adverse effects. Alcohol-Induced Disorders, Nervous System /
drug therapy
. Alcohol-Induced Disorders, Nervous System / metabolism. Alcohol-Induced Disorders, Nervous System / physiopathology. Animals. Body Weight /
drug
effects. Calcium Channel Blockers / pharmacology. Choline / metabolism.
Disease
Models, Animal. Down-Regulation /
drug
effects. Down-Regulation / physiology.
Drug
Interactions / physiology. Epilepsy, Reflex / chemically induced. Epilepsy, Reflex /
drug therapy
. Epilepsy, Reflex / physiopathology. Excitatory Amino Acid Agonists / pharmacology. Glutamic Acid / metabolism. Male. Microdialysis. Neural Pathways /
drug
effects. Neural Pathways / metabolism. Neural Pathways / physiopathology. Rats. Rats, Wistar. Seizures / chemically induced. Seizures /
drug therapy
. Seizures / physiopathology. Synaptic Transmission /
drug
effects. Synaptic Transmission / physiology
Hazardous Substances Data Bank.
GLUTAMIC ACID HYDROCHLORIDE
.
Hazardous Substances Data Bank.
ETHANOL
.
Hazardous Substances Data Bank.
CHOLINE CHLORIDE
.
Hazardous Substances Data Bank.
AMLODIPINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15464861.001).
[ISSN]
0361-9230
[Journal-full-title]
Brain research bulletin
[ISO-abbreviation]
Brain Res. Bull.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Calcium Channel Blockers; 0 / Excitatory Amino Acid Agonists; 0 / Piperazines; 100828-16-8 / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; 1J444QC288 / Amlodipine; 3K9958V90M / Ethanol; 3KX376GY7L / Glutamic Acid; N91BDP6H0X / Choline; N9YNS0M02X / Acetylcholine
48.
Pillai A, Rajeev K, Chandi S, Unnikrishnan M:
Intrinsic brainstem choroid plexus papilloma. Case report.
J Neurosurg
; 2004 Jun;100(6):1076-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Intrinsic brainstem
choroid plexus
papilloma
. Case report.
The authors report an intrinsic brainstem lesion that was diagnosed initially as a pontine cavernoma, which finally proved to be a
choroid plexus
papilloma
.
Choroid plexus papillomas
are rare tumors of the central nervous system and are usually intraventricular in location.
The occurrence of this
tumor
in an intraparenchymal location is extremely rare, and its occurrence within the brainstem is previously unreported.
The authors also report a trial
of chemotherapy
with lomustine in the management of the residual
tumor
.
[MeSH-major]
Brain
Stem Neoplasms / pathology.
Choroid Plexus
Neoplasms / pathology. Glioma / pathology
[MeSH-minor]
Antineoplastic Agents, Alkylating /
therapeutic
use. Female. Humans. Lomustine /
therapeutic
use. Middle Aged
Genetic Alliance.
consumer health - Choroid Plexus Papilloma
.
Hazardous Substances Data Bank.
LOMUSTINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15200124.001).
[ISSN]
0022-3085
[Journal-full-title]
Journal of neurosurgery
[ISO-abbreviation]
J. Neurosurg.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 7BRF0Z81KG / Lomustine
49.
Nomura Y, Yasumoto S, Yanai F, Akiyoshi H, Inoue T, Nibu K, Tsugu H, Fukushima T, Hirose S:
Survival and late effects on development of patients with infantile brain tumor.
Pediatr Int
; 2009 Jun;51(3):337-41
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Survival and late effects on development of patients with infantile
brain tumor
.
BACKGROUND: Most infants
with brain tumor
may have a poor prognosis.
The aim of the present study was to retrospectively analyze the survival and outcome with regard to mental and physical development in 11 subjects
with brain tumor
; these tumors were diagnosed when the patients were under 1 year of age.
METHODS: The histological diagnoses of these tumors were astrocytoma, n = 3; pineocytoma, n = 2; teratoma, n = 1; ependymoma, n = 1; atypical teratoid/rhabdoid
tumor
, n = 1; glioblastoma, n = 1; medulloblastoma, n = 1; and
choroid plexus
papilloma
, n = 1.
Surgical resection was performed in eight patients, and adjuvant
chemotherapy
was administered to all except one patient with
choroid plexus
papilloma
.
Radiotherapy was additionally performed for four of the 10
chemotherapy
patients.
Among the surviving patients, five were under
no treatment
for 50-167 months after
the diagnosis
(median duration, 89 months), while one received
chemotherapy for
20 months.
Five patients exhibited mental retardation, and one patient experienced normal development after surgical removal of his
choroid plexus
papilloma
.
Diencephalic syndrome
developed
in one patient with pilomyxoid astrocytoma that necessitated hormone replacement
therapy
, and bodyweight over +2 SD was observed in two patients.
The remaining five patients died 11-111 months after
diagnosis
(median duration, 24 months).
CONCLUSION: The prognosis of infantile
brain tumor
with regard to mortality and developmental outcome remains poor.
[MeSH-major]
Astrocytoma / mortality.
Brain
Neoplasms / mortality. Child Development. Pinealoma / mortality
[MeSH-minor]
Chemotherapy
, Adjuvant. Female. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Male. Prognosis. Quality of Life. Radiotherapy, Adjuvant
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Infant and Newborn Development
.
MedlinePlus Health Information.
consumer health - Toddler Development
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19400825.001).
[ISSN]
1442-200X
[Journal-full-title]
Pediatrics international : official journal of the Japan Pediatric Society
[ISO-abbreviation]
Pediatr Int
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Australia
50.
Karim A, Fowler M, McLaren B, Cardenas R, Patwardhan R, Nanda A:
Concomitant choroid plexus papillomas involving the third and fourth ventricles: A case report and review of the literature.
Clin Neurol Neurosurg
; 2006 Sep;108(6):586-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Concomitant
choroid plexus papillomas
involving the third and fourth ventricles: A case report and review of the literature.
Choroid plexus papillomas
(
CPP
) are histopathologically
benign
and rare central nervous system (CNS) neoplasms arising from the epithelium of the
choroid plexus
.
Third ventricular
CPP
are uncommon.
In this study, we present a case
of a
66-year-old woman with complaints of progressive confusion, lethargy, and weakness who was found to have concomitant third and fourth ventricular masses on imaging studies.
Pathology from the biopsy and both resections was
benign CPP
.
Multifocal concomitant
CPP
is rare.
Concomitant CPPs may be secondary to mere coincidental
tumor
occurrence or to biologic seeding of cerebrospinal fluid (CSF) from a primary
CPP
despite otherwise
benign
histopathology.
The primary
treatment for CPP
is surgical resection.
Post-operative
chemotherapy
or radiation
for CPP
is of controversial benefit.
[MeSH-major]
Fourth Ventricle.
Papilloma
,
Choroid Plexus
/ pathology. Third Ventricle
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15963638.001).
[ISSN]
0303-8467
[Journal-full-title]
Clinical neurology and neurosurgery
[ISO-abbreviation]
Clin Neurol Neurosurg
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
Netherlands
[Number-of-references]
21
51.
Tatò L, Savage MO, Antoniazzi F, Buzi F, Di Maio S, Oostdijk W, Pasquino AM, Raiola G, Saenger P, Tonini G, Voorhoeve PG, International Workshop on Management of Puberty for Optimum Auxological Results:
Optimal therapy of pubertal disorders in precocious/early puberty.
J Pediatr Endocrinol Metab
; 2001 Jul;14 Suppl 2:985-95
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Optimal
therapy
of pubertal disorders in precocious/early puberty.
GnRHa have been used in
the treatment
of central precocious puberty (
CPP
)
for a
decade and some final results of this
therapy
are now available.
Treatment
preserves height potential in younger patients and a complete recovery of the hypothalamic-pituitary-gonadal axis occurs at the end
of treatment
.
However, some aspects of the management
of CPP
are still debated.
The possibility of progression of premature thelarche into precocious puberty, the pathogenesis of organic and idiopathic precocious puberty, the criteria
for decision
to treat and to stop
treatment
and the utility of an association with GH
treatment
will be better understood in the future.
Follow-up of patients after stopping
therapy
includes frequency and characteristics of menses, the possible higher incidence of polycystic ovary-like syndrome and the correct achievement
of a
normal peak bone mass and body composition.
[MeSH-major]
Puberty, Precocious /
therapy
[MeSH-minor]
Adolescent. Body Height /
drug
effects. Child. Female. Growth Hormone / adverse effects. Growth Hormone /
therapeutic
use. Humans. Male
Genetic Alliance.
consumer health - Precocious puberty
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 11529405.001).
[ISSN]
0334-018X
[Journal-full-title]
Journal of pediatric endocrinology & metabolism : JPEM
[ISO-abbreviation]
J. Pediatr. Endocrinol. Metab.
[Language]
eng
[Publication-type]
Guideline; Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
9002-72-6 / Growth Hormone
[Number-of-references]
76
52.
Patel MB, Feinstein AJ, Saenz AD, Majetschak M, Proctor KG:
Prehospital HBOC-201 after traumatic brain injury and hemorrhagic shock in swine.
J Trauma
; 2006 Jul;61(1):46-56
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prehospital HBOC-201 after traumatic
brain
injury and hemorrhagic shock in swine.
BACKGROUND: Data are limited on the actions of hemoglobin based oxygen carriers (HBOCs) after traumatic
brain
injury (TBI).
Supplemental NS was administered to both groups to maintain mean arterial pressure (MAP) >60 mm Hg until 60 minutes, and to maintain cerebral perfusion pressure (
CPP
) >70 mm Hg from 60 to 300 minutes.
The control group received mannitol (1 g/kg) and blood (10 mL/kg) at 90 minutes and half (n = 5) received
CPP
directed phenylephrine (PE)
therapy
after 120 minutes.
RESULTS: With HBOC administration, MAP,
CPP
, and
brain tissue
PO2 were restored within 30 minutes and maintained until 300 minutes.
In contrast, with control, MAP and
brain tissue
PO2 did not correct until 120 minutes, after mannitol, transfusion and 40% more crystalloid.
Furthermore, without PE,
CPP
did not reach target and 0/5 could be extubated.
CONCLUSIONS: After TBI, a single HBOC-201 bolus with minimal supplements provided rapid resuscitation, while maintaining
CPP
and improving
brain
oxygenation, without causing cardiac dysfunction, coagulopathy, cytokine release, or
brain
structural changes.
[MeSH-major]
Blood Substitutes / toxicity.
Brain
Injuries /
therapy
. Fluid
Therapy
/ methods. Hemoglobins / toxicity. Shock, Hemorrhagic /
therapy
[MeSH-minor]
Analysis of Variance. Animals. Blood Coagulation /
drug
effects.
Brain
/
drug
effects.
Brain
/ pathology. Cerebrovascular Circulation /
drug
effects. Cytokines / blood.
Drug
-Related Side Effects and Adverse Reactions. Female. Hemodynamics /
drug
effects. Male. Swine
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16832248.001).
[ISSN]
0022-5282
[Journal-full-title]
The Journal of trauma
[ISO-abbreviation]
J Trauma
[Language]
eng
[Grant]
United States / NIGMS NIH HHS / GM / T32 GM08749-01
[Publication-type]
Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Blood Substitutes; 0 / Cytokines; 0 / HBOC 201; 0 / Hemoglobins
53.
Esmaeili B, Basseda Z, Dehpour AR:
Antagonism of muscarinic M1 receptors by dicyclomine inhibits the consolidation of morphine-associated contextual memory.
Brain Res Bull
; 2008 Jul 1;76(4):380-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
M1 muscarinic receptor has been shown to be involved in cognitive functions of the
brain
.
Conditioned place preference (
CPP
) paradigm involves memory for the association between environmental stimuli and the rewarding properties produced by
a treatment
.
Using a balanced
CPP
design, we studied the possible involvement of M1 muscarinic receptors on the acquisition, expression and consolidation of morphine place conditioning in male mice.
Subcutaneous administration of morphine sulphate-induced
CPP
in a dose-dependent manner.
Using a 6-day schedule of conditioning, it was found that dicyclomine, an M1 muscarinic antagonist, significantly reduced
the time
spent by mice in the morphine compartment when given immediately, but not 6h, after each conditioning session (consolidation).
It had no effect when administered 30 min before each conditioning session during
CPP
training period (acquisition) or 30 min before testing for place preference in the absence of morphine (expression).
It is concluded that M1 muscarinic receptors may play
a time
-dependent role in the consolidation of reward-related memory of morphine.
[MeSH-major]
Dicyclomine / pharmacology. Learning /
drug
effects. Memory /
drug
effects. Morphine / pharmacology. Receptor, Muscarinic M1 / antagonists & inhibitors
[MeSH-minor]
Animals.
Brain
/
drug
effects.
Brain
/ metabolism. Conditioning (Psychology) /
drug
effects. Conditioning (Psychology) / physiology. Dose-Response Relationship,
Drug
.
Drug
Interactions / physiology. Male. Mice. Morphine Dependence /
drug therapy
. Morphine Dependence / metabolism. Muscarinic Antagonists / pharmacology. Narcotics / pharmacology. Reward.
Time
Factors
MedlinePlus Health Information.
consumer health - Memory
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
MORPHINE
.
Hazardous Substances Data Bank.
DICYCLOMINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18502314.001).
[ISSN]
1873-2747
[Journal-full-title]
Brain research bulletin
[ISO-abbreviation]
Brain Res. Bull.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Muscarinic Antagonists; 0 / Narcotics; 0 / Receptor, Muscarinic M1; 4KV4X8IF6V / Dicyclomine; 76I7G6D29C / Morphine
54.
Wang B, Luo F, Xia YQ, Han JS:
Peripheral electric stimulation inhibits morphine-induced place preference in rats.
Neuroreport
; 2000 Apr 7;11(5):1017-20
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Conditioned place preference (
CPP
) is a commonly used model to detect rewarding effect
of drugs
.
To observe the effect of peripheral electric stimulation (PES) on morphine-induced
CPP
, we trained the rats with morphine in
a CPP
paradigm.
PES of 2 and 2/100 Hz significantly decreased
CPP
in morphine-trained animals in a naloxone reversible manner, while PES of 100 Hz, foot shock, needle insertion, or plain restraining, showed no effect.
Thus, PES
with a
low-frequency component (2 Hz) could specifically inhibit the expression of morphine-induced
CPP
, presumably via activation of opioid receptors.
[MeSH-major]
Acupuncture
Therapy
/ methods. Analgesics, Opioid / pharmacology. Conditioning (Psychology) /
drug
effects. Morphine / pharmacology. Morphine Dependence /
therapy
. Peripheral Nerves / physiology
[MeSH-minor]
Animals. Dose-Response Relationship,
Drug
. Male. Rats. Rats, Sprague-Dawley.
Time
Factors. Transcutaneous Electric Nerve Stimulation
MedlinePlus Health Information.
consumer health - Acupuncture
.
Hazardous Substances Data Bank.
MORPHINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 10790875.001).
[ISSN]
0959-4965
[Journal-full-title]
Neuroreport
[ISO-abbreviation]
Neuroreport
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
ENGLAND
[Chemical-registry-number]
0 / Analgesics, Opioid; 76I7G6D29C / Morphine
55.
Eun JS, Bae K, Yun YP, Hong JT, Kwon HN, Oh KW:
Inhibitory effects of paeonol on morphine-induced locomotor sensitization and conditioned place preference in mice.
Arch Pharm Res
; 2006 Oct;29(10):904-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The inhibitory effects of paeonol, a major compound of Paeoniae radix, on the development of locomotor sensitization, conditioned place preference (
CPP
) and dopamine receptor supersensitivity induced by the repeated administration of morphine were investigated through behavioral experiments.
Repeated administration of morphine develops sensitization (reverse tolerance), a progressive enhancement of locomotion, which is used as a model for studying the
drug
-induced
drug
-seeking behaviors, and
CPP
, which is used as a model for studying
drug
reinforcement.
Paeonol inhibited morphine-induced hyperlocomotion, sensitization and
CPP
.
In addition, paeonol inhibited the development of postsynaptic dopamine receptors supersensitivity, which may be an underlying common mechanism that mediates the morphine-induced dopaminergic behaviors such as sensitization and
CPP
.
These results provide evidence that paeonol exerts anti-dopaminergic activity, and it is suggested that paeonol may be useful for the prevention and
therapy
of these adverse actions of morphine.
[MeSH-major]
Acetophenones / pharmacology. Conditioning (Psychology) /
drug
effects. Morphine / antagonists & inhibitors. Motor Activity /
drug
effects. Spatial Behavior /
drug
effects
[MeSH-minor]
Administration, Oral. Animals. Behavior, Animal /
drug
effects. Dopamine Antagonists / administration & dosage. Dopamine Antagonists / pharmacology. Dose-Response Relationship,
Drug
. Injections, Subcutaneous. Male. Mice. Mice, Inbred ICR. Paeonia / chemistry. Plant Roots / chemistry. Receptors, Dopamine / physiology
Hazardous Substances Data Bank.
MORPHINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17121187.001).
[ISSN]
0253-6269
[Journal-full-title]
Archives of pharmacal research
[ISO-abbreviation]
Arch. Pharm. Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Korea (South)
[Chemical-registry-number]
0 / Acetophenones; 0 / Dopamine Antagonists; 0 / Receptors, Dopamine; 3R834EPI82 / paeonol; 76I7G6D29C / Morphine
56.
McCall T, Binning M, Blumenthal DT, Jensen RL:
Variations of disseminated choroid plexus papilloma: 2 case reports and a review of the literature.
Surg Neurol
; 2006 Jul;66(1):62-7; discussion 67-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Variations of disseminated
choroid plexus
papilloma
: 2 case reports and a review of the literature.
BACKGROUND:
Choroid plexus papillomas
are typically considered
benign
lesions, but histology is not always predictive of their behavior.
We present 2 cases that illustrate the wide diversity with which
choroid plexus papillomas
can disseminate.
CASE DESCRIPTIONS: The patient described in case 1 had a primary fourth ventricular
choroid plexus
papilloma
that produced diffuse cystic subarachnoid and leptomeningeal lesions.
Patient 2 also had a primary fourth ventricular
tumor
but with subsequent suprasellar and spinal drop metastases.
Patient 2 has been treated with several modalities, including radiation
therapy
and
chemotherapy
, with slowing of symptom progression.
CONCLUSIONS: Variations of
choroid plexus
papilloma
dissemination include intraventricular, subarachnoid, and leptomeningeal nodules or cystic lesions, and intraparenchymal locations.
There is no consensus on the most effective
treatment for
choroid plexus
papilloma
metastases; surgical resection,
chemotherapy
, and radiation
therapy
may all yield benefits.
The prognosis for patients with disseminated
choroid plexus
papilloma
can range from prolonged stable
disease
and symptoms to death within months.
[MeSH-major]
Choroid Plexus
/ pathology.
Choroid Plexus
/ surgery. Meningeal Neoplasms /
diagnosis
. Meningeal Neoplasms /
therapy
.
Papilloma
,
Choroid Plexus
/
diagnosis
.
Papilloma
,
Choroid Plexus
/
therapy
[MeSH-minor]
Adult. Antineoplastic Agents /
therapeutic
use. Arachnoid / pathology. Arachnoid / physiopathology. Arachnoid / surgery.
Disease
Progression. Female. Humans. Pia Mater / pathology. Pia Mater / physiopathology. Pia Mater / surgery. Subarachnoid Space / pathology. Subarachnoid Space / physiopathology. Subarachnoid Space / surgery.
Treatment
Outcome
Genetic Alliance.
consumer health - Choroid Plexus Papilloma
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16793445.001).
[ISSN]
0090-3019
[Journal-full-title]
Surgical neurology
[ISO-abbreviation]
Surg Neurol
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents
[Number-of-references]
34
57.
Yu LL, Wang XY, Zhao M, Liu Y, Li YQ, Li FQ, Wang X, Xue YX, Lu L:
Effects of cannabinoid CB1 receptor antagonist rimonabant in consolidation and reconsolidation of methamphetamine reward memory in mice.
Psychopharmacology (Berl)
; 2009 Jun;204(2):203-11
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVES: The purpose of this study was to examine whether rimonabant, a cannabinoid CB1 receptor antagonist, would disrupt the consolidation and reconsolidation of methamphetamine-related reward memory, using conditioned place preference paradigm (
CPP
).
MATERIALS AND METHODS: Separate groups of male Kunming mice were trained to acquire methamphetamine
CPP
.
Vehicle or rimonabant (1 mg/kg or 3 mg/kg, i.p.) was given at different
time
points: immediately after each
CPP
training session (consolidation), 30 min before the reactivation
of CPP
(retrieval), or immediately after the reactivation
of CPP
(reconsolidation).
Methamphetamine
CPP
was retested 24 h and 1 and 2 weeks after rimonabant administration.
RESULTS: Rimonabant at doses of 1 and 3 mg/kg significantly inhibited the consolidation of methamphetamine
CPP
.
Only high-dose rimonabant (3 mg/kg) disrupted the retrieval and reconsolidation of methamphetamine
CPP
.
Rimonabant had no effect on methamphetamine
CPP
in the absence of methamphetamine
CPP
reactivation.
CONCLUSIONS: Our findings suggest that cannabinoid CB1 receptors play a major role in methamphetamine reward memory, and cannabinoid CB1 receptor antagonists may be a potential
pharmacotherapy
to manage relapse associated with
drug
-reward-related memory.
[MeSH-major]
Central Nervous System Stimulants / pharmacology. Memory /
drug
effects. Methamphetamine / pharmacology. Piperidines / pharmacology. Pyrazoles / pharmacology. Receptor, Cannabinoid, CB1 / antagonists & inhibitors
[MeSH-minor]
Animals. Dose-Response Relationship,
Drug
. Male. Mice. Reward
MedlinePlus Health Information.
consumer health - Memory
.
MedlinePlus Health Information.
consumer health - Methamphetamine
.
Hazardous Substances Data Bank.
d-METHAMPHETAMINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Neurobiol Learn Mem. 2008 Jul;90(1):1-9
[
18342551.001
]
[Cites]
Drug Alcohol Rev. 2008 May;27(3):236-42
[
18368604.001
]
[Cites]
Addiction. 1996 Jul;91(7):921-49; discussion 951-65
[
8688822.001
]
[Cites]
Learn Mem. 2006 May-Jun;13(3):316-21
[
16705137.001
]
[Cites]
Eur J Neurosci. 2007 Apr;25(7):2191-200
[
17419755.001
]
[Cites]
Annu Rev Neurosci. 2007;30:123-52
[
17417939.001
]
[Cites]
Neuropharmacology. 2002 Oct;43(5):857-67
[
12384171.001
]
[Cites]
Eur J Neurosci. 2004 Oct;20(7):1849-57
[
15380006.001
]
[Cites]
Acta Pharmacol Sin. 2007 Oct;28(10):1505-18
[
17883935.001
]
[Cites]
Nat Med. 2001 Oct;7(10 ):1151-4
[
11590440.001
]
[Cites]
J Neurosci. 2008 May 21;28(21):5602-10
[
18495894.001
]
[Cites]
Nature. 1993 Sep 2;365(6441):61-5
[
7689702.001
]
[Cites]
Drug Alcohol Rev. 2008 May;27(3):253-62
[
18368606.001
]
[Cites]
Neuroscience. 1998 Mar;83(2):393-411
[
9460749.001
]
[Cites]
Psychopharmacology (Berl). 2006 Mar;185(1):19-28
[
16374599.001
]
[Cites]
Dialogues Clin Neurosci. 2007;9(4):389-97
[
18286799.001
]
[Cites]
Science. 2002 Apr 26;296(5568):678-82
[
11976437.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2932-7
[
16473939.001
]
[Cites]
Am J Addict. 2001 Summer;10(3):201-17
[
11579619.001
]
[Cites]
J Neurosci. 2008 Dec 3;28(49):13248-57
[
19052216.001
]
[Cites]
Brain Res. 2006 Feb 23;1075(1):60-7
[
16464439.001
]
[Cites]
Trends Neurosci. 2003 Feb;26(2):65-72
[
12536129.001
]
[Cites]
Ann N Y Acad Sci. 2004 Oct;1025:515-27
[
15542757.001
]
[Cites]
Neurosci Lett. 2005 Jun 3;380(3):270-5
[
15862900.001
]
[Cites]
J Psychopharmacol. 2002 Jun;16(2):139-43
[
12095072.001
]
[Cites]
Drug Alcohol Rev. 2008 May;27(3):243-52
[
18368605.001
]
[Cites]
Neuropsychopharmacology. 2004 Aug;29(8):1470-8
[
15085091.001
]
[Cites]
Behav Brain Res. 2007 Mar 12;178(1):146-53
[
17239969.001
]
[Cites]
Neurobiol Learn Mem. 2007 Jan;87(1):93-100
[
16905344.001
]
[Cites]
Learn Mem. 2008 May 05;15(5):304-14
[
18463174.001
]
[Cites]
J Neurochem. 2007 Dec;103(6):2505-17
[
17953657.001
]
[Cites]
Nature. 2005 Sep 22;437(7058):556-9
[
16100511.001
]
[Cites]
Drug Alcohol Rev. 2008 May;27(3):229-35
[
18368603.001
]
[Cites]
Psychopharmacology (Berl). 2007 Apr;191(2):223-31
[
17211653.001
]
[Cites]
Neuroreport. 2007 Jul 16;18(11):1153-6
[
17589317.001
]
[Cites]
Hippocampus. 2001;11(1):8-17
[
11261775.001
]
[Cites]
Learn Mem. 2006 Jul-Aug;13(4):426-30
[
16882859.001
]
[Cites]
Eur J Pharmacol. 2008 Jul 28;589(1-3):122-6
[
18534572.001
]
[Cites]
Alcohol Clin Exp Res. 2007 Dec;31(12):2001-5
[
17949470.001
]
[Cites]
Am J Psychiatry. 2005 Aug;162(8):1414-22
[
16055762.001
]
[Cites]
Drug Alcohol Rev. 2008 Mar;27(2):185-9
[
18264880.001
]
[Cites]
Behav Pharmacol. 2005 Sep;16(5-6):395-404
[
16148444.001
]
[Cites]
Eur J Pharmacol. 2003 Sep 23;477(3):213-7
[
14522359.001
]
[Cites]
J Neurosci. 2001 Dec 1;21(23 ):9506-18
[
11717385.001
]
[Cites]
Prog Neurobiol. 1999 Jul;58(4):315-48
[
10368032.001
]
[Cites]
Neurobiol Learn Mem. 2005 Mar;83(2):119-24
[
15721795.001
]
[Cites]
Pharmacol Biochem Behav. 2005 Jun;81(2):396-406
[
15925401.001
]
[Cites]
J Pharmacol Exp Ther. 2005 Mar;312(3):875-83
[
15525797.001
]
[Cites]
Alcohol Alcohol. 2005 Jan-Feb;40(1):46-53
[
15582988.001
]
[Cites]
Neurosci Biobehav Rev. 2004 Jan;27(8):827-39
[
15019432.001
]
[Cites]
Trends Pharmacol Sci. 1994 Oct;15(10):374-9
[
7809953.001
]
[Cites]
Trends Pharmacol Sci. 2005 Aug;26(8):420-6
[
15992935.001
]
[Cites]
Jpn J Pharmacol. 2000 Nov;84(3):229-36
[
11138722.001
]
[Cites]
Neuron. 2005 Sep 15;47(6):873-84
[
16157281.001
]
[Cites]
Nat Rev Neurosci. 2008 Mar;9(3):182-94
[
18270514.001
]
[Cites]
J Neurosci. 1995 Mar;15(3 Pt 2):2301-11
[
7891168.001
]
[Cites]
J Physiol Biochem. 2000 Mar;56(1):17-24
[
10879677.001
]
[Cites]
Neuroreport. 2006 Sep 18;17(13):1443-7
[
16932155.001
]
[Cites]
Nature. 1990 Aug 9;346(6284):561-4
[
2165569.001
]
[Cites]
J Neurosci. 2006 Aug 16;26(33):8531-6
[
16914679.001
]
[Cites]
Eur J Neurosci. 2007 Jun;25(11):3417-21
[
17553010.001
]
[Cites]
Acta Pharmacol Sin. 2006 Feb;27(2):140-4
[
16412261.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11580-4
[
17592122.001
]
[Cites]
Eur J Pharmacol. 2004 Sep 13;498(1-3):119-23
[
15363985.001
]
[Cites]
Psychopharmacology (Berl). 2007 Dec;195(2):193-201
[
17661018.001
]
[Cites]
Pharmacol Biochem Behav. 2005 Jun;81(2):387-95
[
15935455.001
]
[Cites]
Neuropharmacology. 2004;47 Suppl 1:33-46
[
15464124.001
]
[Cites]
Annu Rev Neurosci. 2006;29:565-98
[
16776597.001
]
[Cites]
Neurocase. 2001;7(5):357-82
[
11744778.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1393-8
[
12538878.001
]
[Cites]
Neurobiol Learn Mem. 2008 Sep;90(2):374-81
[
18524639.001
]
[Cites]
Trends Neurosci. 2006 Dec;29(12):695-703
[
17084911.001
]
[Cites]
Trends Neurosci. 1990 Oct;13(10):420-3
[
1700516.001
]
[Cites]
Pharmacol Biochem Behav. 2005 Jun;81(2):263-84
[
15936806.001
]
(PMID = 19148622.001).
[ISSN]
1432-2072
[Journal-full-title]
Psychopharmacology
[ISO-abbreviation]
Psychopharmacology (Berl.)
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Central Nervous System Stimulants; 0 / Piperidines; 0 / Pyrazoles; 0 / Receptor, Cannabinoid, CB1; 44RAL3456C / Methamphetamine; RML78EN3XE / rimonabant
58.
Follis F, Blisard K, Varvitsiotis PS, Pett SB Jr, Temes T, Wernly JA:
Competitive NMDA receptor antagonists and spinal-cord ischemia.
J Invest Surg
; 2000 Mar-Apr;13(2):117-21; discussion 123-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Accordingly, we investigated the protective effect during spinal cord ischemia of two competitive antagonists, 4-(3-phosphonopropyl)-2-piperazine-carboxylic acid (
CPP
) and cis-4-(phosphonomethyl)-2-piperidine-carboxylic acid (CGS).
Male Sprague-Dawley rats underwent intrathecal administration of 10 microL saline, CGS, and
CPP
10 mM solutions, in a randomized blinded fashion, and were subjected to balloon occlusion of the thoracic aorta.
In the acute protocol, 21 rats divided in 3 groups of 7 (saline,
CPP
, and CGS) were used to calculate the aortic occlusion
time
(AOT) resulting in paraplegia in 50% of animals (P50).
In the chronic study, 24 rats divided in 4 groups of 6 (saline,
CPP
, CGS, sham) underwent 12-min occlusion.
In the acute study, the P50 of CGS (10 min 48 s) and
CPP
(11 min 11 s) was longer than saline (10 min 27 s).
In the chronic groups, analysis of variance of neurologic (p = .66) and histologic (p = .66) scores did not disclose differences between CGS,
CPP
, and saline.
In conclusion, blockade of NMDA receptors
with CPP
or CGS may afford some protection for durations of occlusion around the P50, but it is not beneficial when ischemic injury is more protracted.
[MeSH-major]
Excitatory Amino Acid Antagonists / pharmacology. Pipecolic Acids / pharmacology. Piperazines / pharmacology. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors. Spinal Cord Ischemia /
drug therapy
[MeSH-minor]
Acute
Disease
. Animals. Arterial Occlusive
Diseases
/
drug therapy
. Chronic
Disease
.
Disease
Models, Animal. Male. Paraplegia /
drug therapy
. Rats. Rats, Sprague-Dawley. Spinal Cord / blood supply. Spinal Cord / chemistry
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 10801049.001).
[ISSN]
0894-1939
[Journal-full-title]
Journal of investigative surgery : the official journal of the Academy of Surgical Research
[ISO-abbreviation]
J Invest Surg
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
UNITED STATES
[Chemical-registry-number]
0 / Excitatory Amino Acid Antagonists; 0 / Pipecolic Acids; 0 / Piperazines; 0 / Receptors, N-Methyl-D-Aspartate; 100828-16-8 / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; 4VGJ4A41L2 / selfotel
59.
Russo SJ, Festa ED, Fabian SJ, Gazi FM, Kraish M, Jenab S, Quiñones-Jenab V:
Gonadal hormones differentially modulate cocaine-induced conditioned place preference in male and female rats.
Neuroscience
; 2003;120(2):523-33
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In the present study, conditioned place preference (
CPP
), a measure of non-contingent reward, was used to determine the effects of endogenous gonadal hormones and of estrogen and progesterone replacement on cocaine reward.
Although both intact and gonadectomized male and female rats showed a significant
CPP for
cocaine, ovariectomy attenuated the magnitude
of CPP
.
These alterations coincided
with a
decrease in serum levels of corticosterone.
In ovariectomized rats, pretreatment with progesterone inhibited cocaine
CPP
while estrogen plus progesterone potentiated the magnitude
of CPP
.
[MeSH-major]
Cocaine / pharmacology. Conditioning (Psychology) /
drug
effects. Estrogens / pharmacology. Progesterone / pharmacology. Sex Characteristics
[MeSH-minor]
Analysis of Variance. Anesthetics, Local / pharmacology. Animals. Behavior, Animal. Biogenic Monoamines / metabolism. Cesarean Section / methods. Chromatography, High Pressure Liquid / instrumentation. Chromatography, High Pressure Liquid / methods. Corticosterone / blood.
Drug
Interactions. Exploratory Behavior /
drug
effects. Exploratory Behavior / physiology. Female. Hormone Replacement
Therapy
/ methods. Male. Motor Activity /
drug
effects. Motor Activity / physiology. Nucleus Accumbens /
drug
effects. Nucleus Accumbens / metabolism. Radioimmunoassay / methods. Rats. Rats, Inbred F344. Reaction
Time
. Reward.
Time
Factors. Ventral Tegmental Area /
drug
effects. Ventral Tegmental Area / metabolism
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
COCAINE
.
Hazardous Substances Data Bank.
PROGESTERONE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 12890521.001).
[ISSN]
0306-4522
[Journal-full-title]
Neuroscience
[ISO-abbreviation]
Neuroscience
[Language]
eng
[Grant]
United States / NIDA NIH HHS / DA / DA12136; United States / NIGMS NIH HHS / GM / GM60654; United States / NINDS NIH HHS / NS / NS-41073; United States / NCRR NIH HHS / RR / RR-03037
[Publication-type]
Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Anesthetics, Local; 0 / Biogenic Monoamines; 0 / Estrogens; 4G7DS2Q64Y / Progesterone; I5Y540LHVR / Cocaine; W980KJ009P / Corticosterone
60.
Gupta B, Torchilin VP:
Transactivating transcriptional activator-mediated drug delivery.
Expert Opin Drug Deliv
; 2006 Mar;3(2):177-90
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Transactivating transcriptional activator-mediated
drug
delivery.
However, the TATp remains the most popular
CPP
used
for a
variety of purposes.
This review article attempts to bring together the available data on TAT-mediated intracellular uptake
of a
broad range of molecules and nanoparticles.
[MeSH-major]
Drug
Carriers. Gene Products, tat / administration & dosage
[MeSH-minor]
Animals. Antibodies. Arginine / chemistry. Cell Membrane / metabolism. Genetic
Therapy
. Humans. Nanostructures. Peptides / administration & dosage. Peptides / chemistry. Protein Transport
Hazardous Substances Data Bank.
(L)-ARGININE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16506946.001).
[ISSN]
1742-5247
[Journal-full-title]
Expert opinion on drug delivery
[ISO-abbreviation]
Expert Opin Drug Deliv
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies; 0 / Drug Carriers; 0 / Gene Products, tat; 0 / Peptides; 94ZLA3W45F / Arginine
[Number-of-references]
120
61.
Jackson KJ, Walters CL, Miles MF, Martin BR, Damaj MI:
Characterization of pharmacological and behavioral differences to nicotine in C57Bl/6 and DBA/2 mice.
Neuropharmacology
; 2009 Sep;57(4):347-55
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Characterization
of pharmacological
and behavioral differences to nicotine in C57Bl/6 and DBA/2 mice.
Approximately 50-70% of the risk for developing nicotine dependence is attributed to genetics; therefore, it is of great significance to characterize the genetic mechanisms involved in nicotine reinforcement and dependence in hopes of generating better smoking cessation
therapies
.
The overall goal of these studies was to characterize behavioral and
pharmacological
responses to nicotine in C57Bl/6 (B6) and DBA/2 (D2) mice, two inbred strains commonly used for genetic studies on behavioral traits.
B6 and D2 mice where subjected to a battery of behavioral tests to measure nicotine's acute effects, calcium-mediated antinociceptive responses, tolerance to chronic
treatment with
osmotic mini pumps, and following three days of nicotine withdrawal.
B6, but not D2 mice,
developed
tolerance to nicotine and nicotine conditioned place preference (
CPP
).
These results provide a thorough, simultaneous evaluation of the
pharmacological
and behavioral differences to experimenter-administered nicotine as measured in several behavioral tests of aspects that contribute to smoking behavior.
Hazardous Substances Data Bank.
NICOTINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Psychopharmacology (Berl). 2007 Feb;190(3):269-319
[
16896961.001
]
[Cites]
Psychopharmacology (Berl). 2006 Mar;184(3-4):456-63
[
16463055.001
]
[Cites]
Eur J Pharmacol. 2005 May 23;516(1):40-5
[
15922326.001
]
[Cites]
Pharmacol Biochem Behav. 1999 Oct;64(2):221-8
[
10515295.001
]
[Cites]
Addiction. 1997 Oct;92(10):1277-87
[
9489045.001
]
[Cites]
J Pharmacol Exp Ther. 1991 Oct;259(1):392-402
[
1920127.001
]
[Cites]
Pharmacol Biochem Behav. 1989 Jul;33(3):667-78
[
2587608.001
]
[Cites]
Pharmacol Biochem Behav. 1988 May;30(1):269-78
[
3174752.001
]
[Cites]
Pharmacol Biochem Behav. 1985 Aug;23(2):325-30
[
4059317.001
]
[Cites]
Pharmacol Biochem Behav. 1977 Jan;6(1):25-30
[
850690.001
]
[Cites]
Mol Pharmacol. 2002 Aug;62(2):334-42
[
12130686.001
]
[Cites]
Eur J Pharmacol. 2000 Sep 15;404(1-2):103-10
[
10980268.001
]
[Cites]
Neuropsychopharmacology. 2000 May;22(5):451-65
[
10731620.001
]
[Cites]
J Pharmacol Exp Ther. 1983 Jul;226(1):291-302
[
6864548.001
]
[Cites]
J Pharmacol Exp Ther. 2008 Apr;325(1):302-12
[
18184829.001
]
[Cites]
J Pharmacol Exp Ther. 2007 Jul;322(1):399-407
[
17446302.001
]
[Cites]
Mol Pharmacol. 2007 Mar;71(3):826-34
[
17158199.001
]
[Cites]
Eur J Pharmacol. 1980 Oct 17;67(2-3):313-6
[
6893963.001
]
(PMID = 19619563.001).
[ISSN]
1873-7064
[Journal-full-title]
Neuropharmacology
[ISO-abbreviation]
Neuropharmacology
[Language]
ENG
[Grant]
United States / NIDA NIH HHS / DA / DA012610-02; United States / NIAAA NIH HHS / AA / U01 AA016662; United States / NIDA NIH HHS / DA / R01 DA012610; United States / NIAAA NIH HHS / AA / R01 AA013678; United States / NIAAA NIH HHS / AA / U01 AA016667; United States / NIDA NIH HHS / DA / #DA/ 12610; United States / NIDA NIH HHS / DA / R01 DA012610-02
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Enzyme Inhibitors; 0 / Nicotinic Agonists; 6M3C89ZY6R / Nicotine; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinase Type 2
[Other-IDs]
NLM/ NIHMS133451; NLM/ PMC2753410
62.
Bidwell GL 3rd, Raucher D:
Cell penetrating elastin-like polypeptides for therapeutic peptide delivery.
Adv Drug Deliv Rev
; 2010 Dec 30;62(15):1486-96
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cell penetrating elastin-like
polypeptides for therapeutic
peptide delivery.
Current
treatment of
solid tumors is limited by side effects that result from the non-specific delivery
of drugs
to
the tumor
site.
Alternative targeted
therapeutic
approaches for localized tumors would significantly reduce systemic toxicity.
Peptide
therapeutics
are a promising new strategy for targeted cancer
therapy
because of the ease of peptide design and the specificity of peptides for their intracellular molecular targets.
However, the utility of peptides is limited by their poor pharmacokinetic parameters and poor
tissue
and cellular membrane permeability in vivo.
This review article summarizes the development of elastin-like
polypeptide
(ELP) as a potential carrier for thermally targeted delivery
of therapeutic
peptides (TP), and the use of cell penetrating peptides (
CPP
) to enhance the intracellular delivery of the ELP-fused TPs.
CPP
-fused ELPs have been used to deliver a peptide inhibitor of c-Myc function and a peptide mimetic of p21 in several cancer models in vitro, and both
polypeptides
are currently yielding promising results in in vivo models of breast and
brain
cancer.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2010 Elsevier B.V. All rights reserved.
[Cites]
Cancer Res. 1987 Dec 15;47(24 Pt 1):6437-43
[
2824033.001
]
[Cites]
Cancer Metastasis Rev. 1987;6(4):559-93
[
3327633.001
]
[Cites]
J Cell Biol. 1989 Feb;108(2):389-400
[
2563728.001
]
[Cites]
J Natl Cancer Inst. 1989 Apr 19;81(8):570-6
[
2649688.001
]
[Cites]
Prog Biophys Mol Biol. 1992;57(1):23-57
[
1549698.001
]
[Cites]
J Biol Chem. 1994 Jan 21;269(3):1785-93
[
8294427.001
]
[Cites]
J Biol Chem. 1994 Apr 8;269(14):10444-50
[
8144628.001
]
[Cites]
Recent Results Cancer Res. 1995;138:81-90
[
7899701.001
]
[Cites]
Curr Biol. 1995 Mar 1;5(3):275-82
[
7780738.001
]
[Cites]
Molecules. 2009;14(6):1999-2015
[
19513001.001
]
[Cites]
Crit Rev Ther Drug Carrier Syst. 2009;26(2):119-55
[
19673689.001
]
[Cites]
Expert Opin Drug Deliv. 2009 Oct;6(10):1033-47
[
19637980.001
]
[Cites]
Expert Opin Drug Deliv. 2009 Oct;6(10):1079-90
[
19645633.001
]
[Cites]
Expert Opin Drug Deliv. 2009 Oct;6(10):1049-64
[
19743895.001
]
[Cites]
Nat Mater. 2009 Dec;8(12):993-9
[
19898461.001
]
[Cites]
Int J Cancer. 2010 Jan 15;126(2):533-44
[
19588502.001
]
[Cites]
Adv Drug Deliv Rev. 2010 Feb 17;62(2):231-9
[
20004693.001
]
[Cites]
Biochem Pharmacol. 2007 Mar 1;73(5):620-31
[
17161827.001
]
[Cites]
Cancer Res. 2007 May 1;67(9):4418-24
[
17483356.001
]
[Cites]
Invest New Drugs. 2007 Aug;25(4):313-26
[
17483874.001
]
[Cites]
J Drug Target. 2007 Aug-Sep;15(7-8):457-64
[
17671892.001
]
[Cites]
Mol Pharmacol. 2000 Apr;57(4):679-86
[
10727512.001
]
[Cites]
Eur J Pharm Biopharm. 2000 Jul;50(1):147-60
[
10840198.001
]
[Cites]
FASEB J. 2001 Jan;15(1):31-33
[
11099487.001
]
[Cites]
Int J Hyperthermia. 2001 Jan-Feb;17(1):1-18
[
11212876.001
]
[Cites]
Cancer Res. 2001 Feb 15;61(4):1548-54
[
11245464.001
]
[Cites]
Exp Cell Res. 2001 May 1;265(2):234-41
[
11302688.001
]
[Cites]
Annu Rev Biomed Eng. 1999;1:241-63
[
11701489.001
]
[Cites]
J Histochem Cytochem. 2002 Feb;50(2):185-95
[
11799137.001
]
[Cites]
Surgery. 2002 Jan;131(1 Suppl):S78-84
[
11821791.001
]
[Cites]
Biomacromolecules. 2002 Mar-Apr;3(2):357-67
[
11888323.001
]
[Cites]
J Urol. 2002 Oct;168(4 Pt 1):1597-602
[
12352464.001
]
[Cites]
Nat Rev Cancer. 2002 Oct;2(10):764-76
[
12360279.001
]
[Cites]
Biochemistry. 2002 Dec 3;41(48):14150-7
[
12450378.001
]
[Cites]
J Biol Chem. 2003 Jan 3;278(1):585-90
[
12411431.001
]
[Cites]
AAPS PharmSci. 2002;4(4):E26
[
12645998.001
]
[Cites]
Curr Protein Pept Sci. 2003 Apr;4(2):125-32
[
12678851.001
]
[Cites]
Curr Protein Pept Sci. 2003 Apr;4(2):133-40
[
12678852.001
]
[Cites]
J Control Release. 2003 Aug 28;91(1-2):31-43
[
12932635.001
]
[Cites]
Pharm Res. 2004 Mar;21(3):389-93
[
15070086.001
]
[Cites]
Science. 1983 Jul 22;221(4608):368-70
[
6408733.001
]
[Cites]
Biopolymers. 1985 Dec;24(12):2345-56
[
4092092.001
]
[Cites]
Proc Natl Acad Sci U S A. 1986 Aug;83(16):5948-52
[
3461466.001
]
[Cites]
J Biol Chem. 1995 Jun 16;270(24):14255-8
[
7782278.001
]
[Cites]
J Biol Chem. 1995 Sep 15;270(37):22008-16
[
7665622.001
]
[Cites]
Oncogene. 1996 Feb 1;12(3):595-607
[
8637717.001
]
[Cites]
Curr Biol. 1997 Jan 1;7(1):71-80
[
8999999.001
]
[Cites]
Br J Cancer. 1997;75(7):1028-34
[
9083339.001
]
[Cites]
J Biol Chem. 1997 Jun 20;272(25):16010-7
[
9188504.001
]
[Cites]
Anticancer Res. 1997 Jul-Aug;17(4B):2895-7
[
9329557.001
]
[Cites]
J Control Release. 1996 May;39(2-3):121-9
[
11539926.001
]
[Cites]
Semin Oncol. 1997 Dec;24(6):616-25
[
9422258.001
]
[Cites]
Oncogene. 1998 Jan 22;16(3):311-20
[
9467956.001
]
[Cites]
Trends Cell Biol. 1998 Feb;8(2):84-7
[
9695814.001
]
[Cites]
Cancer Res. 1998 Aug 15;58(16):3654-9
[
9721875.001
]
[Cites]
Cancer Res. 1999 Jul 15;59(14):3480-8
[
10416614.001
]
[Cites]
Science. 1999 Sep 3;285(5433):1569-72
[
10477521.001
]
[Cites]
Drug Discov Today. 2004 Dec 1;9(23):1012-9
[
15574317.001
]
[Cites]
Adv Drug Deliv Rev. 2005 Feb 28;57(4):609-36
[
15722167.001
]
[Cites]
Adv Drug Deliv Rev. 2005 Feb 28;57(4):637-51
[
15722168.001
]
[Cites]
Mol Cancer Ther. 2005 Jul;4(7):1076-85
[
16020665.001
]
[Cites]
J Control Release. 2005 Nov 28;108(2-3):396-408
[
16157413.001
]
[Cites]
Biochem Pharmacol. 2006 Jan 12;71(3):248-56
[
16316634.001
]
[Cites]
Trends Biotechnol. 2006 Jan;24(1):39-47
[
16307811.001
]
[Cites]
Drug Discov Today. 2006 Sep;11(17-18):812-8
[
16935749.001
]
[Cites]
J Control Release. 2006 Nov 28;116(2):170-8
[
16919353.001
]
[Cites]
Chemotherapy. 2007;53(1):73-6
[
17202815.001
]
[Cites]
Pharm Res. 2008 Mar;25(3):683-91
[
17762916.001
]
[Cites]
Adv Drug Deliv Rev. 2008 May 22;60(8):899-914
[
18406004.001
]
[Cites]
Curr Opin Oncol. 2008 Jul;20(4):438-43
[
18525341.001
]
[Cites]
J Control Release. 2008 Aug 7;129(3):179-86
[
18547669.001
]
[Cites]
Biochim Biophys Acta. 2008 Dec;1786(2):126-38
[
18440319.001
]
[Cites]
Curr Pharm Des. 2008;14(34):3628-36
[
19075739.001
]
[Cites]
Eur J Pharm Biopharm. 2009 Mar;71(3):409-19
[
19070661.001
]
[Cites]
J Control Release. 2009 Apr 2;135(1):2-10
[
19095020.001
]
[Cites]
Br J Pharmacol. 2009 May;157(2):195-206
[
19309362.001
]
(PMID = 20478348.001).
[ISSN]
1872-8294
[Journal-full-title]
Advanced drug delivery reviews
[ISO-abbreviation]
Adv. Drug Deliv. Rev.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R21 CA113813; United States / NCI NIH HHS / CA / R43 CA135799; United States / NCI NIH HHS / CA / R43 CA135799-01A2; United States / NCI NIH HHS / CA / R21 CA113813-01A2
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Cell-Penetrating Peptides; 0 / Peptides; 9007-58-3 / Elastin
[Other-IDs]
NLM/ NIHMS206184; NLM/ PMC2964383
63.
Takahashi M, Yamamoto J, Aoyama Y, Soejima Y, Akiba D, Nishizawa S:
Efficacy of multi-staged surgery and adjuvant chemotherapy for successful treatment of atypical choroid plexus papilloma in an infant: case report.
Neurol Med Chir (Tokyo)
; 2009 Oct;49(10):484-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Efficacy of multi-staged surgery and adjuvant
chemotherapy for
successful
treatment of
atypical
choroid plexus
papilloma
in an infant: case report.
A 12-month-old girl presented
with a
rare atypical
choroid plexus
papilloma
manifesting as conscious disturbance and vomiting.
Only partial removal of the
tumor
was performed because of excessive intraoperative hemorrhage at the first surgery.
The histological
diagnosis
was atypical
choroid plexus
papilloma
.
To control the intraoperative hemorrhage, embolization of the feeding artery was performed before the second surgery, and
the tumor
was macroscopically totally removed.
MR imaging disclosed a small residual
tumor
which showed relatively rapid growth.
Two months later, MR imaging showed a cystic lesion
with a
small nodule adjacent to the midbrain, indicating dissemination of the
tumor
.
The lesion was successfully treated
with chemotherapy
.
Atypical
choroid plexus
papilloma
was recently defined in
the classification
of the World Health Organization, so clinical data based on these criteria are lacking to establish
the therapeutic
strategy.
Total resection of atypical
choroid plexus
papilloma
is the most reliable
treatment
at present.
However, postoperative
chemotherapy
should be considered for recurrence or dissemination.
[MeSH-major]
Brain
/ surgery. Lateral Ventricles / surgery.
Papilloma
,
Choroid Plexus
/
drug therapy
.
Papilloma
,
Choroid Plexus
/ surgery
[MeSH-minor]
Antineoplastic Combined
Chemotherapy
Protocols /
therapeutic
use. Cerebral Arteries / pathology. Cerebral Arteries / physiopathology. Craniotomy. Embolization,
Therapeutic
. Female. Humans. Infant. Intraoperative Complications / etiology. Intraoperative Complications / physiopathology. Intraoperative Complications /
therapy
. Lethargy / etiology. Magnetic Resonance Imaging.
Neoplasm
Metastasis /
drug therapy
.
Neoplasm
Metastasis / pathology. Neurosurgical Procedures. Postoperative Hemorrhage / etiology. Postoperative Hemorrhage / physiopathology. Postoperative Hemorrhage /
therapy
. Reoperation.
Tomography
, X-Ray Computed.
Treatment
Outcome. Ventriculostomy. Vomiting / etiology
Genetic Alliance.
consumer health - Choroid Plexus Papilloma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19855149.001).
[ISSN]
1349-8029
[Journal-full-title]
Neurologia medico-chirurgica
[ISO-abbreviation]
Neurol. Med. Chir. (Tokyo)
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
64.
Bitler BG, Schroeder JA:
Anti-cancer therapies that utilize cell penetrating peptides.
Recent Pat Anticancer Drug Discov
; 2010 Jun;5(2):99-108
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anti-cancer
therapies
that utilize cell penetrating peptides.
Importantly, they can be linked to a variety of cargo, including anti-cancer
therapeutics
, making CPPs an efficient, effective and non-toxic mechanism for
drug
delivery.
In this review, we discuss a number
of CPP
conjugated
therapies
(CTTs) that are either patented are in the progress of patenting, and show strong promise for clinical efficacy.
In addition, many of these CTTs also increase sensitivity to current anti-cancer
therapy
modalities, including radiation and other DNA damaging chemotherapies, thereby decreasing the toxic dosage required for effective
treatment
.
Mechanistically, these CTTs function in a dominant-negative manner by blocking
tumor
-specific protein-protein interactions with the
CPP
-conjugated peptide or protein.
The treatment
of both cell lines and mouse models demonstrates that this method of molecular targeting results in equal if not greater efficacy than current standards of care, including DNA damaging agents and topoisomerase inhibitors.
For the
treatment of
invasive carcinoma, these CTTs have significant clinical potential to deliver highly targeted
therapies
without sacrificing the patient's quality of life.
[MeSH-major]
Antineoplastic Agents / administration & dosage. Cells / metabolism.
Drug
Delivery Systems / methods. Peptide Fragments / administration & dosage. Peptide Fragments / pharmacokinetics
[MeSH-minor]
Amino Acid Sequence. Animals. Gene Expression Regulation, Neoplastic /
drug
effects. Humans. Mice. Models, Biological
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19961434.001).
[ISSN]
2212-3970
[Journal-full-title]
Recent patents on anti-cancer drug discovery
[ISO-abbreviation]
Recent Pat Anticancer Drug Discov
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
[Publication-country]
United Arab Emirates
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Peptide Fragments
[Number-of-references]
85
65.
Szendei G, Hernádi Z, Dévényi N, Csapó Z:
Is there any correlation between stages of endometriosis and severity of chronic pelvic pain? Possibilities of treatment.
Gynecol Endocrinol
; 2005 Aug;21(2):93-100
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Is there any correlation between stages of endometriosis and severity of chronic pelvic pain? Possibilities
of treatment
.
We report herein findings on 181 patients, suffering from pelvic endometriosis confirmed by histology, whose main symptom was chronic pelvic pain (
CPP
).
The short form of the McGill pain questionnaire was used for the evaluation
of CPP
.
After the first operative intervention,
therapy
with a
gonadotropin-releasing hormone (GnRH) analog was given for 6 months.
Second-look laparoscopy was performed 8-10 weeks after the end of GnRH-analog
treatment
, which was followed by a non-conventionally administered, monophasic oral contraceptive (OC)
treatment
.
In the long term, 118 patients received the non-conventionally administered, monophasic OC
treatment
, which contained a third-generation progestogen, to be taken continuously for at least 6 months.
The other 63 patients who did not receive OC
treatment for
one reason or another were evaluated as a control group.
We analyzed data on
CPP
before the first surgical intervention, then following
therapy
with the GnRH analog at the second-look operation, and then after 6, 12, 18 and 24 months.
We also reviewed potential causes
of CPP
, especially focused on endometriosis.
No correlation was found between the stage of endometriosis according to R-AFS score and the severity
of CPP
.
At the 24-month follow-up after second-look laparoscopy, the non-conventionally administered monophasic OC
treatment
was found not only to significantly reduce pain scores, but also the required radical operative solution (hysterectomy plus bilateral adnexectomy)
for CPP
by OC users.
[MeSH-major]
Contraceptives, Oral, Combined /
therapeutic
use. Endometriosis /
drug therapy
. Gonadotropin-Releasing Hormone /
therapeutic
use. Pelvic Pain / prevention & control
[MeSH-minor]
Combined Modality
Therapy
.
Drug
Administration Schedule. Dysmenorrhea /
drug therapy
. Dyspareunia /
drug therapy
. Female. Humans. Laparoscopy. Pain Measurement. Secondary Prevention
Genetic Alliance.
consumer health - Endometriosis
.
MedlinePlus Health Information.
consumer health - Endometriosis
.
MedlinePlus Health Information.
consumer health - Pelvic Pain
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16109595.001).
[ISSN]
0951-3590
[Journal-full-title]
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
[ISO-abbreviation]
Gynecol. Endocrinol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Contraceptives, Oral, Combined; 33515-09-2 / Gonadotropin-Releasing Hormone
66.
Stoilova TB, Kovalchuk SI, Egorova NS, Surovoy AY, Ivanov VT:
Gramicidin A-based peptide vector for intracellular protein delivery.
Biochim Biophys Acta
; 2008 Oct;1778(10):2026-31
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The development of the peptide-based vectors for the intracellular delivery of biologically active macromolecules has opened new prospects of their application in research and
therapy
.
Earlier the amphipathic cell-penetrating peptide (
CPP
) Pep-1 was reported to mediate cellular uptake of proteins without covalent binding to them.
In this work we studied the ability
of a
series of membrane-active amphipathic peptides, based on the gramicidin A sequence, to transport a model protein across the eukaryotic cell membrane.
In addition, a series of new gramicidin analogues were prepared and the effect
of N
-terminus modification of gramicidin on the protein transduction efficiency was studied.
[MeSH-major]
Anti-Bacterial Agents / metabolism. Cell Membrane Permeability.
Drug
Delivery Systems. Genetic Vectors / metabolism. Gramicidin / metabolism. Peptides / metabolism
MedlinePlus Health Information.
consumer health - Antibiotics
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18339303.001).
[ISSN]
0006-3002
[Journal-full-title]
Biochimica et biophysica acta
[ISO-abbreviation]
Biochim. Biophys. Acta
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Anti-Bacterial Agents; 0 / Peptides; 1405-97-6 / Gramicidin; EC 3.2.1.23 / beta-Galactosidase
67.
Li SX, Wang ZR, Li J, Peng ZG, Zhou W, Zhou M, Lu L:
Inhibition of Period1 gene attenuates the morphine-induced ERK-CREB activation in frontal cortex, hippocampus, and striatum in mice.
Am J Drug Alcohol Abuse
; 2008;34(6):673-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVE: Recent studies demonstrated that the Period1 gene (Per1) is involved in behavioral alterations induced by addictive
drugs
.
We explored the effects of inhibiting expression in
brain of
Per1 on morphine conditioned place preference (
CPP
) and morphine-induced phosphorylation of extracellular signal-regulated kinase (ERK) and cAMP-response element binding protein (CREB) in mice.
After testing
CPP
, mice were sacrificed and phosphorylated ERK and CREB in the frontal cortex, hippocampus, and striatum were examined by immunohistochemistry.
RESULTS: Mice pretreated with DRz164 did not acquire morphine
CPP
.
We suggested that per1 gene may be a potential
treatment
target for
drug
addition.
[MeSH-major]
Cell Cycle Proteins /
drug
effects. Cyclic AMP Response Element-Binding Protein /
drug
effects. Extracellular Signal-Regulated MAP Kinases /
drug
effects. Morphine / pharmacology. Nuclear Proteins /
drug
effects
[MeSH-minor]
Animals. Conditioning, Operant /
drug
effects. Corpus Striatum / metabolism. DNA, Catalytic / pharmacology.
Drug
Delivery Systems. Frontal Lobe / metabolism. Gene Expression Regulation /
drug
effects. Hippocampus / metabolism. Male. Mice. Mice, Inbred BALB C. Morphine Dependence /
drug therapy
. Morphine Dependence / physiopathology. Period Circadian Proteins. Phosphorylation /
drug
effects. RNA, Messenger /
drug
effects. RNA, Messenger / metabolism. Reward
Hazardous Substances Data Bank.
MORPHINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18850497.001).
[ISSN]
1097-9891
[Journal-full-title]
The American journal of drug and alcohol abuse
[ISO-abbreviation]
Am J Drug Alcohol Abuse
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Cell Cycle Proteins; 0 / Cyclic AMP Response Element-Binding Protein; 0 / DNA, Catalytic; 0 / Nuclear Proteins; 0 / Per1 protein, mouse; 0 / Period Circadian Proteins; 0 / RNA, Messenger; 76I7G6D29C / Morphine; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
68.
Langford CF, Udvari Nagy S, Ghoniem GM:
Levator ani trigger point injections: An underutilized treatment for chronic pelvic pain.
Neurourol Urodyn
; 2007;26(1):59-62
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Levator ani trigger point injections: An underutilized
treatment for
chronic pelvic pain.
AIMS: We conducted this study to examine the role of trigger point injections in females with chronic pelvic pain (
CPP
) of at least 6 months duration and specific levator ani trigger points.
METHODS: This prospective study included 18 consecutive female patients
with CPP
and specific palpable levator ani trigger points.
CONCLUSION: In the management
of CPP
, a non-surgical office-based
therapy
such as trigger point injections can be effective in selected patients.
[MeSH-major]
Anesthetics, Local / administration & dosage. Anus
Diseases
/ complications. Bupivacaine / administration & dosage. Myofascial Pain Syndromes /
drug therapy
. Pelvic Pain /
drug therapy
[MeSH-minor]
Adult. Aged. Anti-Inflammatory Agents / administration & dosage. Chronic
Disease
.
Drug Therapy
, Combination. Female. Humans. Injections, Intramuscular. Lidocaine / administration & dosage. Middle Aged. Pain Measurement. Palpation. Prospective Studies. Spasm /
diagnosis
. Spasm /
drug therapy
. Spasm / etiology.
Treatment
Outcome. Triamcinolone / administration & dosage. Vagina
MedlinePlus Health Information.
consumer health - Anal Disorders
.
MedlinePlus Health Information.
consumer health - Pelvic Pain
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
TRIAMCINOLONE
.
Hazardous Substances Data Bank.
LIDOCAINE
.
SciCrunch.
The Antibody Registry: Reagent: Antibodies
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2006 Wiley-Liss, Inc.
(PMID = 17195176.001).
[ISSN]
0733-2467
[Journal-full-title]
Neurourology and urodynamics
[ISO-abbreviation]
Neurourol. Urodyn.
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Anesthetics, Local; 0 / Anti-Inflammatory Agents; 1ZK20VI6TY / Triamcinolone; 98PI200987 / Lidocaine; Y8335394RO / Bupivacaine
69.
Lee PA, Houk CP:
Gonadotropin-releasing hormone analog therapy for central precocious puberty and other childhood disorders affecting growth and puberty.
Treat Endocrinol
; 2006;5(5):287-96
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Gonadotropin-releasing hormone analog
therapy
for central precocious puberty and other childhood disorders affecting growth and puberty.
Gonadotropin-releasing hormone (GnRH) analog
therapy
relies primarily on the ability of these compounds to bind to and modulate GnRH-receptor activity.
GnRH analogs have been used in pediatric patients where endogenous gonadotropin release is undesirable or potentially harmful, such as in: (i) patients with central precocious puberty (
CPP
);.
(ii) healthy short children where pubertal delay would provide an opportunity to supplement pre-pubertal linear growth; and (iii) children with malignancies and other disorders where
treatment
requires the use of gonadotoxic compounds.
In the first two groups of patients, GnRH agonists may be used alone or in conjunction with somatropin (growth hormone [GH]) to prevent early skeletal maturation and increase the subsequent adult height, while in the latter case, GnRH agonists are used alone or in conjunction with GnRH antagonists in an attempt to preserve gonadal function.In children and adolescents
with CPP
, timely use of GnRH agonists alone can result in an adult height within the genetic potential of the individual (target height); however, minimal height is gained when GnRH agonist
therapy
is commenced after a marked advancement of skeletal age.
This provides the rationale for combined
therapy
with GnRH agonists and somatropin in such patients, and studies have shown improved growth with this approach compared with GnRH agonists alone.
Combination
therapy
with GnRH agonists and somatropin has also been shown to increase adult heights to a greater extent than GnRH agonists alone in pediatric patients with concomitant
CPP
and GH deficiency, those with idiopathic short stature, and those born small for gestational age; however, such combination
therapy
has shown no increased benefit over somatropin alone in pediatric patients with GH deficiency.
Limited results in children and adolescents with congenital adrenal hyperplasia and chronic primary hypothyroidism have also shown increased growth rates, while no growth benefit was seen in pediatric renal transplant recipients.GnRH analogs also have potential as gonadoprotective agents; studies of GnRH agonists used alone and in combination with GnRH antagonists in women undergoing cytotoxic
therapy
have shown increased preservation of reproductive potential in patients who were receiving GnRH analog
therapy
versus those who were not.The adverse effects of GnRH analogs mainly consist of menopausal-like complaints.
Increases in bodyweight and body mass index in children receiving GnRH agonist
therapy
have been shown; however, these increases do not persist after discontinuation of
therapy
.
Adult bone mineral density and fertility are also not adversely affected by childhood GnRH agonist
therapy
.GnRH analog
therapy
appears to be both well tolerated and effective in pediatric patients, as it allows the preservation or improvement of adult height, and shows no longstanding negative effects on body composition, bone density, reproductive function, or endocrine physiology.
These agents may also be useful for preservation of gonadal function in children and adolescents undergoing cytotoxic
therapy
.
[MeSH-minor]
Body Height /
drug
effects.
Drug Therapy
, Combination. Humans. Puberty. Sexual Maturation
Genetic Alliance.
consumer health - Precocious puberty
.
Genetic Alliance.
consumer health - Central precocious puberty
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17002488.001).
[ISSN]
1175-6349
[Journal-full-title]
Treatments in endocrinology
[ISO-abbreviation]
Treat Endocrinol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
New Zealand
[Chemical-registry-number]
33515-09-2 / Gonadotropin-Releasing Hormone
70.
Biala G, Staniak N, Budzynska B:
Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats.
Naunyn Schmiedebergs Arch Pharmacol
; 2010 Apr;381(4):361-70
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by
drug
priming in rats.
In the present study, we used the conditioned place preference (
CPP
) paradigm to investigate the establishment, extinction, reinstatement, and cross-reinstatement of nicotine-induced place conditioning in rats.
Once established, nicotine
CPP
was extinguished by repeated testing.
These priming injections of both
drugs
induced a marked preference for the compartment previously paired with nicotine.
Furthermore, given the important role of alpha4beta2 (a4b2) nicotinic receptor
subtype
in the acquisition and maintenance of nicotine dependence, we evaluated and compared the efficacy of varenicline, a partial a4b2 nicotinic receptor agonist (0.5, 1, and 2 mg/kg, subcutaneously (s.c.
), a non-selective nicotinic receptor antagonist, in blocking nicotine-induced
CPP
as well as reinstatement of nicotine
CPP
provoked by nicotine and morphine.
It was shown that both nicotinic receptor ligands attenuated the acquisition and expression of nicotine
CPP
as well as the expression of reinstatement of nicotine
CPP
provoked by both
drugs
.
Our results indicate similar cholinergic mechanisms, probably through the a4b2 receptors involved in the rewarding effects of nicotine and morphine in rats and may suggest that nicotinic receptors could be a potential target for developing
pharmacotherapeutic
strategies to treat and prevent nicotine and/or opioid addiction and relapse.
[MeSH-major]
Nicotine / administration & dosage. Nicotinic Agonists / pharmacology. Nicotinic Antagonists / pharmacology. Receptors, Nicotinic /
drug
effects
[MeSH-minor]
Animals. Benzazepines / administration & dosage. Benzazepines / pharmacology. Conditioning, Classical /
drug
effects. Dose-Response Relationship,
Drug
. Male. Mecamylamine / administration & dosage. Mecamylamine / pharmacology. Morphine / administration & dosage. Morphine / pharmacology. Quinoxalines / administration & dosage. Quinoxalines / pharmacology. Rats. Rats, Wistar. Reward. Tobacco Use Disorder / physiopathology. Varenicline
Hazardous Substances Data Bank.
VARENICLINE
.
Hazardous Substances Data Bank.
NICOTINE
.
Hazardous Substances Data Bank.
MORPHINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Addiction. 2008 Jan;103(1):146-54
[
18028247.001
]
[Cites]
Neuropharmacology. 2007 Mar;52(3):985-94
[
17157884.001
]
[Cites]
Prog Neurobiol. 1998 Dec;56(6):613-72
[
9871940.001
]
[Cites]
Prog Neurobiol. 2004 Dec;74(6):363-96
[
15649582.001
]
[Cites]
Naunyn Schmiedebergs Arch Pharmacol. 1993 Jan;347(1):9-13
[
8095326.001
]
[Cites]
Brain Res. 2001 Jun 8;903(1-2):62-5
[
11382388.001
]
[Cites]
Nicotine Tob Res. 2007 Mar;9(3):315-27
[
17365764.001
]
[Cites]
Neuron. 2002 Mar 14;33(6):905-19
[
11906697.001
]
[Cites]
J Med Chem. 2005 May 19;48(10):3474-7
[
15887955.001
]
[Cites]
J Neurosci. 2002 Dec 15;22(24):10935-40
[
12486188.001
]
[Cites]
J Neurosci. 2003 Apr 15;23(8):3176-85
[
12716925.001
]
[Cites]
Neuropharmacology. 2007 Mar;52(3):755-63
[
17097117.001
]
[Cites]
Behav Neurosci. 1993 Dec;107(6):1077-87
[
8136061.001
]
[Cites]
Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):413-21
[
12769613.001
]
[Cites]
J Pharmacol Exp Ther. 2009 Apr;329(1):225-30
[
19126781.001
]
[Cites]
Psychopharmacology (Berl). 2006 Mar;184(3-4):619-27
[
16308727.001
]
[Cites]
Trends Neurosci. 1997 Feb;20(2):92-8
[
9023878.001
]
[Cites]
J Neurosci. 1992 Jul;12(7):2765-84
[
1613557.001
]
[Cites]
Neuroscience. 2005;136(2):531-8
[
16216430.001
]
[Cites]
Eur Neuropsychopharmacol. 1999 Mar;9(3):227-33
[
10208292.001
]
[Cites]
Psychopharmacology (Berl). 1999 Nov;147(2):135-42
[
10591880.001
]
[Cites]
Neuropharmacology. 2000 Oct;39(13):2740-55
[
11044744.001
]
[Cites]
Trends Pharmacol Sci. 2007 Jul;28(7):316-25
[
17573127.001
]
[Cites]
Eur J Pharmacol. 2007 May 7;562(1-2):92-102
[
17336285.001
]
[Cites]
Nature. 2005 Jul 7;436(7047):103-7
[
16001069.001
]
[Cites]
Pharmacol Rep. 2005 Nov-Dec;57(6):755-60
[
16382193.001
]
[Cites]
Psychopharmacology (Berl). 1999 Feb;142(1):85-94
[
10102787.001
]
[Cites]
JAMA. 2006 Jul 5;296(1):64-71
[
16820548.001
]
[Cites]
JAMA. 1994 Feb 23;271(8):589-94
[
8301790.001
]
[Cites]
J Pharmacol Exp Ther. 2003 Jul;306(1):407-20
[
12682217.001
]
[Cites]
Eur J Pharmacol. 2006 May 10;537(1-3):85-93
[
16616917.001
]
[Cites]
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jan;30(1):15-21
[
16202496.001
]
[Cites]
Psychopharmacology (Berl). 2006 Nov;189(1):27-36
[
17019569.001
]
[Cites]
Nat Med. 2002 May;8(5):447-9
[
11984581.001
]
[Cites]
Nature. 1998 Jan 8;391(6663):173-7
[
9428762.001
]
[Cites]
Synapse. 2000 Feb;35(2):129-36
[
10611638.001
]
[Cites]
Am J Health Syst Pharm. 2007 Jul 1;64(13):1381-4
[
17592002.001
]
[Cites]
Prog Neuropsychopharmacol Biol Psychiatry. 1994 Sep;18(5):925-33
[
7972862.001
]
[Cites]
Pharmacol Biochem Behav. 1997 Aug;57(4):915-21
[
9259024.001
]
[Cites]
Pharmacol Biochem Behav. 2008 Mar;89(1):116-25
[
18178244.001
]
[Cites]
Neuron. 2001 Aug 16;31(3):349-52
[
11516393.001
]
[Cites]
Eur J Neurosci. 2003 Apr;17 (7):1329-37
[
12713636.001
]
[Cites]
Psychopharmacology (Berl). 2000 Jan;147(4):347-55
[
10672627.001
]
[Cites]
Psychopharmacology (Berl). 1992;107(2-3):285-9
[
1615127.001
]
[Cites]
Pol J Pharmacol. 2003 May-Jun;55(3):327-35
[
14506311.001
]
[Cites]
Curr Opin Pharmacol. 2005 Feb;5(1):53-9
[
15661626.001
]
[Cites]
Pharmacol Biochem Behav. 1999 Apr;62(4):743-51
[
10208381.001
]
(PMID = 20217050.001).
[ISSN]
1432-1912
[Journal-full-title]
Naunyn-Schmiedeberg's archives of pharmacology
[ISO-abbreviation]
Naunyn Schmiedebergs Arch. Pharmacol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Benzazepines; 0 / Nicotinic Agonists; 0 / Nicotinic Antagonists; 0 / Quinoxalines; 0 / Receptors, Nicotinic; 0 / nicotinic receptor alpha4beta2; 6EE945D3OK / Mecamylamine; 6M3C89ZY6R / Nicotine; 76I7G6D29C / Morphine; W6HS99O8ZO / Varenicline
71.
Stubbe HD, Greiner C, Westphal M, Rickert CH, Aken HV, Eichel V, Wassmann H, Daudel F, Hinder F:
Cerebral response to norepinephrine compared with fluid resuscitation in ovine traumatic brain injury and systemic inflammation.
Crit Care Med
; 2006 Oct;34(10):2651-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cerebral response to norepinephrine compared with fluid resuscitation in ovine traumatic
brain
injury and systemic inflammation.
OBJECTIVE: Traumatic
brain
injury is frequently accompanied by a systemic inflammatory response.
The present study investigated the cerebral effects of cerebral perfusion pressure (
CPP
) management performed by either fluid resuscitation or vasopressor
treatment of
low
CPP
induced by systemic inflammation.
At hour 10, one group (n = 6) was infused with hydroxyethyl starch until
CPP
reached 60-70 mm Hg.
A second group (n = 6) received norepinephrine
for CPP
elevation.
Head trauma increased
intracranial
pressure and decreased
brain tissue
oxygen
tension
.
Endotoxemia induced a hyperdynamic cardiovascular response with increased internal carotid blood flow in the presence of systemic hypotension and decreased
CPP
.
Hydroxyethyl starch infusion further increased internal carotid blood flow from (mean +/- sd) 247 +/- 26 (hour 10) to 342 +/- 42 mL/min (hour 13) and
intracranial
pressure from 20 +/- 4 (hour 10) to a maximum of 25 +/- 3 mm Hg (hour 12) but did not significantly affect
brain tissue
oxygen
tension
, sinus venous oxygen saturation and oxygen extraction fraction.
Norepinephrine increased internal carotid blood flow from 268 +/- 19 to 342 +/- 58 mL/min and
intracranial
pressure from 22 +/- 11 to 24 +/- 11 mm Hg (hour 10 vs. hour 13) but significantly increased sinus venous oxygen saturation from 49 +/- 4 (hour 10) to a maximum of 59 +/- 6 mm Hg (hour 12) and decreased oxygen extraction fraction.
The increase in
brain tissue
oxygen
tension
during norepinephrine
treatment
was not significant.
CONCLUSION: We conclude that despite identical carotid blood flows, only
CPP
management with norepinephrine reduced the cerebral oxygen deficit in this model.
[MeSH-major]
Brain
Injuries /
therapy
. Cerebrovascular Circulation. Fluid
Therapy
. Norepinephrine /
therapeutic
use. Systemic Inflammatory Response Syndrome /
therapy
. Vasoconstrictor Agents /
therapeutic
use
[MeSH-minor]
Animals. Hemodynamics /
drug
effects.
Intracranial
Pressure /
drug
effects. Sheep
Hazardous Substances Data Bank.
Norepinephrine
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Crit Care Med. 2006 Oct;34(10):2697-8
[
16983278.001
]
(PMID = 16932232.001).
[ISSN]
0090-3493
[Journal-full-title]
Critical care medicine
[ISO-abbreviation]
Crit. Care Med.
[Language]
eng
[Publication-type]
Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Vasoconstrictor Agents; X4W3ENH1CV / Norepinephrine
72.
Klouche K, Weil MH, Sun S, Tang W, Zhao DH:
A comparison of alpha-methylnorepinephrine, vasopressin and epinephrine for cardiac resuscitation.
Resuscitation
; 2003 Apr;57(1):93-100
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We had previously observed significantly better outcomes
with a
selective alpha(2)-adrenergic agonist when compared with epinephrine.
The present study was, therefore, undertaken to compare a selective alpha(2)-adrenergic vasopressor
drug
with vasopressin, epinephrine, and saline placebo.
Left ventricular pressure, dP/
dt
(40), -dP/
dt
, and cardiac index were measured for an interval of 240 min after resuscitation.
Except for saline controls, comparable increases in coronary perfusion pressure (
CPP
) were observed after each
drug
intervention.
[MeSH-major]
Cardiopulmonary Resuscitation / methods. Nordefrin / pharmacology. Vasoconstrictor Agents / pharmacology. Vasopressins / pharmacology. Ventricular Fibrillation /
therapy
[MeSH-minor]
Analysis of Variance. Animals. Cardiac Output / physiology.
Disease
Models, Animal. Dose-Response Relationship,
Drug
.
Drug
Administration Schedule. Electrocardiography. Hemodynamics / physiology. Male. Probability. Rats. Rats, Sprague-Dawley. Sensitivity and Specificity. Survival Rate
MedlinePlus Health Information.
consumer health - CPR
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
VASOPRESSIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 12668305.001).
[ISSN]
0300-9572
[Journal-full-title]
Resuscitation
[ISO-abbreviation]
Resuscitation
[Language]
eng
[Grant]
United States / NHLBI NIH HHS / HL / HL-54322
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
Ireland
[Chemical-registry-number]
0 / Vasoconstrictor Agents; 11000-17-2 / Vasopressins; R81X549E70 / Nordefrin
73.
Koos B, Paulsson J, Jarvius M, Sanchez BC, Wrede B, Mertsch S, Jeibmann A, Kruse A, Peters O, Wolff JE, Galla HJ, Söderberg O, Paulus W, Ostman A, Hasselblatt M:
Platelet-derived growth factor receptor expression and activation in choroid plexus tumors.
Am J Pathol
; 2009 Oct;175(4):1631-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Platelet-derived growth factor receptor expression and activation in
choroid plexus
tumors.
Choroid plexus
tumors are intraventricular neoplasms predominantly affecting young children.
In contrast to
choroid plexus papillomas
,
choroid plexus
carcinomas progress frequently, necessitating the development of adjuvant
treatment
concepts.
The finding
of PDGF receptor expression in
choroid plexus
tumors prompted us to elucidate PDGF receptor activation state using a novel method, in situ proximity ligation assay, on formalin-fixed, paraffin-embedded, archival samples of 19
choroid plexus
tumors.
As assessed by in situ proximity ligation assay, the proportion of phosphorylated PDGF receptor alpha was low in
choroid plexus papillomas
and
choroid plexus
carcinomas, whereas phosphorylated PDGF receptor beta was found to be significantly higher in
choroid plexus
carcinomas.
In the immortalized
choroid plexus
epithelial cell line Z310 expressing PDGF receptor beta, PDGF-BB exhibited
a time
- and dose-dependent proliferative response, which was significantly attenuated by imatinib (gleevec).
In conclusion, our findings suggest that PDGF receptor beta is functionally involved in the biology of
choroid plexus
tumors and may represent a molecular target for
therapy
.
In addition, this study demonstrates the feasibility and usefulness of in situ proximity ligation assay for monitoring receptor tyrosine kinase activation in formalin-fixed, paraffin-embedded, archival
tissues
.
[MeSH-major]
Choroid Plexus
Neoplasms / metabolism. Receptor, Platelet-Derived Growth Factor alpha / metabolism. Receptor, Platelet-Derived Growth Factor beta / metabolism
[MeSH-minor]
Animals. Cell Line. Cell Line, Transformed. Cell Proliferation /
drug
effects. Epithelial Cells /
drug
effects. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Infant. Male.
Papilloma
/ metabolism.
Papilloma
/ pathology. Phosphorylation /
drug
effects. Platelet-Derived Growth Factor / pharmacology. Rats
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nat Genet. 2001 Oct;29(2):143-52
[
11544480.001
]
[Cites]
Comput Methods Programs Biomed. 2009 Apr;94(1):58-65
[
18950895.001
]
[Cites]
Brain Res. 2002 Dec 27;958(2):371-80
[
12470873.001
]
[Cites]
Cytokine Growth Factor Rev. 2004 Aug;15(4):197-204
[
15207811.001
]
[Cites]
Mol Cancer. 2003 Jan 3;2:1
[
12537587.001
]
[Cites]
Blood. 2004 Nov 1;104(9):2655-60
[
15231574.001
]
[Cites]
EMBO J. 1992 Feb;11(2):543-50
[
1311251.001
]
[Cites]
J Neuropathol Exp Neurol. 2005 May;64(5):391-7
[
15892296.001
]
[Cites]
Am J Surg Pathol. 2006 Jan;30(1):66-74
[
16330944.001
]
[Cites]
J Neurooncol. 2006 Jan;76(2):105-9
[
16205964.001
]
[Cites]
J Neuropathol Exp Neurol. 2006 Nov;65(11):1069-73
[
17086103.001
]
[Cites]
Adv Cancer Res. 2007;97:247-74
[
17419949.001
]
[Cites]
Acta Neuropathol. 2007 Aug;114(2):97-109
[
17618441.001
]
[Cites]
Mol Cell Proteomics. 2007 Sep;6(9):1500-9
[
17565975.001
]
[Cites]
Mod Pathol. 2008 Mar;21(3):265-70
[
18157090.001
]
[Cites]
Genes Dev. 2008 May 15;22(10):1276-312
[
18483217.001
]
[Cites]
Nat Rev Drug Discov. 2002 Jul;1(7):493-502
[
12120256.001
]
(PMID = 19717644.001).
[ISSN]
1525-2191
[Journal-full-title]
The American journal of pathology
[ISO-abbreviation]
Am. J. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Platelet-Derived Growth Factor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
[Other-IDs]
NLM/ PMC2751559
74.
Lewis HD, Husain A, Donnelly RJ, Barlos D, Riaz S, Ginjupalli K, Shodeinde A, Barton BE:
Creation of a novel peptide with enhanced nuclear localization in prostate and pancreatic cancer cell lines.
BMC Biotechnol
; 2010 Oct 28;10:79
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Creation
of a
novel peptide with enhanced nuclear localization in prostate and
pancreatic
cancer cell lines.
BACKGROUND: For improved uptake of oligonucleotide-based
therapy
, the oligonucleotides often are coupled to peptides that facilitate entry into cells.
To this end, novel cell-penetrating peptides (CPPs) were designed for mediating intracellular uptake of oligonucleotide-based
therapeutics
.
The novel peptides were based on taking advantage of the nuclear localization properties of transcription factors in combination
with a
peptide that would bind putatively to cell surfaces.
It was observed that adding a glutamate peptide to
the N
-terminus of the nuclear localization signal (NLS) of the Oct6 transcription factor resulted in a novel
CPP with
better uptake and better nuclear colocalization than any other peptide tested.
RESULTS: Uptake of the novel peptide Glu-Oct6 by cancer cell lines was rapid (in less than 1 hr, more than 60%
of DU
-145 cells were positive for FITC), complete (by 4 hr, 99% of cells were positive for FITC), concentration-dependent, temperature-dependent, and inhibited by sodium azide (NaN3).
Substitution of Phe, Tyr, or Asn moieties for the glutamate portion of the novel peptide resulted in abrogation of novel
CPP
uptake; however none of the substituted peptides inhibited uptake of the novel
CPP
when coincubated with cells.
Live-cell imaging and analysis by imaging flow cytometry revealed that the novel
CPP
accumulated in nuclei.
Finally, the novel
CPP
was coupled to a carboxyfluorescein-labeled synthetic oligonucleotide, to see if the peptide could ferry
a therapeutic
payload into cells.
CONCLUSIONS: These studies document the creation
of a
novel
CPP
consisting
of a
glutamate peptide coupled to
the N
-terminus of the Oct6 NLS; the novel
CPP
exhibited nuclear colocalization as well as uptake by prostate and
pancreatic
cancer cell lines.
Genetic Alliance.
consumer health - Pancreatic cancer
.
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
Hazardous Substances Data Bank.
GLUTAMIC ACID HYDROCHLORIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Curr Pharm Des. 2001 Nov;7(17):1839-62
[
11562312.001
]
[Cites]
Cell Mol Life Sci. 2010 Mar;67(5):715-26
[
19898741.001
]
[Cites]
Chem Biol. 2002 Aug;9(8):943-8
[
12204694.001
]
[Cites]
Cancer Res. 2002 Oct 1;62(19):5470-5
[
12359755.001
]
[Cites]
J Biol Chem. 2003 Jan 3;278(1):585-90
[
12411431.001
]
[Cites]
Adv Drug Deliv Rev. 2003 Feb 10;55(2):267-80
[
12564980.001
]
[Cites]
Biochem Biophys Res Commun. 2003 Jul 18;307(1):100-7
[
12849987.001
]
[Cites]
Cancer Res. 2003 Aug 15;63(16):4766-72
[
12941791.001
]
[Cites]
J Cell Biochem. 2004 Feb 15;91(3):528-39
[
14755683.001
]
[Cites]
Cancer Biol Ther. 2004 Jun;3(6):551-8
[
15044850.001
]
[Cites]
Cancer Biol Ther. 2004 Jun;3(6):559-60
[
15153802.001
]
[Cites]
Mol Cancer Ther. 2004 Oct;3(10):1183-91
[
15486184.001
]
[Cites]
EMBO J. 1991 Jul;10(7):1733-9
[
2050110.001
]
[Cites]
J Biol Chem. 1992 Nov 25;267(33):23484-8
[
1429691.001
]
[Cites]
Biochem Pharmacol. 1994 Sep 15;48(6):1310-3
[
7945427.001
]
[Cites]
J Biol Chem. 1996 May 31;271(22):13228-33
[
8662737.001
]
[Cites]
J Biol Chem. 1996 Jul 19;271(29):17512-8
[
8663425.001
]
[Cites]
Front Biosci. 2005;10:1302-12
[
15769626.001
]
[Cites]
Clin Cancer Res. 2005 May 1;11(9):3288-95
[
15867225.001
]
[Cites]
J Control Release. 2005 Dec 10;110(1):189-201
[
16253378.001
]
[Cites]
Ann N Y Acad Sci. 2005 Nov;1059:106-44
[
16382049.001
]
[Cites]
Bioconjug Chem. 2006 May-Jun;17(3):750-8
[
16704214.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12505-10
[
16895983.001
]
[Cites]
Cancer Res. 2006 Sep 15;66(18):9171-7
[
16982760.001
]
[Cites]
Biochem J. 2007 Apr 15;403(2):335-42
[
17217340.001
]
[Cites]
Virology. 2007 Jun 20;363(1):91-103
[
17320140.001
]
[Cites]
Biochemistry. 2007 Jun 26;46(25):7581-9
[
17536840.001
]
[Cites]
Mol Cancer Ther. 2008 Jun;7(6):1543-50
[
18566225.001
]
[Cites]
J Immunol Methods. 2008 Jul 31;336(2):91-7
[
18539294.001
]
[Cites]
Neuropharmacology. 2008 Sep;55(4):396-402
[
18554669.001
]
[Cites]
Cancer Gene Ther. 2009 Oct;16(10):786-93
[
19363465.001
]
[Cites]
Clin Cancer Res. 2002 Apr;8(4):1271-6
[
11948142.001
]
(PMID = 21029412.001).
[ISSN]
1472-6750
[Journal-full-title]
BMC biotechnology
[ISO-abbreviation]
BMC Biotechnol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA 121782
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
England
[Chemical-registry-number]
0 / Cell-Penetrating Peptides; 0 / Nuclear Localization Signals; 0 / Organic Cation Transport Proteins; 0 / Peptide Nucleic Acids; 0 / SLC22A16 protein, human; 3KX376GY7L / Glutamic Acid
[Other-IDs]
NLM/ PMC2987774
75.
Takamatsu Y, Yamamoto H, Ogai Y, Hagino Y, Markou A, Ikeda K:
Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: studies in mice.
Ann N Y Acad Sci
; 2006 Aug;1074:295-302
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Fluoxetine as a potential
pharmacotherapy for
methamphetamine dependence: studies in mice.
The monoamine transporters are the main targets of psychostimulant
drugs
, including methamphetamine (METH) and cocaine.
Interestingly, the rewarding effects of cocaine are retained in dopamine transporter (DAT) knockout (KO) mice, while serotonin transporter (SERT) and DAT double KO mice do not exhibit conditioned place preference (
CPP
) to cocaine.
)
CPP
and locomotor sensitization to 1 mg/kg METH (i.p.) in C57BL/6J mice.
Fluoxetine
treatment
before both the conditioning and preference tests abolished METH
CPP
.
A two-way analysis of variance (ANOVA) revealed that METH
CPP
tended to be lower in mice pretreated with fluoxetine before the preference test than in control mice pretreated with saline before the preference test.
These results suggest that fluoxetine, a widely used
medication for
depression, may be also a useful tool for treating METH dependence.
[MeSH-major]
Amphetamine-Related Disorders /
drug therapy
. Dopamine Agents / toxicity. Fluoxetine /
therapeutic
use. Methamphetamine / toxicity. Motor Activity /
drug
effects. Serotonin Uptake Inhibitors /
therapeutic
use
MedlinePlus Health Information.
consumer health - Methamphetamine
.
Hazardous Substances Data Bank.
d-METHAMPHETAMINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17105925.001).
[ISSN]
0077-8923
[Journal-full-title]
Annals of the New York Academy of Sciences
[ISO-abbreviation]
Ann. N. Y. Acad. Sci.
[Language]
eng
[Grant]
United States / NIDA NIH HHS / DA / R01 DA11946
[Publication-type]
Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Dopamine Agents; 0 / Serotonin Uptake Inhibitors; 01K63SUP8D / Fluoxetine; 44RAL3456C / Methamphetamine
76.
Narotam PK, Puri V, Roberts JM, Taylon C, Vora Y, Nathoo N:
Management of hypertensive emergencies in acute brain disease: evaluation of the treatment effects of intravenous nicardipine on cerebral oxygenation.
J Neurosurg
; 2008 Dec;109(6):1065-74
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Management of hypertensive emergencies in acute
brain disease
: evaluation of the
treatment
effects of intravenous nicardipine on cerebral oxygenation.
This study explores the effect of nicardipine on regional
brain tissue
O(2) (PbtO(2)) during
treatment of
acute hypertensive emergencies.
All patients had a parenchymal PbtO(2) and
intracranial
pressure bolt inserted following resuscitation.
Intravenous nicardipine (5-15 mg/hour) was titrated to systolic BP < 160 mm Hg,
diastolic
BP < 90 mm Hg, mean arterial BP (MABP) 90-110 mm Hg, and PbtO(2) > 20 mm Hg.
Physiological parameters-
intracranial
pressure, PbtO(2), central venous pressure, systolic BP,
diastolic
BP, MABP, fraction of inspired O(2), and cerebral perfusion pressure (
CPP
)-were compared before infusion, at 4 hours, and at 8 hours using
a t
-test.
RESULTS: Sixty episodes of hypertension were reported in 30 patients (traumatic
brain
injury in 13 patients; aneurysmal subarachnoid hemorrhage in 11; intracerebral and intraventricular hemorrhage in 3 and 1, respectively; arteriovenous malformation in 1; and hypoxic
brain
injury in 1).
Nicardipine was effective in 87% of the patients (with intravenous beta blockers in 4 patients),
with a
19.7% reduction in mean 4-hour MABP (115.3 +/- 13.1 mm Hg preinfusion vs 92.9 +/- 11.40 mm Hg after 4 hours of
therapy
, p < 0.001).
No deleterious effect on mean PbtO(2) was recorded (26.74 +/- 15.42 mm Hg preinfusion vs 27.68 +/- 12.51 mm Hg after 4 hours of
therapy
, p = 0.883) despite significant reduction in
CPP
.
Less dependence on normobaric hyperoxia was achieved at 8 hours (0.72 +/- 0.289 mm Hg preinfusion vs 0.626 +/- 0.286 mm Hg after 8 hours of
therapy
, p < 0.01).
Subgroup analysis revealed that 12 patients had low pretreatment PbtO(2) (10.30 +/- 6.49 mm Hg), with higher
CPP
(p < 0.001) requiring hyperoxia (p = 0.02).
In this group, intravenous nicardipine resulted in an 83% improvement in 4- and 8-hour PbtO(2) levels (18.1 +/- 11.33 and 19.59 +/- 23.68 mm Hg, respectively; p < 0.01) despite significant reductions in both mean MABP (120.6 +/- 16.65 vs 95.8 +/- 8.3 mm Hg, p < 0.001) and
CPP
(105.00 +/- 20.7 vs 81.2 +/- 15.4 mm Hg, p < 0.001).
CONCLUSIONS: Intravenous nicardipine is effective for the
treatment of
hypertensive neurological emergencies and has no adverse effect on PbtO(2).
[MeSH-major]
Antihypertensive Agents /
therapeutic
use.
Brain
Injuries / physiopathology. Cerebral Hemorrhage / physiopathology. Hypertension /
drug therapy
.
Intracranial
Arteriovenous Malformations / physiopathology. Nicardipine /
therapeutic
use. Subarachnoid Hemorrhage / physiopathology
[MeSH-minor]
Acute
Disease
. Adult. Aged. Blood Pressure /
drug
effects. Blood Pressure / physiology.
Brain
/ metabolism. Female. Humans. Hypoxia,
Brain
/ physiopathology. Infusions, Intravenous. Male. Middle Aged. Oxygen / metabolism. Prospective Studies
MedlinePlus Health Information.
consumer health - Blood Pressure Medicines
.
MedlinePlus Health Information.
consumer health - High Blood Pressure
.
COS Scholar Universe.
author profiles
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
Hazardous Substances Data Bank.
OXYGEN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19035721.001).
[ISSN]
0022-3085
[Journal-full-title]
Journal of neurosurgery
[ISO-abbreviation]
J. Neurosurg.
[Language]
eng
[Publication-type]
Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antihypertensive Agents; CZ5312222S / Nicardipine; S88TT14065 / Oxygen
77.
Endoh T, Ohtsuki T:
Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape.
Adv Drug Deliv Rev
; 2009 Jul 25;61(9):704-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
RNAi-mediated silencing of specific genes is a promising strategy for gene
therapy
.
To utilize RNAi for
therapy
, an efficient and safe method for delivery of RNA into the cell cytosol is necessary.
This review focuses on
CPP
-based RNA delivery strategies.
In using
CPP
-based RNA delivery, most of the RNA internalized by the cell is entrapped in endosomes.
[MeSH-minor]
Amino Acid Sequence. Animals.
Drug
Carriers. Fluorescent Dyes. Gene Silencing. Genetic
Therapy
. Humans. Molecular Sequence Data. Photosensitizing Agents / pharmacology. RNA Interference. RNA-Binding Proteins / chemistry. RNA-Binding Proteins / metabolism
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19383521.001).
[ISSN]
1872-8294
[Journal-full-title]
Advanced drug delivery reviews
[ISO-abbreviation]
Adv. Drug Deliv. Rev.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Drug Carriers; 0 / Fluorescent Dyes; 0 / Peptides; 0 / Photosensitizing Agents; 0 / RNA, Small Interfering; 0 / RNA-Binding Proteins
[Number-of-references]
74
78.
Sadler R, Herzig V, Schmidt WJ:
Repeated treatment with the NMDA antagonist MK-801 disrupts reconsolidation of memory for amphetamine-conditioned place preference.
Behav Pharmacol
; 2007 Nov;18(7):699-703
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Repeated
treatment with
the NMDA antagonist MK-801 disrupts reconsolidation of memory for amphetamine-conditioned place preference.
Long-lasting
drug
-associated memories can contribute to relapse; therefore these memories must be inactivated to enable sustainable success in addiction
therapy
.
As
drug
associations are usually acquired over several conditioning events, we assume that an effective
treatment
should be repeatedly applied to achieve persistent effects.
In this study, we examine whether 10 repeated memory reactivation tests followed by systemic N-methyl-D-aspartate receptor antagonist MK-801 (0.1 mg/kg) administrations can disrupt memory reconsolidation in rats, leading to a reduction of well-established amphetamine-conditioned place preference (
CPP
).
We found that immediate (but not 60-min delayed) administration of MK-801 after the tests reduced amphetamine-
CPP
expression after at least four
treatments
.
These effects were specific to
CPP
expression as no MK-801-induced change in locomotion was observed during all tests.
We discuss these results as being caused by MK-801 disrupting memory reconsolidation and we propose the applied repeated-
treatment
regimen as a new
therapeutic
research strategy to persistently disrupt
drug
-associated memories.
[MeSH-major]
Amphetamine / pharmacology. Central Nervous System Stimulants / pharmacology. Conditioning, Operant /
drug
effects. Dizocilpine Maleate / pharmacology. Memory /
drug
effects. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors
[MeSH-minor]
Animals. Behavior, Animal /
drug
effects. Male. Motor Activity /
drug
effects. Rats. Rats, Sprague-Dawley
MedlinePlus Health Information.
consumer health - Memory
.
Hazardous Substances Data Bank.
AMPHETAMINE
.
Hazardous Substances Data Bank.
DIZOCILPINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17912055.001).
[ISSN]
0955-8810
[Journal-full-title]
Behavioural pharmacology
[ISO-abbreviation]
Behav Pharmacol
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Central Nervous System Stimulants; 0 / Receptors, N-Methyl-D-Aspartate; 6LR8C1B66Q / Dizocilpine Maleate; CK833KGX7E / Amphetamine
79.
Eugster EA, Clarke W, Kletter GB, Lee PA, Neely EK, Reiter EO, Saenger P, Shulman D, Silverman L, Flood L, Gray W, Tierney D:
Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial.
J Clin Endocrinol Metab
; 2007 May;92(5):1697-704
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
CONTEXT: GnRH analog (GnRHa)
therapy
for central precocious puberty (
CPP
) typically involves im injections.
The histrelin implant is a new
treatment
that provides a continuous slow release of the GnRHa histrelin.
OBJECTIVE: The objective of the study was to investigate the safety and efficacy of the subdermal histrelin implant for the
treatment of CPP
in
treatment
naive and previously treated children.
PATIENTS: Girls ages 2-8 yr (naive) or 2-10 yr (previously treated) and boys 2-9 yr (naive) or 2-11 yr (previously treated) with clinical evidence
of CPP
and a pretreatment pubertal response to leuprolide stimulation were eligible.
CONCLUSIONS: The subdermal histrelin implant achieves and maintains excellent suppression of peak LH and sex steroid levels for 1 yr in children
with CPP
.
The treatment
is well tolerated.
[MeSH-major]
Gonadotropin-Releasing Hormone / analogs & derivatives. Puberty, Precocious /
drug therapy
[MeSH-minor]
Age Determination by Skeleton. Body Mass Index. Bone and Bones / radiography. Breast / growth & development. Child. Child, Preschool.
Drug
Implants. Estradiol / blood. Female. Follicle Stimulating Hormone / blood. Growth /
drug
effects. Humans. Luteinizing Hormone / blood. Male. Prospective Studies. Testosterone / blood
Genetic Alliance.
consumer health - Precocious puberty
.
Genetic Alliance.
consumer health - Central precocious puberty
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
ESTRADIOL
.
Hazardous Substances Data Bank.
TESTOSTERONE
.
Hazardous Substances Data Bank.
HISTRELIN
.
Hazardous Substances Data Bank.
MENOTROPINS
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17327379.001).
[ISSN]
0021-972X
[Journal-full-title]
The Journal of clinical endocrinology and metabolism
[ISO-abbreviation]
J. Clin. Endocrinol. Metab.
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Drug Implants; 33515-09-2 / Gonadotropin-Releasing Hormone; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; H50H3S3W74 / histrelin
80.
Anpalagan A, Condous G:
Is there a role for use of levonorgestrel intrauterine system in women with chronic pelvic pain?
J Minim Invasive Gynecol
; 2008 Nov-Dec;15(6):663-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
This review focuses on the available evidence for the use of levonorgestrel (LNG) intrauterine system (IUS) in women with chronic pelvic pain (
CPP
).
Laparoscopic surgery was shown to be useful in clarifying the underlying cause in women
with CPP
, with 70% having abnormal findings at laparoscopy.
Up to 36% need repeated surgery during a 5-year period after the primary
procedure
.
The absolute reduction in recurrence of dysmenorrhea in women who also had the LNG IUS inserted at
the time
of surgery was 35% (95% CI 9%-61%).
Insertion of the LNG IUS at
the time
of primary laparoscopic surgery in women
with CPP
caused by endometriosis has the potential to reduce postoperative pain scores.
This nonsurgical option could potentially reduce the rate of repeated laparoscopies in women
with CPP
and, in turn, reduce overall intervention rates.
[MeSH-major]
Contraceptive Agents, Female /
therapeutic
use. Levonorgestrel /
therapeutic
use. Pelvic Pain /
drug therapy
[MeSH-minor]
Clinical Trials as Topic. Dysmenorrhea /
drug therapy
. Female. Humans. Menstruation Disturbances / complications. Menstruation Disturbances /
diagnosis
MedlinePlus Health Information.
consumer health - Pelvic Pain
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
LEVONORGESTREL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18774757.001).
[ISSN]
1553-4650
[Journal-full-title]
Journal of minimally invasive gynecology
[ISO-abbreviation]
J Minim Invasive Gynecol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Contraceptive Agents, Female; 5W7SIA7YZW / Levonorgestrel
[Number-of-references]
21
81.
El-Gaidi MA, Eissa EM:
Infantile intracranial neoplasms: characteristics and surgical outcomes of a contemporary series of 21 cases in an Egyptian referral center.
Pediatr Neurosurg
; 2010;46(4):272-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Infantile
intracranial
neoplasms: characteristics and surgical outcomes
of a
contemporary series of 21 cases in an Egyptian referral center.
OBJECTIVE: To investigate the demographic, clinical, radiological, pathological and surgical features and outcomes of infantile
intracranial
neoplasms, the second most common
neoplasm
in infants.
RESULTS: Out of 451 patients with primary
intracranial
neoplasms (age 0-14 years), 21 infants (<1 year) underwent surgery, representing 4.7% of total cases.
The most common
tumor
was
choroid plexus
papilloma
(23.8%), followed by teratoma (19%) then astrocytoma and ependymoma (14.3% each).
Three patients received
chemotherapy
, but none received radiotherapy.
The statistically significant predictors of prognosis were the extent of resection and
tumor
grade.
CONCLUSION: Although the prognosis for infantile
intracranial
neoplasms is worse than for older children, an overall promising outcome with low operative morbidity and mortality was achieved using gross total excision and appropriate adjuvant
chemotherapy
as part
of a
multidisciplinary approach.
[MeSH-major]
Brain
Neoplasms / mortality.
Brain
Neoplasms / surgery.
Papilloma
,
Choroid Plexus
/ mortality.
Papilloma
,
Choroid Plexus
/ surgery
[MeSH-minor]
Adolescent. Astrocytoma /
drug therapy
. Astrocytoma / mortality. Astrocytoma / surgery.
Chemotherapy
, Adjuvant. Child. Child, Preschool. Combined Modality
Therapy
. Egypt / epidemiology. Ependymoma /
drug therapy
. Ependymoma / mortality. Ependymoma / surgery. Female. Humans. Infant. Infant, Newborn. Male. Medulloblastoma /
drug therapy
. Medulloblastoma / mortality. Medulloblastoma / surgery. Morbidity. Neurilemmoma /
drug therapy
. Neurilemmoma / mortality. Neurilemmoma / surgery. Prognosis. Quality of Life. Referral and Consultation / statistics & numerical data. Retrospective Studies. Teratoma /
drug therapy
. Teratoma / mortality. Teratoma / surgery
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2010 S. Karger AG, Basel.
(PMID = 21160236.001).
[ISSN]
1423-0305
[Journal-full-title]
Pediatric neurosurgery
[ISO-abbreviation]
Pediatr Neurosurg
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Switzerland
82.
Stoner J, Martin G, O'Mara K, Ehlers J, Tomlanovich M:
Amiodarone and bretylium in the treatment of hypothermic ventricular fibrillation in a canine model.
Acad Emerg Med
; 2003 Mar;10(3):187-91
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Amiodarone and bretylium in
the treatment
of hypothermic ventricular fibrillation in
a canine
model.
Despite mixed experimental data, some authors view bretylium as the
drug
of choice in hypothermic VF.
OBJECTIVES: To compare defibrillation rates from hypothermic VF after
drug therapy
with amiodarone, bretylium, and placebo.
Thirty anesthetized dogs were mechanically ventilated and instrumented to monitor coronary perfusion pressure (
CPP
), rectal core temperature, and electrocardiogram (ECG).
Ventricular fibrillation was induced as needed
with a
transthoracic AC current.
Return of spontaneous circulation (ROSC) was defined as a sustainable ECG rhythm generating a corresponding arterial pressure
tracing
lasting a minimum of 15 minutes.
RESULTS: CPR was adequate based on
CPP
> 15 mm Hg in all animals.
Mean (+/-SD)
CPP
was 35.3 +/- 18.8 mm Hg with an overall lower trend in the amiodarone group (p = 0.06).
[MeSH-major]
Amiodarone /
therapeutic
use. Anti-Arrhythmia Agents /
therapeutic
use. Bretylium Compounds /
therapeutic
use. Ventricular Fibrillation /
drug therapy
[MeSH-minor]
Animals.
Disease
Models, Animal. Dogs. Hypothermia, Induced. Random Allocation
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 12615580.001).
[ISSN]
1069-6563
[Journal-full-title]
Academic emergency medicine : official journal of the Society for Academic Emergency Medicine
[ISO-abbreviation]
Acad Emerg Med
[Language]
eng
[Publication-type]
Comparative Study; Evaluation Studies; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Anti-Arrhythmia Agents; 0 / Bretylium Compounds; N3RQ532IUT / Amiodarone; RZR75EQ2KJ / bretylium
83.
Cavus E, Meybohm P, Doerges V, Hugo HH, Steinfath M, Nordstroem J, Scholz J, Bein B:
Cerebral effects of three resuscitation protocols in uncontrolled haemorrhagic shock: a randomised controlled experimental study.
Resuscitation
; 2009 May;80(5):567-72
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: To compare haemodynamic and cerebral variables during aggressive fluid resuscitation vs. administration
of a
hypertonic starch solution (HS) combined with either noradrenaline [norepinephrine] or arginine vasopressin in an animal model of uncontrolled haemorrhagic shock.
Thirty minutes after
drug
administration, bleeding was controlled manually.
RESULTS: Mean arterial blood pressure (MAP), cerebral perfusion pressure (
CPP
), and
brain tissue
oxygen pressure (P(bt)O(2)) decreased significantly with haemorrhage in all groups (p<0.05).
AVP/HS resulted in a faster and higher increase of MAP and
CPP
compared to both NA/HS and FR (p<0.001 vs. FR; p<0.01 vs. NA/HS).
Compared to FR, P(bt)O(2) increased faster with AVP/HS and NA/HS (p<0.05) after
therapy
, and ICP was lower at the end of the study period (p<0.05).
CONCLUSIONS: Following uncontrolled haemorrhagic shock in this animal model, combination of HS with arginine vasopressin increased
CPP
and cerebral oxygenation faster than aggressive fluid resuscitation, without re-increasing ICP.
[MeSH-major]
Clinical Protocols. Resuscitation / methods. Shock, Hemorrhagic /
therapy
[MeSH-minor]
Animals. Arginine Vasopressin / administration & dosage.
Brain
/ blood supply.
Brain
/
drug
effects.
Brain
/ physiopathology. Cerebrovascular Circulation /
drug
effects. Combined Modality
Therapy
/ methods.
Disease
Models, Animal. Female. Fluid
Therapy
/ methods. Hydroxyethyl Starch Derivatives / administration & dosage. Hypertonic Solutions / administration & dosage. Male. Norepinephrine / administration & dosage. Oxygen Consumption /
drug
effects. Plasma Substitutes / administration & dosage. Prospective Studies. Random Allocation. Swine.
Treatment
Outcome. Vasoconstrictor Agents / administration & dosage
Hazardous Substances Data Bank.
Norepinephrine
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19217706.001).
[ISSN]
0300-9572
[Journal-full-title]
Resuscitation
[ISO-abbreviation]
Resuscitation
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Ireland
[Chemical-registry-number]
0 / Hydroxyethyl Starch Derivatives; 0 / Hypertonic Solutions; 0 / Plasma Substitutes; 0 / Vasoconstrictor Agents; 113-79-1 / Arginine Vasopressin; X4W3ENH1CV / Norepinephrine
84.
Iwasaki K, Mishima K, Egashira N, Al-Khatib IH, Ishibashi D, Irie K, Kobayashi H, Egawa T, Fujiwara M:
Effect of nilvadipine on the cerebral ischemia-induced impairment of spatial memory and hippocampal apoptosis in rats.
J Pharmacol Sci
; 2003 Oct;93(2):188-96
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
However, mRNA expression of the apoptosis-related early oncogene bax and
CPP
32 (caspase-3) was observed after 24 h.
In these rats, nilvadipine, but not amlodipine, significantly improved memory, concomitantly decreased hippocampal apoptosis, and suppressed both bax and
CPP
32 expression.
These results suggest that nilvadipine improved the memory impairment in repeated ischemia by reducing bax and
CPP
32 expression and suppressing the induction of apoptosis in the hippocampus.
Nilvadipine may have a neuroprotective effect and could be a useful
pharmacotherapeutic
agent for cerebrovascular dementia.
[MeSH-major]
Brain
Ischemia / psychology. Calcium Channel Blockers / pharmacology. Hippocampus / cytology. Memory Disorders /
drug therapy
. Memory Disorders / psychology. Nifedipine / pharmacology. Space Perception /
drug
effects
[MeSH-minor]
Animals. Apoptosis /
drug
effects. Calibration. Genes, bcl-2 / genetics. Glyceraldehyde-3-Phosphate Dehydrogenases / genetics. Male. Maze Learning /
drug
effects. RNA, Messenger / biosynthesis. Rats. Rats, Wistar. Reverse Transcriptase Polymerase Chain Reaction
MedlinePlus Health Information.
consumer health - Memory
.
Hazardous Substances Data Bank.
Nifedipine
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 14578587.001).
[ISSN]
1347-8613
[Journal-full-title]
Journal of pharmacological sciences
[ISO-abbreviation]
J. Pharmacol. Sci.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Japan
[Chemical-registry-number]
0 / Calcium Channel Blockers; 0 / RNA, Messenger; 0214FUT37J / nilvadipine; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases; I9ZF7L6G2L / Nifedipine
85.
Biala G, Budzynska B, Staniak N:
Effects of rimonabant on the reinstatement of nicotine-conditioned place preference by drug priming in rats.
Behav Brain Res
; 2009 Sep 14;202(2):260-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Effects of rimonabant on the reinstatement of nicotine-conditioned place preference by
drug
priming in rats.
Drug
addiction is a chronic disorder characterized by a relatively high rate of relapse even after long period of abstinence.
In the present study, we used the conditioned place preference (
CPP
) paradigm to investigate the establishment, extinction, reinstatement and cross-reinstatement of nicotine-induced place conditioning in rats.
Nicotine produced a place preference to the initially less-preferred compartment paired with its injections during conditioning (0.5mg/kg, i.p., three
drug
sessions).
Once established, nicotine
CPP
was extinguished by repeated testing.
Following this extinction phase, the reinstatement
of CPP
was investigated.
These priming injections of both
drugs
induced a marked preference for the compartment previously paired with nicotine.
Furthermore, the objective of the present study was to evaluate the efficacy of CB1 cannabinoid receptor antagonist rimonabant (0.5, 1 and 2mg/kg, i.p.) in blocking the reinstatement of nicotine-induced
CPP
provoked by nicotine and morphine.
It was shown that rimonabant attenuated the reinstatement of nicotine-conditioned response induced by both
drugs
.
The outcome of our studies may suggest that CB1 receptor antagonists may become a promising target for effective
pharmacotherapy of
tobacco addiction and polydrug abuse.
[MeSH-major]
Central Nervous System Agents / administration & dosage. Conditioning, Classical /
drug
effects. Morphine / administration & dosage. Nicotine / administration & dosage. Nicotinic Agonists / administration & dosage. Piperidines / administration & dosage. Pyrazoles / administration & dosage
[MeSH-minor]
Analysis of Variance. Animals. Extinction, Psychological. Male. Random Allocation. Rats. Rats, Wistar. Receptor, Cannabinoid, CB1 / antagonists & inhibitors. Spatial Behavior /
drug
effects
Gene Ontology.
gene/protein/disease-specific - Gene Ontology annotations from this paper
.
Hazardous Substances Data Bank.
NICOTINE
.
Hazardous Substances Data Bank.
MORPHINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19463710.001).
[ISSN]
1872-7549
[Journal-full-title]
Behavioural brain research
[ISO-abbreviation]
Behav. Brain Res.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Central Nervous System Agents; 0 / Nicotinic Agonists; 0 / Piperidines; 0 / Pyrazoles; 0 / Receptor, Cannabinoid, CB1; 158681-13-1 / rimonabant; 6M3C89ZY6R / Nicotine; 76I7G6D29C / Morphine
86.
Bordman R, Jackson B:
Below the belt: approach to chronic pelvic pain.
Can Fam Physician
; 2006 Dec;52(12):1556-62
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVE: To present a practical approach to the symptom complex called chronic pelvic pain (
CPP
).
Chronic pelvic pain is defined as nonmenstrual pain lasting 6 months or more that is severe enough to cause functional disability or require medical or surgical
treatment
.
MAIN MESSAGE: While the source of pain in
CPP
can be gynecologic, urologic, gastrointestinal, musculoskeletal, or psychoneurologic, 4 conditions account for most
CPP
: endometriosis, adhesions, interstitial cystitis, and irritable bowel syndrome.
Nonnarcotic analgesics are first-line
therapy
for pain relief; hormonal
therapies
are beneficial if the pain has a cyclical component.
CONCLUSION: Although caring for patients
with CPP
can be challenging and frustrating, family physicians are in an ideal position to manage and coordinate their care.
[MeSH-major]
Pelvic Pain /
diagnosis
. Pelvic Pain /
therapy
[MeSH-minor]
Abdominal Pain / etiology. Adult. Chronic
Disease
. Cystitis, Interstitial / complications. Cystitis, Interstitial /
diagnosis
. Cystitis, Interstitial /
drug therapy
. Endometriosis / complications. Endometriosis /
diagnosis
. Endometriosis /
drug therapy
. Female. Humans. Irritable Bowel Syndrome / complications. Irritable Bowel Syndrome /
diagnosis
. Irritable Bowel Syndrome /
therapy
. Physical Examination
MedlinePlus Health Information.
consumer health - Pelvic Pain
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br Med Bull. 2004;72:15-29
[
15767561.001
]
[Cites]
Clin Obstet Gynecol. 1998 Jun;41(2):422-35
[
9646974.001
]
[Cites]
Am Fam Physician. 1999 Oct 15;60(6):1753-62, 1767-8
[
10537390.001
]
[Cites]
Baillieres Best Pract Res Clin Obstet Gynaecol. 2000 Jun;14(3):467-94
[
10962637.001
]
[Cites]
Cochrane Database Syst Rev. 2000;(4):CD000387
[
11034686.001
]
[Cites]
J Am Board Fam Pract. 2001 Mar-Apr;14(2):95-106
[
11314930.001
]
[Cites]
Int J Gynaecol Obstet. 2001 Sep;74 Suppl 1:S15-20
[
11549395.001
]
[Cites]
Obstet Gynecol Surv. 2001 Dec;56(12):757-64
[
11753178.001
]
[Cites]
J Obstet Gynaecol Can. 2002 Jan;24(1):37-61; quiz 74-6
[
12196887.001
]
[Cites]
Fertil Steril. 2002 Nov;78(5):961-72
[
12413979.001
]
[Cites]
Obstet Gynecol. 2003 Mar;101(3):594-611
[
12636968.001
]
[Cites]
Obstet Gynecol Clin North Am. 2003 Mar;30(1):133-50
[
12699262.001
]
[Cites]
J Urol. 2003 Sep;170(3):807-9
[
12913704.001
]
[Cites]
Obstet Gynecol Surv. 2003 Sep;58(9):615-23
[
12972837.001
]
[Cites]
J Fam Pract. 2003 Dec;52(12):942-50
[
14653980.001
]
[Cites]
Obstet Gynecol. 2004 Mar;103(3):589-605
[
14990428.001
]
[Cites]
J Reprod Med. 2004 Mar;49(3 Suppl):230-4
[
15088861.001
]
[Cites]
Obstet Gynecol. 1991 May;77(5):740-4
[
1826544.001
]
[Cites]
Br J Obstet Gynaecol. 1992 Jan;99(1):59-62
[
1547175.001
]
[Cites]
Urology. 1997 May;49(5A Suppl):58-63
[
9146003.001
]
[Cites]
J Gen Intern Med. 1997 Jul;12(7):439-45
[
9229283.001
]
[Cites]
Clin Obstet Gynecol. 1997 Sep;40(3):554-63
[
9328736.001
]
[Cites]
Obstet Gynecol. 2003 Aug;102(2):397-408
[
12907119.001
]
(PMID = 17279236.001).
[ISSN]
1715-5258
[Journal-full-title]
Canadian family physician Médecin de famille canadien
[ISO-abbreviation]
Can Fam Physician
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Canada
[Other-IDs]
NLM/ PMC1783755
87.
Bourré L, Giuntini F, Eggleston IM, Mosse CA, Macrobert AJ, Wilson M:
Effective photoinactivation of Gram-positive and Gram-negative bacterial strains using an HIV-1 Tat peptide-porphyrin conjugate.
Photochem Photobiol Sci
; 2010 Dec;9(12):1613-20
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Given that cell-penetrating peptides (
CPP
) are cationic and often amphipathic, similar to membrane-active antimicrobial peptides, it may be possible to use
CPP
conjugation to improve the delivery of photosensitisers for antimicrobial photodynamic
therapy
(antimicrobial PDT).
Using the highest light dose,
treatment with
the Tat-porphyrin achieved reductions of 6.6 log(10) and 6.37 log(10) in the viable counts of Staphylococcus aureus and Streptococcus pyogenes, and reductions of 5.74 log(10) and 6.6 log(10) in the viable counts of Pseudomonas aeruginosa and Escherichia coli.
These findings demonstrate that the use
of CPP
to deliver a photosensitiser is an effective way of improving the uptake and
the treatment
efficacy of antimicrobial PDT.
[MeSH-major]
Gram-Negative Bacteria /
drug
effects. Gram-Positive Bacteria /
drug
effects. Peptides / chemistry. Photosensitizing Agents / chemistry. Porphyrins / chemistry. tat Gene Products, Human Immunodeficiency Virus / chemistry
[MeSH-minor]
Amino Acid Sequence. Antimicrobial Cationic Peptides / pharmacology. Escherichia coli /
drug
effects. Pseudomonas aeruginosa /
drug
effects. Spectrometry, Fluorescence. Staphylococcus aureus /
drug
effects. Streptococcus pyogenes /
drug
effects
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20931134.001).
[ISSN]
1474-9092
[Journal-full-title]
Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology
[ISO-abbreviation]
Photochem. Photobiol. Sci.
[Language]
eng
[Grant]
United Kingdom / Biotechnology and Biological Sciences Research Council / / BB/D011329/1; United Kingdom / Biotechnology and Biological Sciences Research Council / / BBD0113291; United Kingdom / Biotechnology and Biological Sciences Research Council / / BBD0127831
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antimicrobial Cationic Peptides; 0 / Peptides; 0 / Photosensitizing Agents; 0 / Porphyrins; 0 / tat Gene Products, Human Immunodeficiency Virus
88.
Johnston AJ, Steiner LA, O'Connell M, Chatfield DA, Gupta AK, Menon DK:
Pharmacokinetics and pharmacodynamics of dopamine and norepinephrine in critically ill head-injured patients.
Intensive Care Med
; 2004 Jan;30(1):45-50
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
PATIENTS: Eight patients
with a
head injury, requiring dopamine or norepinephrine infusions to support cerebral perfusion pressure (
CPP
).
INTERVENTION: Patients received in randomised order, either dopamine or norepinephrine to achieve and maintain
a CPP
of 70 mmHg, and then, following a 30-min period of stable haemodynamics,
a CPP
of 90 mmHg.
However, there was a significant quadratic relationship between the infusion rate of dopamine and cardiac index (r2=0.431), and systemic vascular resistance index (r2=0.605),
with a
breakpoint (at which cardiac index reduced and SVRI increased) at a dopamine plasma level of approximately 50 nM/l (corresponding to an infusion rate of approximately 15 microg.kg(-1).min(-1)).
[MeSH-major]
Craniocerebral Trauma /
drug therapy
. Dopamine. Norepinephrine. Vasoconstrictor Agents
[MeSH-minor]
Adult. Cardiotonic Agents / metabolism. Cardiotonic Agents / pharmacokinetics. Cardiotonic Agents / pharmacology. Catecholamines / blood. Critical Illness /
therapy
. Cross-Over Studies. Dose-Response Relationship,
Drug
.
Drug
Monitoring. Female. Heart Rate /
drug
effects. Humans. Infusions, Intravenous.
Intracranial
Pressure /
drug
effects. Linear Models. Male. Metabolic Clearance Rate. Middle Aged. Prospective Studies. Vascular Resistance /
drug
effects
MedlinePlus Health Information.
consumer health - Head Injuries
.
Hazardous Substances Data Bank.
Norepinephrine
.
Hazardous Substances Data Bank.
DOPAMINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Eur J Clin Pharmacol. 1984;26(2):163-9
[
6723754.001
]
[Cites]
Am J Med Genet. 2001 Jul 8;105(5):464-70
[
11449400.001
]
[Cites]
Clin Exp Pharmacol Physiol. 1990 May;17(5):361-9
[
2354553.001
]
[Cites]
Am J Hum Genet. 2001 Feb;68(2):515-22
[
11170900.001
]
[Cites]
Crit Care Med. 2000 May;28(5):1353-62
[
10834678.001
]
[Cites]
Hum Genet. 2002 Dec;111(6):521-37
[
12436243.001
]
[Cites]
Intensive Care Med. 1998 Jun;24(6):564-8
[
9681777.001
]
[Cites]
Br J Pharmacol. 1991 Apr;102(4):831-6
[
1713108.001
]
[Cites]
Crit Care Med. 2001 Jul;29(7 Suppl):S117-20
[
11445745.001
]
[Cites]
Crit Care Med. 1993 Nov;21(11):1652-7
[
8222680.001
]
[Cites]
Intensive Care Med. 1997 Jan;23(1):31-7
[
9037637.001
]
[Cites]
Am J Med Genet. 1997 Jul 25;74(4):439-42
[
9259381.001
]
[Cites]
Anesthesiology. 2000 Feb;92(2):338-46
[
10691218.001
]
[Cites]
Eur J Pharmacol. 2000 Feb 11;389(1):1-12
[
10686290.001
]
[Cites]
J Chromatogr. 1982 Aug 13;231(1):25-39
[
7119063.001
]
[Cites]
Crit Care Med. 1988 Mar;16(3):217-20
[
3342635.001
]
[Cites]
J Pharmacol Exp Ther. 1989 Apr;249(1):131-3
[
2709327.001
]
[Cites]
Intensive Care Med. 1998 Nov;24(11):1217-20
[
9876986.001
]
[Cites]
Int J Clin Monit Comput. 1994 Nov;11(4):223-32
[
7738416.001
]
[Cites]
Intensive Care Med. 2002 May;28(5):547-53
[
12029400.001
]
[Cites]
Am J Med Genet. 2002 Jul 8;114(5):491-6
[
12116182.001
]
[Cites]
J Pediatr. 1990 Sep;117(3):472-6
[
2391608.001
]
[Cites]
Crit Care Med. 1984 Jan;12(1):22-5
[
6690200.001
]
[Cites]
Crit Care Med. 1991 Aug;19(8):1008-11
[
1860323.001
]
[Cites]
Acta Anaesthesiol Scand. 1981 Aug;25(4):328-31
[
7315181.001
]
[Cites]
Crit Care Med. 2001 Aug;29(8):1526-31
[
11505120.001
]
[Cites]
Hum Genet. 1998 Sep;103(3):273-9
[
9799080.001
]
[Cites]
Am J Med Genet. 2002 Mar 8;114(2):154-8
[
11857576.001
]
[Cites]
Crit Care Med. 1989 Nov;17(11):1166-9
[
2791595.001
]
[Cites]
Br J Anaesth. 1995 Apr;74(4):419-23
[
7734262.001
]
(PMID = 14586494.001).
[ISSN]
0342-4642
[Journal-full-title]
Intensive care medicine
[ISO-abbreviation]
Intensive Care Med
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Cardiotonic Agents; 0 / Catecholamines; 0 / Vasoconstrictor Agents; VTD58H1Z2X / Dopamine; X4W3ENH1CV / Norepinephrine
89.
Schulz D, Buddenberg T, Huston JP:
Extinction-induced "despair" in the water maze, exploratory behavior and fear: effects of chronic antidepressant treatment.
Neurobiol Learn Mem
; 2007 May;87(4):624-34
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Extinction-induced "despair" in the water maze, exploratory behavior and fear: effects of chronic antidepressant
treatment
.
Specifically, the removal
of a
hidden platform in the water maze induced extinction of previously reinforced escape behavior and behavioral immobility, indicative of "despair", which also correlated with indices of fear.
Here, we tested the effects of antidepressants on extinction in the water maze, and expected that such
drugs
would attenuate the rate of extinction
of a
conditioned place preference (
CPP
) and also any emotionally relevant behavior that is induced by the loss of reinforcement, such as immobility.
Daily
treatment with
desipramine hydrochloride (DMI, 10mg/kg) or fluoxetine (FLX, 10 mg/kg) commenced 1 day before the first of 11 extinction trials without the platform, administered 48 h apart, and continued thereafter, as the rats were tested in an open field and elevated-plus maze.
As compared to controls, DMI increased the resistance-to-extinction
of CPP
, attenuated immobility, and increased wall climbing behavior.
[MeSH-major]
Antidepressive Agents / pharmacology. Exploratory Behavior /
drug
effects. Extinction, Psychological / physiology. Fear /
drug
effects. Maze Learning /
drug
effects
[MeSH-minor]
Affect. Animals. Conditioning, Classical /
drug
effects. Conditioning, Classical / physiology. Depressive Disorder /
drug therapy
. Desipramine / pharmacology.
Disease
Models, Animal.
Drug
Administration Schedule. Escape Reaction. Fluoxetine / pharmacology. Immobility Response, Tonic /
drug
effects. Immobility Response, Tonic / physiology. Male. Rats. Rats, Wistar. Statistics, Nonparametric
MedlinePlus Health Information.
consumer health - Antidepressants
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
DESIPRAMINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17223365.001).
[ISSN]
1074-7427
[Journal-full-title]
Neurobiology of learning and memory
[ISO-abbreviation]
Neurobiol Learn Mem
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
[Publication-country]
United States
[Chemical-registry-number]
0 / Antidepressive Agents; 01K63SUP8D / Fluoxetine; TG537D343B / Desipramine
90.
Jacka MJ, Zygun D:
Survey of management of severe head injury in Canada.
Can J Neurol Sci
; 2007 Aug;34(3):307-12
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVE: To determine: 1. the degrees of consensus and disagreement among Canadian critical care clinicians regarding the appropriateness (benefit exceeding risk) of common
therapeutic
manoeuvres in patients with severe closed head injury (CHI), and 2. the frequency with which clinicians employed these manoeuvres.
In a scenario of diffuse axonal injury (DAI), clinicians agreed strongly that fever reduction, early enteral feeding, intensive glucose control, and cerebral perfusion pressure (
CPP
)-directed management were appropriate.
The appropriateness ratings of the interventions considered in the scenario of an
intracranial
contusion mirrored the DAI scenario.
The correlation between
CPP
-guided
therapy
and the use of the EVD was weak.
CONCLUSIONS: This survey has described current practice with regard to
treatment of
patients with severe CHI.
Suggested priorities for evaluation include the use of osmotic diuretics, anticonvulsants, and
intracranial
manometry.
[MeSH-major]
Brain
Injuries /
therapy
. Critical Care / methods. Head Injuries, Closed /
therapy
. Health Care Surveys. Neurology / methods. Neurosurgery / methods. Practice Patterns, Physicians' / statistics & numerical data
[MeSH-minor]
Adult. Anticonvulsants /
therapeutic
use. Canada / epidemiology. Diffuse Axonal Injury /
drug therapy
. Diffuse Axonal Injury / physiopathology. Diuretics, Osmotic /
therapeutic
use. Female. Hematoma, Epidural, Cranial /
drug therapy
. Hematoma, Epidural, Cranial / physiopathology. Hematoma, Epidural, Cranial / surgery. Humans. Hypothermia, Induced / utilization. Intensive Care Units.
Intracranial
Hypertension /
diagnosis
.
Intracranial
Hypertension / prevention & control.
Intracranial
Hypertension /
therapy
. Male. Malnutrition / prevention & control. Malnutrition /
therapy
. Middle Aged. Risk Assessment
MedlinePlus Health Information.
consumer health - Critical Care
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17803027.001).
[ISSN]
0317-1671
[Journal-full-title]
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
[ISO-abbreviation]
Can J Neurol Sci
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Canada
[Chemical-registry-number]
0 / Anticonvulsants; 0 / Diuretics, Osmotic
91.
Lamvu G, Williams R, Zolnoun D, Wechter ME, Shortliffe A, Fulton G, Steege JF:
Long-term outcomes after surgical and nonsurgical management of chronic pelvic pain: one year after evaluation in a pelvic pain specialty clinic.
Am J Obstet Gynecol
; 2006 Aug;195(2):591-8; discussion 598-600
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVE: The purpose of this study was to describe long-term outcomes for women with chronic pelvic pain (
CPP
) after evaluation in
a CPP
specialty clinic.
STUDY DESIGN: This was a prospective observational cohort study of women treated
for CPP
at the UNC Pelvic Pain clinic between 1993 and 2000.
The primary outcome was improvement in pain and the main exposure was
treatment
group: primarily medical (
pharmacotherapy
, psychotherapy, physical
therapy
, or combinations of the 3) or surgical (hysterectomy, resection or ablative procedures, oophrectomy, diagnostic surgery, pain mapping, vulvar or vestibular repair).
Univariate, bivariate, and multivariable analyses were performed to look for relationships between background characteristics,
treatment
group, and improvement in pain.
RESULTS: Of 370 participants; 189 had surgical
treatment
and 181 had medical
treatment
.
Improvement in pain was similar in both
treatment
groups and odds of improvement were equal even after adjusting for background characteristics, psychosocial comorbidity, and previous
treatments
.
CONCLUSION: One year after evaluation in
a CPP
specialty clinic, women experienced modest improvements in pain and depression after recommended surgical or